Selectively substituted quinoline compounds

ABSTRACT

Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. provisional patent applicationNo. 61/890,718, filed on Oct. 14, 2013. That application is incorporatedby reference herein.

BACKGROUND

1. Field of the Disclosure

Embodiments of the disclosure relate to selectively substitutedquinoline compounds and pharmaceutical agents comprising one or more ofthose compounds as active ingredient(s). More particularly, embodimentsof the disclosure relate to those compounds that act as an antagonist orinhibitor for Toll-like receptors (TLR) 7 and 8, and their use in apharmaceutical composition effective for treatment of systemic lupuserythematosus (SLE) and lupus nephritis.

2. Description of Related Art

Systemic lupus erythematosus (SLE) and lupus nephritis are autoimmunediseases characterized by inflammation and tissue damage. For example,SLE may cause damage to the skin, liver, kidneys, joints, lungs, andcentral nervous system. SLE sufferers may experience general symptomssuch as extreme fatigue, painful and swollen joints, unexplained fever,skin rash, and kidney dysfunction. Because organ involvement differsamongst patients, symptoms may vary. SLE is predominantly a disease ofyounger women, with peak onset between 15-40 years of age and anapproximate 10-fold higher prevalence in women vs. men.

Current treatments for SLE typically involve immunomodulatory drugs suchas belimumab, hydroxychloroquine, prednisone, and cyclophosphamide. Allof these drugs may have dose-limiting side effects, and many patientsstill have poorly controlled disease.

BRIEF SUMMARY OF THE DISCLOSURE

Embodiments of the disclosure provide compounds and methods of use forpreventing or treating diseases or conditions characterized by Toll-likereceptor 7 or 8 activation in patients. One embodiment features acompound of formula (I):

wherein at least one of R₁ and R₂ is —H, methyl, or ethyl, and the otheris

-   -   —H; or the other is    -   C₁-C₆ alkyl that is optionally substituted with:        -   —OH, methoxy, ethoxy, —OCH(CH₃)₂, —O(CH₂)₂CH₃, phenyl,            furanyl, —O(CH₂)₂OH, phenoxy, methylthio, —F, —N(CH₃)₂,            cyano, pyridinyloxy, fluorophenoxy, isochromanyl, phenol,            benzylamino, —NHCH₃, oxo-, amino, carboxyl, 7-member            spiroaminyl, a three to six member cycloalkyl, saturated or            unsaturated and optionally including one or more heteroatoms            selected from O and N, and optionally substituted at one or            more C or N atoms by methyl, cyano, fluoro, methylamino, or            trifluoromethyl; or the other is    -   C₃-C₇ cycloalkane, saturated or unsaturated, optionally bridged,        optionally including one or more heteroatoms selected from O, S,        and N, and optionally substituted at one or more C or N atoms by        methyl, ethyl, pyridinyl, azetidinyl, acetamidyl, carboxamidyl,        cyano, fluoro, methylamino, or trifluoromethyl; or        R₁ and R₂, together with the nitrogen atom to which they are        attached, form an 8 to 11 member spirodiamine, an 8 member        bicyclodiamine, a 7 member spiroxamine, a piperidinyl optionally        substituted with ethyl, or a four to six member cycloalkyl,        optionally substituted with at least one of carboxamidyl,        aminomethyl, methyl, (ethylamino)methyl, (dimethylamino)methyl,        dimethylamino, (methylamino)methyl, and amino; and wherein        R₃ is —H or methyl.

In a further embodiment the compound is a compound of Formula (I),having the stereochemistry set forth in one of Formula (Ia), (Ib), (Ic),or (Id), having the same substituent options as set forth above forFormula (Ia):

A further embodiment provides a compound of Formula (Ie) (relativestereochemistry indicated):

In a further embodiment the compound is a compound of Formula (II):

wherein

-   R₄ is —H or methyl;-   R₅ is C₁-C₅ alkyl that is saturated, partially saturated, or    unsaturated, and that is optionally substituted with:    -   —H, —Cl, —F, —OH, —NH₂, oxo-, —N(CH₂CH₃)₂, phenyl, cyclohexyl,        phenyltriazolyl, cyclohexyltriazolyl, pyridinyl, pyrrolidinyl,    -   morpholinyl optionally substituted with methyl or hydroxymethyl,    -   —O—, substituted with:        -   C₁-C₆ alkyl, methylphenyl, methylcyclohexyl, pyridinyl,            diazinyl, or phenyl optionally substituted with —F or            methyl,    -   —NH—, substituted with:        -   C₂-C₇ alkyl that is linear, branched, or cyclic, saturated            or unsaturated, and optionally substituted with oxo-,            phenyl, methyl, or —OH,        -   pyridinyl optionally substituted with methyl, methoxy,            phenyl, or amino, diazinyl optionally substituted with            ethyl,        -   benzoimidazolyl, methylphenyl, phenylpyrazolyl,            naphthyridyl, phenyl optionally substituted with —F, methyl,            ethyl, or ethoxy, imidazolidinyl optionally substituted with            methyl            or R₅ is

wherein n is 1-3, and wherein the cyclic amine is optionally substitutedwith

-   -   C₁-C₃ alkyl optionally substituted with        -   —OH, —F, phenyl, —NH₂, cyclohexyl, —N(CH₃)₂, —C(O)NH₂,            methylsulfonamidyl, benzenesulfonamidyl,            methylbenzenesulfonamidyl, or        -   pyrrolidinyl optionally substituted with methyl or hydroxyl,            or    -   —NHC(O)R₆, wherein R₆ is        -   C₁-C₅ alkyl, phenyl, pyridinyl, fluorophenyl,            methylsulfonyl, fluorobenzenesulfonyl, dimethyl pyrazole            sulfonyl, or        -   pyrazolyl optionally substituted with methyl;    -   piperidinyl optionally substituted with —C(O)CH₃, —C(O)CH₂CH₃,        methyl, oxo-, C(O)Ph,        —NH₂, —NH—C(O)CH₃, or

-   -   piperazinyl optionally substituted with —C(O)OC(CH₃)₃, methyl,        —C(O)CH₃, —C(O)Ph, C(O)CH(CH₃)₂, —C(O)CH₃, or methylsulfonyl; or        R₅ is

where n is 1 or 2, and wherein the cyclic diamine is optionallysubstituted on at least one carbon atom with

-   -   methyl, oxo-, —N(CH₃)₂, amino, —CH₂CH₃, or    -   piperidinyl optionally substituted with methyl, —C(O)CH₃,        —C(O)CH(CH₃)₂, —C(O)Ph, or —C(O)OC(CH₃)₃, and    -   wherein R₇ is —H, phenyl, —C(O)CH₃, C₁-C₃ alkyl, —C(O)NH₂, or        —C(O)Ph; and R₈ is methoxy or cyano.

A further embodiment provides a compound of Formula (III):

wherein

-   R₁₁ is H or methyl;-   R₁₀ is H or, when both R₁₄ and R₉ are H, is    methyl-1,4′-bipiperidinyl;-   R₉ is —H or is —CH₂— substituted by 1,4′-bipiperidinyl, oxo-,    hydroxyl, methylpyridinyl, or piperidinyl optionally substituted    with hydroxyl, —N(CH₃)₂, or piperidinyl.

In a further embodiment the compound is selected fromrel-(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((3R,4S)-4-fluoropyrrolidin-3-yl)-6-methylmorpholine-2-carboxamidehydrochloride,(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(1-methylpiperidin-4-yl)morpholine-2-carboxamide,5-((2S,6R)-2-([1,4′-bipiperidin]-1′-ylmethyl)-6-methylmorpholino)quinoline-8-carbonitrile,and5-((2R,7R)-2-(hydroxymethyl)-7-methyl-1,4-oxazepan-4-yl)quinoline-8-carbonitrile.

In a further embodiment the compound or pharmaceutically effective saltthereof of the preceding paragraph has an IC50 less than or equal to 20nM against human TLR7 receptors expressed in a HEK-293 cell line. In afurther embodiment the compound or pharmaceutically effective saltthereof of the preceding paragraph of this disclosure has an IC50 lessthan or equal to 100 nM against human TLR7 receptors expressed in aHEK-293 cell line. In a further embodiment the IC50 against human TLR7receptors expressed in a HEK-293 cell line is measured by (1) platingcells of the HEK-293 cell line stably expressing TLR7 in Dulbecco'smodified Eagle's medium containing 10% fetal bovine serum at a densityof 2.22×105 cells/ml into a 384-well plate and incubating for 2 days at37° C., 5% CO₂; (2) adding the compound or pharmaceutically acceptablesalt thereof and incubating the cells for 30 minutes; (3) adding CL097(InvivoGen) at 3 ug/ml and incubating the cells for approximately 20hours; and (4) quantifying NF-kappaB dependent reporter activation bymeasuring luminescence.

In further embodiments of the disclosure, compounds have an IC50 againsthuman TLR7 receptors expressed in a HEK-293 cell line less than or equalto 200 nM, less than or equal to 180 nM, less than or equal to 160 nM,less than or equal to 140 nM, less than or equal to 120 nM, less than orequal to 100 nM, less than or equal to 80 nM, less than or equal to 60nM, less than or equal to 40 nM, or less than or equal to 20 nM. Infurther embodiments of the disclosure, compounds have an IC50 againsthuman TLR7 receptors expressed in a HEK-293 cell line from 10 nM to 30nM, from 10 nM to 50 nM, from 10 nM to 100 nM, from 30 nM to 50 nM, from30 nM to 100 nM, or from 50 nM to 100 nM. In further embodiments theIC50 against human TLR7 receptors expressed in a HEK-293 cell line ismeasured by (1) plating cells of the HEK-293 cell line stably expressingTLR7 in Dulbecco's modified Eagle's medium containing 10% fetal bovineserum at a density of 2.22×105 cells/ml into a 384-well plate andincubating for 2 days at 37° C., 5% CO₂; (2) adding the compound orpharmaceutically acceptable salt thereof and incubating the cells for 30minutes; (3) adding CL097 (InvivoGen) at 3 ug/ml and incubating thecells for approximately 20 hours; and (4) quantifying NF-kappaBdependent reporter activation by measuring luminescence.

Further embodiments provide methods for treatment of lupus, includingbut not limited to treatment of systemic lupus erythematosus, cutaneouslupus, neuropsychiatric lupus, fetal heart block, and antiphospholipidsyndrome, including administering a pharmaceutically effective amount ofa compound or pharmaceutically acceptable salt of the disclosure.

Further embodiments provide methods for antagonizing TLR7, includingadministering a pharmaceutically effective amount of a compound orpharmaceutically acceptable salt of the disclosure.

Further embodiments provide methods for antagonizing TLR8, includingadministering a pharmaceutically effective amount of a compound orpharmaceutically acceptable salt of the disclosure.

Further embodiments provide pharmaceutical compositions comprising atleast one compound or pharmaceutically acceptable salt of the disclosureand at least one pharmaceutically acceptable carrier.

Further embodiments provide methods for treatment of systemic lupuserythematosus or lupus, including administering a pharmaceuticallyeffective amount of a compound or pharmaceutically acceptable salt ofthe disclosure.

Further embodiments provide methods for antagonizing TLR7, includingadministering a pharmaceutically effective amount of a compound orpharmaceutically acceptable salt of the disclosure.

Further embodiments provide methods for antagonizing TLR8, includingadministering a pharmaceutically effective amount of a compound orpharmaceutically acceptable salt of the disclosure.

Further embodiments provide pharmaceutical compositions comprising atleast one compound or pharmaceutically acceptable salt of the disclosureand at least one pharmaceutically acceptable carrier.

The term “optionally substituted,” as used herein, means that thesubject structure may include, but is not required to include, one ormore substituents independently selected from lower alkyl, methoxy-,—OH, —NH₂, —CH₂—NH—CH₂, —OCH₂CH₂CH₃, or —OCH(CH₃)₂. If the optionallysubstituted moiety is cyclic, then the optional substitution may be amethyl bridge between two atoms in the ring.

The symbol “C(O)” as used herein refers to a carbonyl group having theformula C═O.

Unless otherwise specified, “a” and “an” as used in this disclosure,including the claims, mean “one or more.”

As used herein, “lower alkyl” refers to straight, or, in the case ofthree- and four-carbon groups, straight, branched, or cyclic saturatedhydrocarbons having between one and four carbon atoms.

As used herein, the term “attached through a nitrogen” when referring toa heterocyclic moiety including nitrogen, means that a point ofattachment of the moiety to another structure is through a nitrogen thatis part of the heterocycle.

As used herein, the term “TLR7/8” means “TLR7 and TLR8” or “TLR7 orTLR8” or “TLR7 and/or TLR8.” The particular meaning can be understood bya person skilled in the art based upon the context in which “TLR7/8”appears.

Heterocyclic moieties recited herein include azetidinyl, pyrrolidinyl,piperidinyl, methylazetidinyl, pyrazolyl, piperazinyl, morpholinyl,thiazolyl, pyrrolopyrrolyl, imidazolidinyl, and isothiazolyl. Where aheterocyclic group is mentioned, unless otherwise indicated it will beunderstood that the heterocyclic atom(s) in the group may be at anyposition in the group. It will further be understood that imidazolyl,pyrazolyl, thiazolyl, and pyrrolyl may be unsaturated or partiallyunsaturated. An embodiment of the disclosure may include apharmaceutical composition that includes one or more compounds of thedisclosure with a pharmaceutically acceptable excipient. Thesepharmaceutical compositions may be used to treat or prevent a disease orcondition characterized by TLR7/8 activation in a patient, typically ahuman patient, who has or is predisposed to have such a condition ordisease. Examples of diseases or conditions characterized by TLR7/8activation include systemic lupus erythematosus (SLE) and lupusnephritis.

As used herein, “effective amount” of a compound of an embodiment of thedisclosure is effective amount of the above-identified compounds in anamount sufficient to treat or prevent SLE and lupus nephritis.

Embodiments presented herein may include asymmetric or chiral centers.Embodiments include the various stereoisomers and mixtures thereof.Individual stereoisomers of compounds of embodiments of the disclosuremay be prepared synthetically from commercially available startingmaterials that contain asymmetric or chiral centers, or by preparationof mixtures of enantiomeric compounds followed by resolution of thosecompounds. Suitable methods of resolution include attachment of aracemic mixture of enantiomers, designated (+/−), to a chiral auxiliary,separation of the resulting diastereomer by chromatography orrecrystallization and separation of the optically pure product from theauxiliary; or direct separation of the mixture of optical enantiomers onchiral chromatographic columns.

Embodiments of the disclosure also include a pharmaceutical compositionincluding any compound of the disclosure as well as a pharmaceuticallyacceptable excipient. The pharmaceutical compositions can be used totreat or prevent SLE and lupus nephritis. Therefore, embodiments of thedisclosure may also feature a method for treating or preventing SLE orlupus nephritis in a human patient having or predisposed to having lupusnephritis or SLE.

Embodiments of the disclosure include pharmaceutically acceptable saltsof the compounds presented herein. The term “pharmaceutically acceptablesalt” refers to those salts that are, within the scope of sound medicaljudgment, suitable for use in contact with the tissues of humans andanimals without undue toxicity, irritation, or allergic response.Pharmaceutically acceptable salts are well known in the art. Forexample, S. M. Berge, et al., describes pharmaceutically acceptablesalts in detail in J. Pharmaceutical Sciences 66:1-19, 1977. Salts canbe prepared in situ during final isolation and purification of acompound or separately by reacting a free base group with a suitableorganic acid. Representative acid addition salts include acetate,adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate,bisulfate, borate, butyrate, camphorate, camphersulfonate, citrate,cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate,fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate,hexanoate, hydrobromide, hydrochloride, hydroiodide,2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, laurylsulfate, malate, maleate, monomaleate, malonate, methanesulfonate,2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate,pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate,pivalate, propionate, stearate, succinate, sulfate, tartrate,thiocyanate, toluenesulfonate, trifluoroacetate, undecanoate, valeratesalts, and the like. Representative alkali or alkaline earth metal saltsinclude sodium, lithium, potassium, calcium, magnesium and the like, aswell as nontoxic ammonium, quaternary ammonium, and amine cations,including, but not limited to ammonium, tetramethylammonium,tetraethylammonium, methylamine, dimethylamine, trimethylamine,triethylamine, ethylamine, and the like.

The term “pharmaceutically acceptable ester,” as used herein, representsesters that hydrolyze in vivo and include those that break down readilyin the human body to leave the parent compound or a salt thereof.Suitable ester groups include, for example, those derived frompharmaceutically acceptable aliphatic carboxylic acids, particularlyalkanoic, alkenoic, cycloalkanoic, and alkanedioic acids, in which eachalkyl or alkenyl group typically has not more than 6 carbon atoms.Examples of particular esters include formates, acetates, propionates,butyates, acrylates, and ethylsuccinates.

In this application enantiomers are designated by the symbols “R” or “S”or are drawn by conventional means with a bolded line defining asubstituent above the plane of the page in three-dimensional space and ahashed or dashed line defining a substituent beneath the plane of theprinted page in three-dimensional space. If no stereochemicaldesignation is made, then the structure definition includes bothstereochemical options. If a structure or chemical name includes “REL”or “rel” then that structure is understood to show relativestereochemistry.

BRIEF SUMMARY OF THE FIGURES

FIG. 1A and FIG. 1B show short-term in vivo suppression of the TLR7pathway in mouse by compounds ER-899742 and ER-899464. Figure Legend:Female BALB/c mice were dosed by oral gavage with Vehicle alone (0.5%aqueous methyl-cellulose) or compound formulated in Vehicle at 33 mg/kg,100 mg/kg or 300 mg/kg. At 6, 13 or 24 hours following oral dosing, micewere injected subcutaneously with 15 ug R848 to stimulate TLR7. Bloodplasma was collected by cardiac puncture, and the IL-6 level at 1.5hours after TLR7 stimulation was then assessed by standard ELISAprocedure. (FIG. 1A). ER-899742 and ER-899464 were tested side by sidein a single experiment. (FIG. 1B) A repeat experiment was done withER-899742 examining all three doses at all three timepoints.

FIG. 2A through FIG. 2C show results of testing ER-899742 in the NZBxNZWstrain (abbreviated hereafter as NZBWF1/J or NZB/W) lupus disease model.Figure Legend: Female NZBWF1/J mice were received at 5 weeks of age,baseline bleeds were performed, and mice were monitored for diseaseprogression by following anti-dsDNA titers. At 27 weeks of age, micewere randomized into groups with equivalent median anti-dsDNA titers andtreated at 29 weeks of age with Vehicle (Veh; 0.5% methyl-cellulose)alone or 33, 100, or 300 mg/kg once-a-day orally (QD PO). At 46 weeks ofage after 17 weeks of treatment mice were bled and tested for anti-dsDNAtiters. All mice were sacrificed at 50 weeks of age (21 weeks ofcompound treatment). (FIG. 2A) Just prior to termination at 50 weeks ofage (following 21 weeks of treatment), urine was collected fromindividual mice, and the Urinary Albumin Creatinine Ratio (UACR,proteinuria) was determined for each animal as an indirect measure ofkidney function. (FIG. 2B) Timecourse of mortality observed in thisstudy for the highest and lowest dose groups. No mortality was seen withcompound treatment. Further, no mortality was observed in the middledose group (not shown). (FIG. 2C) Impact of treatment on anti-dsDNAtiters after 17 weeks of dosing, at 46 weeks of age. No statisticallysignificant effect was observed.

FIG. 3A through FIG. 3E show results of testing compound ER-899742 inthe Pristane: DBA/1 strain lupus disease model. Figure Legend: FemaleDBA/1 mice at 9 weeks of age were given an intraperitoneal injection of0.5 ml pristane or PBS. At 9 weeks post-pristane animals were bled forauto-antibody titers. Once-a-day oral dosing with Vehicle (Veh; 0.5%methyl-cellulose) or 33 mg/kg, 100 mg/kg, or 300 mg/kg of ER-899742 wasbegun 10 weeks after pristane injection and continued for 13 weeks oftreatment. Mice were euthanized after 13 weeks of compound treatment,and anti-dsDNA (FIG. 3A), anti-Sm/nRNP (FIG. 3B), anti-histone (FIG. 3C)and anti-RiboP (FIG. 3D) titers were measured in blood plasma samples byELISA (statistical significance of treatment versus vehicle determinedby ANOVA with Dunnett's post-test). (FIG. 3E) The expression ofIFN-regulated genes in whole blood was measured by a qPCR panel after 13weeks of treatment with 300 mg/kg of ER-899742, and an IFN genesignature score was calculated (see Pharmacology Materials and Methodssection for details regarding IFN score calculation). The table showsthe full list of genes significantly upregulated by pristane treatmentvs. PBS controls. When interferon scores were calculated, no significantdifference was seen between treated and vehicle-treated animals. Howeversix genes were significantly reduced by compound treatment vs. vehicletreatment (Student's t-test) and are marked in the table.

FIG. 4A through FIG. 4C show results of testing ER-899464 in the NZB/Wdisease model in the same experiment as FIG. 2A. Figure Legend: (FIG.4A) Just prior to termination at 50 weeks of age (following 21 weeks oftreatment), urine was collected from individual mice, and the UrinaryAlbumin Creatinine Ratio (UACR, proteinuria) was determined for eachanimal as an indirect measure of kidney function. (FIG. 4B) Summary ofmortality observed in this study for the highest and lowest dose groups.No mortality was seen in the middle dose group (not shown). (FIG. 5C)Impact of treatment on anti-dsDNA titers after 17 weeks of dosing, at 46weeks of age. No statistically significant effect was observed.

FIG. 5A through FIG. 5D show results of testing ER-899464 in thePristane disease model in the same experiment as that shown in FIG. 3Athrough FIG. 3E. Figure Legend: Mice were euthanized after 13 weeks ofcompound treatment, and anti-dsDNA (FIG. 5A), anti-Sm/nRNP (FIG. 5B),anti-histone (FIG. 5C), and anti-RiboP (FIG. 5D) titers were measured inblood plasma samples by ELISA (statistical significance of treatmentversus vehicle determined by ANOVA with Dunnett's post-test). As wasdone for ER-899742, interferon-driven gene expression was tested, butnone of the disease up-regulated genes shown in FIG. 3B were affected bytreatment with ER-899464.

FIG. 6A through FIG. 6GGGG show structures and corresponding chemicalnames according to various embodiments presented herein. “ER-Number” isa reference number assigned to each compound. Where available, activityagainst a HEK cell line stably expressing human TLR7, activity against aHEK cell line stably expressing human TLR9, 1H NMR data, and massspectrometry data are also included.

FIG. 7A through FIG. 7G show the effect of dosing with ER-899742 inPristane-induced disease in DBA/1J mice. Figure Legend: Female DBA/1mice at 9 weeks of age were given an intraperitoneal injection of 0.5 mlpristane or PBS. At 10 weeks post-pristane animals were bled forauto-antibody titers. Once-a-day oral dosing with Vehicle (Veh; 0.5%methyl-cellulose) or 33 mg/kg, or 300 mg/kg of ER-899742 was begun 11weeks after pristane injection and continued for 14 weeks of treatment.Mice were euthanized after 14 weeks of compound treatment, andanti-dsDNA (FIG. 7A), anti-RiboP (FIG. 7B), anti-Sm/nRNP (FIG. 7C), andanti-histone (FIG. 7D) titers were measured in blood plasma samples byELISA (statistical significance of treatment versus vehicle determinedby ANOVA with Dunnett's post-test). The same plasma was used to measuretotal IgG titers by ELISA at the end of dosing (FIG. 7E). Control ofautoantibody against dsDNA and RiboP was seen in the presence of minimalchanges in overall IgG level. Pristane-treated mice in this experimentdeveloped arthritis, with swollen joints in the rear paws. Arthritisscores were assigned according to severity, each paw was scored on ascale of 0-4 based on signs of swelling and inflammation. Scores weresummed for the two hind paws assessed on each animal, and graphed inFIG. 7F with statistical assessment as for ELISA titers above.Dose-dependent statistically significant suppression was observed. Wheninterferon scores were calculated, no significant difference was seenbetween treated and vehicle-treated animals. However FIG. 7Gdemonstrates the downregulation of five out of 28 disease-relatedinterferon-modulated genes upon treatment with ER-899742.

FIG. 8 contains the result of treating for a month with ER-899742 inPristane-induced disease in DBA/1J mice with advanced disease, afterdevelopment of high levels of autoantibody. Figure Legend: DBA/1J micewere injected i.p. with pristane at 10 weeks of age. Three months lateranti-RiboP and anti-dsDNA titers were taken, and animals randomized intogroups with matching mean titers. Groups were sacrificed after one, twoor four weeks of oral dosing with ER-899742, and RiboP titers measuredin serum. FIG. 8 demonstrates no statistically significant reversal ofanti-RiboP or DNA titers after 28 days of dosing, although dosing wasassociated with lack of increase in titers.

FIG. 9 is an ORTEP plot of the crystal structure of ER-899742 as a HClsalt.

DETAILED DESCRIPTION OF THE DISCLOSURE

I. TLRs and Lupus

In addition to their role as innate immune receptors capable ofdetecting exogenous (“non-self”) pathogen-associated molecular patterns(PAMPs—i.e., bacterial LPS detection by TLR4), mammalian Toll-likereceptors (TLRs) are also capable of recognizing endogenous stimuli(DAMPs) released following host tissue damage or stress. Kono, H. and K.L. Rock, How dying cells alert the immune system to danger. Nat RevImmunol, 2008. 8(4): p. 279-89. In the last decade an appreciation forthe link between TLR activation by endogenous (“self”) danger-associatedmolecular patterns (DAMPs) and the etiology of autoimmune disorders hasemerged. Specifically, TLR7 can be activated by single-stranded RNA(ssRNA) derived from both mammalian and viral sources, whereas TLR9 canbe activated by DNA derived from mammalian, viral, and bacterialsources.

Lupus is characterized by auto-antibodies reactive againstdouble-stranded DNA (dsDNA) itself and associated proteins (histones) aswell as against a broad array of RNA-associated proteins such as Ro, La,Smith (Sm), and U1 snRNP. Kirou, K. A., et al., Activation of theinterferon-alpha pathway identifies a subgroup of systemic lupuserythematosus patients with distinct serologic features and activedisease. Arthritis Rheum, 2005. 52(5): p. 1491-503. A second commonhallmark of lupus, which was shown to correlate directly with diseaseseverity, is dysregulated expression of type-1 interferons (IFNs), inparticular IFNα, and the corresponding elevation of a large panel ofIFNalpha-regulated genes in lupus patients' PBMC (the so called “type-1IFN gene signature”). Kirou, K. A., et al., supra. A major source of IFNin the blood is a specialized immunocyte called a plasmacytoid dendriticcell (pDC), which constitutively expresses both TLR7 and TLR9.

A causal relationship between these two disease characteristics,auto-antibodies and IFN levels, was postulated when a number of researchgroups collectively demonstrated that antibody complexes isolated fromlupus patients but not from healthy donors are capable of driving IFNproduction by pDC in a TLR7/9- and RNA/DNA-dependent manner. Means, T.K., et al., Human lupus autoantibody-DNA complexes activate DCs throughcooperation of CD32 and TLR9. J Clin Invest, 2005. 115(2): p. 407-17;Vollmer, J., et al., Immune stimulation mediated by autoantigen bindingsites within small nuclear RNAs involves Toll-like receptors 7 and 8. JExp Med, 2005. 202(11): p. 1575-85; Savarese, E., et al., U1 smallnuclear ribonucleoprotein immune complexes induce type I interferon inplasmacytoid dendritic cells through TLR7. Blood, 2006. 107(8): p.3229-34. Moreover, IFN stimulates increased TLR7/9 expression onB-cells, thereby enhancing TLR/BCR (B-cell receptor) activation ofauto-reactive B-cells to differentiate to antibody-producing plasmacells. Banchereau, J. and V. Pascual, Type I interferon in systemiclupus erythematosus and other autoimmune diseases. Immunity, 2006.25(3): p. 383-92; In this fashion, levels of auto-antibody complexescontaining nucleic acid TLR7/9 ligands drive the pro-inflammatory cycleand lupus disease progression. We believe it is likely thatpharmacological antagonism of TLR7/8 will offer therapeutic benefit tolupus patients by disrupting this pro-inflammatory cycle, decreasing IFNlevels, and dampening the autoimmune disease process mediated by pDC andB-cells.

Several other lines of evidence suggest a role for TLR7 in human lupusetiology and support the notion that TLR receptors are valid targets fordisease intervention. Specific polymorphisms in the 3′ UTR of TLR7 havebeen identified and shown to correlate with both elevated TLR7expression and enhanced IFN gene signature. Shen, N., et al.,Sex-specific association of X-linked Toll-like receptor 7 (TLR7) withmale systemic lupus erythematosus. Proc Natl Acad Sci USA, 2010.107(36): p. 15838-43. Deng, Y. et al., MicroRNA-3148 modulates allelicexpression of toll-like receptor 7 variant associated with systemiclupus erythematosus. PLOS Genetics, 2013. e1003336. In addition, lupusstandard-of-care (SOC) anti-malarial drugs such as chloroquine disruptendosomal TLR7/9 signaling and inhibit PBMC and/or pDC IFNalphaproduction induced by ssRNA-ribonucleoprotein complexes or lupus patientserum. Moreover, myeloid DC and monocytes produce IL-12p40, TNF alpha,and IL-6 following self-RNA/TLR8 signaling, suggesting the additionalcontribution of TLR8-dependent pro-inflammatory cytokines to human lupusetiology in addition to TLR7-driven IFN by pDC. Vollmer, supra; Gorden,K. B., et al., Synthetic TLR agonists reveal functional differencesbetween human TLR7 and TLR8. J Immunol, 2005. 174(3): p. 1259-68.

Mouse model evidence also exists for the role of TLR in lupus. Publishedstudies have collectively demonstrated that both single TLR7 or dualTLR7/9 gene deletion or dual TLR7/9 pharmacologic inhibition reducesdisease severity in four distinct lupus models. Nickerson, K. M., etal., TLR9 regulates TLR7-and MyD88-dependent autoantibody production anddisease in a murine model of lupus. J Immunol, 2010. 184(4): p. 1840-8;Fairhurst, A. M., et al., Yaa autoimmune phenotypes are conferred byoverexpression of TLR7. Eur J Immunol, 2008. 38(7): p. 1971-8; Deane, J.A., et al., Control of toll-like receptor 7 expression is essential torestrict autoimmunity and dendritic cell proliferation. Immunity, 2007.27(5): p. 801-10; Savarese, E., et al., Requirement of Toll-likereceptor 7 for pristane-induced production of autoantibodies anddevelopment of murine lupus nephritis. Arthritis Rheum, 2008. 58(4): p.1107-15. Highlighting the role of TLR7 as a critical determinant ofautoimmunity, transgenic overexpression of TLR7 alone leads tospontaneous anti-RNA auto-reactivity and nephritis in the normallydisease-resistant C57BL/6 strain. Deane, supra.

From a safety perspective, there are no reports that TLR7, 8, or9-single or 7/8- and 7/9-dual gene deficient mice are immune-compromisedto the extent that infection by opportunistic pathogens is observed.Likewise, SOC anti-malarials are thought to be largely safe andeffective for long-term use in humans to control lupus disease flare atdoses predicted to at least partially inhibit TLR7/9 signaling.Lafyatis, R., M. York, and A. Marshak-Rothstein, Antimalarial agents:closing the gate on Toll-like receptors? Arthritis Rheum, 2006. 54(10):p. 3068-70; Costedoat-Chalumeau, N., et al., Low blood concentration ofhydroxychloroquine is a marker for and predictor of diseaseexacerbations in patients with systemic lupus erythematosus. ArthritisRheum, 2006. 54(10): p. 3284-90. In fact, save for increasedsusceptibility to Gram-positive bacterial infections in childhood and toa lesser extent in adulthood, humans with highly compromised TLR andIL-1R signaling pathways (MyD88- or IRAK-4-deficiency) are nonethelesshealthy and maintain sufficient host defense mechanisms. Casanova, J.L., L. Abel, and L. Quintana-Murci, Human TLRs and IL-1Rs in HostDefense: Natural Insights from Evolutionary, Epidemiological, andClinical Genetics. Annu Rev Immunol, 2010.

Based on this and other information, we believe that TLR7 in particularis a well-validated target in the context of mouse pre-clinical SLEmodels. Both genetic and functional human studies support the hypothesisthat antagonism of the TLR7 and/or TLR8 pathways will afford therapeuticbenefit to lupus patients. Moreover, both mouse TLR gene deletionstudies and the long-term use of anti-malarials in humans suggest thatpharmacological TLR7, 8 and/or 9 suppression can be undertaken withoutsignificantly compromising host defense.

A compound that suppresses TLR7, TLR8, or both TLR7 and TLR8 maytherefore be expected to act as a therapeutic or prophylactic agent forSLE or lupus nephritis.

The present inventors have found compounds that suppress TLR 7 and/or 8and are therefore expected to have a prophylactic or therapeutic effecton SLE or lupus nephritis. Compounds and methods of the disclosure aredescribed herein.

II. Therapeutic Use

Dosage levels of active ingredients in the pharmaceutical compositionsof the disclosure may be varied to obtain an amount of the activecompound(s) that achieves the desired therapeutic response for aparticular patient, composition, and mode of administration. Theselected dosage level depends upon the activity of the particularcompound, the route of administration, the severity of the conditionbeing treated, and the condition and prior medical history of thepatient being treated. Doses are determined for each particular caseusing standard methods in accordance with factors unique to the patient,including age, weight, general state of health, and other factors thatcan influence the efficacy of the compound(s) of the disclosure. Ingeneral, in the case of oral administration, the compound according tothe present disclosure or a pharmaceutically acceptable salt thereof isadministered at a dose of approximately 30 μg to 100 μg, a dose of 30 μgto 500 μg, a dose of 30 μg to 10 g, a dose of 100 μg to 5 g, or a doseof 100 μg to 1 g per adult per day. In the case of administration viainjection, it is administered at a dose of approximately 30 μg to 1 g, adose of 100 μg to 500 mg, or a dose of 100 μg to 300 mg per adult perday. In both cases, a dose is administered once or divided over severaladministrations. Dosage may be simulated, for example, using the Simcyp®program.

It is not intended that the administration of a compound of thedisclosure to a mammal, including humans, be limited to a particularmode of administration, dosage, or frequency of dosing. The presentdisclosure contemplates all modes of administration, including oral,intraperitoneal, intramuscular, intravenous, intraarticular,intralesional, subcutaneous, or any other route sufficient to provide adose adequate to prevent or treat SLE or lupus nephritis. One or morecompounds of the disclosure may be administered to a mammal in a singledose or multiple doses. When multiple doses are administered, the dosesmay be separated from one another by, for example, several hours, oneday, one week, one month, or one year. It is to be understood that, forany particular subject, specific dosage regimes should be adjusted overtime according to the individual need and the professional judgment ofthe person administering or supervising the administration of apharmaceutical composition that includes a compound of the disclosure.

For clinical applications, a compound of the present disclosure maygenerally be administered intravenously, subcutaneously,intramuscularly, colonically, nasally, intraperitoneally, rectally,buccally, or orally. Compositions containing at least one compound ofthe disclosure that is suitable for use in human or veterinary medicinemay be presented in forms permitting administration by a suitable route.These compositions may be prepared according to the customary methods,using one or more pharmaceutically acceptable adjuvants or excipients.The adjuvants comprise, inter alia, diluents, sterile aqueous media, andvarious non-toxic organic solvents. Acceptable carriers or diluents fortherapeutic use are well known in the pharmaceutical field, and aredescribed, for example, in Remington: The Science and Practice ofPharmacy (20th ed.), ed. A. R. Gennaro, Lippincott Williams & Wilkins,2000, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds.J. Swarbrick and J. C. Boylan, 1988, 1999, Marcel Dekker, New York. Thecompositions may be presented in the form of tablets, pills, granules,powders, aqueous solutions or suspensions, injectable solutions,elixirs, or syrups, and the compositions may optionally contain one ormore agents chosen from the group comprising sweeteners, flavorings,colorings, and stabilizers to obtain pharmaceutically acceptablepreparations.

The choice of vehicle and the content of active substance in the vehicleare generally determined in accordance with the solubility and chemicalproperties of the product, the particular mode of administration, andthe provisions to be observed in pharmaceutical practice. For example,excipients such as lactose, sodium citrate, calcium carbonate, anddicalcium phosphate and disintegrating agents such as starch, alginicacids, and certain complex silicates combined with lubricants (e.g.,magnesium stearate, sodium lauryl sulfate, and talc) may be used forpreparing tablets. To prepare a capsule, it is advantageous to uselactose and high molecular weight polyethylene glycols. When aqueoussuspensions are used, they may contain emulsifying agents thatfacilitate suspension. Diluents such as sucrose, ethanol, polyethyleneglycol, propylene glycol, glycerol, chloroform, or mixtures thereof mayalso be used.

For parenteral administration, emulsions, suspensions, or solutions ofthe compositions of the disclosure in vegetable oil (e.g., sesame oil,groundnut oil, or olive oil), aqueous-organic solutions (e.g., water andpropylene glycol), injectable organic esters (e.g., ethyl oleate), orsterile aqueous solutions of the pharmaceutically acceptable salts areused. The solutions of the salts of the compositions of the disclosureare especially useful for administration by intramuscular orsubcutaneous injection. Aqueous solutions that include solutions of thesalts in pure distilled water may be used for intravenous administrationwith the proviso that (i) their pH is adjusted suitably, (ii) they areappropriately buffered and rendered isotonic with a sufficient quantityof glucose or sodium chloride, and (iii) they are sterilized by heating,irradiation, or microfiltration. Suitable compositions containing acompound of the disclosure may be dissolved or suspended in a suitablecarrier for use in a nebulizer or a suspension or solution aerosol, ormay be absorbed or adsorbed onto a suitable solid carrier for use in adry powder inhaler. Solid compositions for rectal administration includesuppositories formulated in accordance with known methods and containingat least one compound of the disclosure.

Dosage formulations of a compound of the disclosure to be used fortherapeutic administration should be sterile. Sterility is readilyaccomplished by filtration through sterile membranes (e.g., 0.2 micronmembranes) or by other conventional methods. Formulations typically arestored in lyophilized form or as an aqueous solution. The pH of thecompositions of this disclosure in some embodiments, for example, may bebetween 3 and 11, may be between 5 and 9, or may be between 7 and 8,inclusive.

While one route of administration is by oral dosage administration,other methods of administration may be used. For example, compositionsmay be administered subcutaneously, intravenously, intramuscularly,colonically, rectally, nasally, or intraperitoneally in a variety ofdosage forms such as suppositories, implanted pellets or smallcylinders, aerosols, oral dosage formulations, and topical formulationssuch as ointments, drops, and dermal patches. Compounds of embodimentsof the disclosure may be incorporated into shaped articles such asimplants, including but not limited to valves, stents, tubing, andprostheses, which may employ inert materials such as synthetic polymersor silicones, (e.g., Silastic® compositions, silicone rubber, or othercommercially available polymers). Such polymers can includepolyvinylpyrrolidone, pyran copolymer,polyhydroxy-propyl-methacrylamide-phenol,polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysinesubstituted with palmitoyl residues. Furthermore, a compound of thedisclosure may be coupled to a class of biodegradable polymers useful inachieving controlled release of a drug, for example polylactic acid,polyglycolic acid, copolymers of polylactic and polyglycolic acid,polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters,polyacetals, polydihydropyrans, polycyanoacrylates, and cross linked oramphipathic block copolymers of hydrogels.

A compound of the disclosure may also be administered in the form ofliposome delivery systems, such as small unilamellar vesicles, largeunilamellar vesicles, and multilamellar vesicles. Liposomes can beformed from a variety of lipids, such as cholesterol, stearylamine, orphosphatidylcholines. A compound of the disclosure may also be deliveredusing antibodies, antibody fragments, growth factors, hormones, or othertargeting moieties to which the compound molecules are coupled (e.g.,see Remington: The Science and Practice of Pharmacy, vide supra),including in vivo conjugation to blood components of a compound of anembodiment of the disclosure.

III. Synthesis

General and specific synthesis routes are provided that we found usefulfor preparation of embodiments of the disclosure. Those skilled in theart may recognize that certain variations or modifications of theseprocedures could also lead to synthesis of compounds according to thedisclosure. In some situations the phrase “such as” is used to enumeratevarious alternatives for more generic compounds or structures. It willbe understood that “such as” should not be construed to be limiting, andthat its meaning is in accord with “including, for example, but notlimited to.”

Certain conditions were common to specific examples presented below.Microwave heating was done using a Biotage® Emrys Liberator or Initiatormicrowave reactor. Column chromatography was carried out using Biotage®SP4 flash chromatography system. Solvent removal was carried out usingeither a Büchii rotary evaporator or a Genevac® centrifugal evaporator.NMR spectra were recorded at 400 MHz on a Varian Unity® spectrometerusing deuterated solvents. Chemical shifts are reported relative toresidual protonated solvent.

Thin layer chromatography was performed on Whatman® glass platesprecoated with a 0.25 mm layer of silica gel using various ratios of oneor more of the following solvents: EtOAc, heptane, dichloromethane orMeOH.

Analytical LC/MS was performed for many examples on a Waters Acquity™system using an XBridge™ C18 1.7 μm 2.1×50 mm column. Solvents A and Bare Water w/0.1% formic acid and Acetonitrile w/0.1% formic acid,respectively. 5 minute total method time with 5% B to 99% B over 4minutes with a flow rate of 0.3 ml/min. Mass spectral data were acquiredon a Waters SQD from 100-2000 amu in electrospray positive mode.

Alternatively, purity and mass confirmation were carried out on a WatersAutopurification system using an XBridge™ C8 3.5 μm 4.6×50 mm column.Solvents A and B are water w/0.1% formic acid and acetonitrile w/0.1%formic acid, respectively. 6 minute total method time with 10% B to 95%B over 5 minutes with a flow rate of 2.5 ml/min. Mass spectral data wereacquired on a Micromass ZQ™ from 130-1000 amu in electrospray positivemode.

Preparative reverse phase LC/MS was carried out for many examples on aWaters Autopurification system using an XBridge™ C8 5 μm, 19×100 mmcolumn. Solvents A and B are water w/0.1% formic acid and Acetonitrilew/0.1% formic acid, respectively. 12 minute total method time with 30% Bto 95% B over 10 minutes with a flow rate of 20 ml/min. Mass spectraldata were acquired on a Micromass ZQ™ from 130-1000 amu in electrospraypositive mode.

Preparative HPLC resolution of racemic compounds was carried out formany examples using one of the following chiral columns: Chiralpak® IA(5 cm×50 cm or 2 cm×25 cm), Chiralpak® AD (2 cm×25 cm) or Chiralcel® OD(2 cm×25 cm). Enantiomer ratios of purified compounds were determined byHPLC analysis on a 0.45 cm×25 cm column comprised of the same stationaryphase (IA, AD or OD).

General methods and experimentals for preparing compounds of the presentdisclosure are set forth below. In certain cases, a particular compoundis described by way of example. However, it will be appreciated that ineach case a series of compounds of the present disclosure were preparedin accordance with the schemes and experimentals described below. Forthose compounds where NMR and/or mass spectrometry data are available,the data is presented in FIG. 6.

The following abbreviations are used herein:

Definitions: The following abbreviations have the indicated meanings:

AcOH: acetic acid

anhyd: anhydrous

aq.: aqueous

Bn: benzyl

Boc: tert-butoxycabonyl

CSA: Camphor sulfonic acid

d: day(s)

DAMP: Danger-Associated Molecular Pattern

DBU: 1,8-Diazobicyclo[5.4.0]undec-7-ene

DCE: 1,2-dichloroethane

DCM: dichloromethane

DIPEA: N,N-diisopropylethylamine

DMA: N,N-Dimethylacetamide

DMAP: 4-Dimethylaminopyridine

DMF: N,N-dimethylformamide

DMSO: Dimethyl sulfoxide

dsDNA: double-stranded DNA

EDC: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

ee: enantiomeric excess

EtOAc: ethyl acetate

EtOH: ethanol

h: hour(s)

HATU: N,N,N,N′-Tetramethyl-O-(7-azabenzotriazol-1-yl)uroniumhexafluorophosphate

HCl: hydrochloric acid

HCQ: hydroxychloroquine

hep: n-heptane

HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

HPLC: high performance liquid chromatography

IFN: interferon

IPA: isopropyl alcohol or isopropanol

K₂CO₃: potassium carbonate

MeOH: methanol

MgSO₄: magnesium sulfate (anhydrous)

min: minute(s)

MTBE: methyl tert-butyl ether

Na₂CO₃: sodium carbonate

Na₂SO₄: sodium sulfate (anhydrous)

NaBH₄: sodium borohydride

NaCl: sodium chloride

NaH: 60% sodium hydride dispersed in oil

NaHCO3: sodium bicarbonate

NaOH: sodium hydroxide

NBS: N-bromosuccinimide

NH₄Cl: ammonium chloride

NH₄OH: ammonium hydroxide

NMP: N-methylpyrrolidone

Ns: Nosyl or o-nitrobenzenesulfonyl

° C.: degrees Celsius

PAMP: Pathogen-Associated Molecular Pattern

PBMC: peripheral blood mononuclear cell

PBS: phosphate buffered saline

pDC: plasmacytoid dendritic cell

PhNTf₂: N-phenyltrifluoromethanesulfonimide

qPCR: quantitative polymerase chain reaction

R848: resiquimod

rt: room temperature

sat: saturated

SNAP: BIOTAGE® brand flash chromatography cartridge

SOC: standard-of-care

ssRNA: single-stranded RNA

T3P: Propylphosphonic anhydride

tBuOK: potassium tert-butyloxide

TEA: triethylamine

TEMPO: 2,2,6,6-Tetramethylpiperidine 1-oxyl

Tf: trifluoromethanesulfonate

TFA: trifluoroacetic acid

THF: tetrahydrofuran

TLDA: Taqman® Low Density Array

TLR: Toll-like receptor

TSA: p-toluenesulfonic acid

General Synthetic Methods:

Compounds were made according to the general synthetic methods shown inSchemes 1-31:

The preparation of several of the examples use key intermediate 3, whichis can be prepared according to the route depicted in Scheme 1. Thecommercially available 5-bromoquinoline-8-carbaldehyde 1 (Frédérieric deMontigny, Gilles Argouarch, Claude Lapinte, “New Route to Unsymmetrical9,10-Disubstituted Ethynylanthracene Derivatives,” Synthesis, 2006,293-298.) is treated with hydroxylamine hydrochloride to provide theoxime 2. 2 is subsequently converted to the corresponding nitrile 3 inthe presence of catalytic amount of copper acetate to provide one of thekey intermediates reported herein. Intermediate 3 is used for thegeneration of compounds reported herein by the displacement of the5-position of 5-bromoquinoline-8-carbaldehyde with appropriate aromatic,heteroaromatic and saturated heterocyclic compounds such as piperidines,piperazines and morpholines using appropriate conditions described indetail below.

An alternative method for the generation of the key intermediate 3 isshown in Scheme 2 wherein triethylamine for the first step of thesynthesis is replaced with sodium acetate.

Several examples are produced by the general condensation process asdepicted in Scheme 3, wherein bromoquinoline 3 is condensed with theappropriate nucleophile 4 to form 5 which may be either a keyintermediate or a final compound described in more detailed below.

A number of the examples represented by compound 15 were prepared fromthe advanced intermediate 14 as depicted in the general method shown inScheme 4. An appropriately protected chiral epoxide 6 is condensed withallyl amine to provide the chiral aminoalcohol 7. After protection ofthe secondary amine with a nesylate the resultant intermediate 8 isintermolecularly cyclized to form the unsaturated pyran 9. Reduction ofthe enamine double bond to form 10 was followed by deprotection of thenesyl group to provide 9. Condensation of 11 with the bromide 3 (Scheme1 or 2) with or without the use of a palladium catalyst provides 12,after which deprotection of 13 followed by activation of the resultingalcohol provides the key intermediate 14. Activated 14 can be easilytransformed to a number of the examples provided below by the use of theappropriately substituted amine and condensation reagents to providecompounds of general structure 15.

An alternative method for the preparation of general structure 10 isdepicted in Scheme 5. Radical cyclization of the protected alcohol 8 canbe obtain by treatment with N-bromosuccinimide to provide 16.Elimination of the bromo-group using base provides the enol 17, which isthen reduced with a silane to provide intermediate 10.

An alternative method for the preparation of general structure 11 isdepicted in Scheme 6. Starting with the chiral epoxy starting material6, one forms the alcohol 18 after protection of the secondary amine witha Boc-protecting group. Lactonation using water soluble DCC provides 19which then can be subjected to alkylation using an alkyl lithium, suchas methyl lithium to form a mixture of ketals, 20 and 21. The ketalmixture is subsequently reduced to form a diastereomeric mixture ofmorpholine compounds 22 (being the desired diastereomer isomer) and 23which can be easily separated by silica gel column chromatography. Theratio of the methyl morpholine mixture was found to be from 4:1 to 9:1in favor of structure 22. X-ray crystal structures were obtained ofsubsequent, advanced compounds to confirm the absolute stereochemistryof compound 22. Compound 22 is easily converted to 11 by deprotectionwith acid such as TFA followed by neutralization with a base.

A third method for the preparation of key intermediate 11 is shown inScheme 7. The commercially available protected epoxide 6 is condensedwith aqueous ammonia to provide the amino alcohol 23 which in turn iscondensed with the chiral chloropropinate 24 to form theenantiomerically pure amide 25. Ether formation using a strong base suchas sodium hydride provides lactam 26, which can be converted tointermediate 11 by amide reduction to the cyclic amine.

An alternative method for the production of examples encompassed in thegeneric structure 5 in Scheme 3 and compound 12 in Scheme 4 isillustrated in Scheme 8. The starting materials 28 and 30, prepared fromcommercially available sources (27 & 29), can be easily condensed in thepresence of an inorganic base to form 31. The phenolic protecting groupis removed via reductive hydrolysis to form 32, the acetal protectinggroup is hydrolized with acid to form the aldehyde 33, and thenformation of the bicyclic heterocycle 34 under catalytic acidic,condensation conditions. The phenolic hydroxyl group on 34 is thenactivated to form 35, which subsequently can be condensed with 11 toform 12 as shown in Scheme 4. Compound 11 can be replaced by othernucleophiles as shown in the examples below.

Two alternative methods for the preparation of compounds with generalstructure 15 use the processes depicted in Scheme 9 and 10. Intermediate13 is activated by forming the triflate 36 followed by displacement withthe appropriate amine in the presence of base such as potassiumcarbonate to form the desired target compound 15 as depicted in Scheme9.

Starting with the Boc-protected chiral morpholine 22 from Scheme 6, onefamiliar in the art is able to produce additional examples of compoundswith general structure 15 by the conversion of the protected alcohol tothe azide intermediate 37 as shown in Scheme 10. 37 is easily convertedto the primary amine ER-884884 after reduction of the azide,deprotection of the Boc-group, and condensation with 3. ER-884884likewise can be converted to additional analogs depicted by generalstructure 15 by either alkylation or acylation processes.

Preparation of alternative set of compound examples is by oxidation ofthe key intermediate 13 to form 38 followed by formation of the examplesvia amide coupling conditions to form 39 as shown in Scheme 11. Thepreparation of some of the examples using this general method willrequire one or two additional steps to provide the desired targetcompounds of general structure 40. Likewise various esters depicted bygeneral structure 41 can be easily produced from 38 using variousmethods by those persons familiar with the art.

Likewise, ether examples are prepared by two possible methods: (1) thedisplacement of activated group on an alkyl, alkenyl or aryl functionalgroup using base and compound 11 from Scheme 4; or using the activatedalcohol 14 or 36 with phenols or alkyl alcohols in the presences of anappropriate base. Both methods to provide examples with the generalchemical structure 42 are shown in Scheme 12.

Key intermediate 13 may also be oxidized to form an aldehyde 43 followedby condensation with various alkyl and aryl coupling reagents to provideexamples 44 or 46 as depicted in Scheme 13. The resultant products canthen be transformed to additional examples by either oxidation of 44 toprovide compounds of general structure 45 or reduction of 46 to providecompounds of general structure 47 where n=2. Likewise persons familiarwith the art may generate the additional examples from intermediate 44by activation of the hydroxyl group such as forming the triflatefollowed by reduction using several possible reducing reagents toprovide examples that contains one less methylene group or 47 where n=1.

A final set of examples are prepared by the use of Scheme 14. Using thesame synthetic methodology to prepare compound 13 in Scheme 4, one canprepare the desired seven-membered heterocycle 68 replacing allyl aminewith 1-amino-3-butente 62. 68 can then be activated and then condensedwith various substituted amines to generate additional analogs in asimilar manner as shown in several the schemes depicted above.

Preparation of Examples

Compound 3—Scheme 1

To a suspension of 5-bromoquinoline-8-carbaldehyde 1 (1.00 g, 4.24 mmol)and hydroxylamine hydrochloride (1.177 g, 16.94 mmol) in acetonitrile(110 mL) was added TEA (2.362 mL, 16.94 mmol) followed by heating toreflux for 3 h to afford a yellow suspension. The completed reactioncompletion was cooled to rt, the precipitate was filtered, and thefilter cake rinsed with acetonitrile (50 mL). The crude solid waspurified over a short pad of silica gel (10 g) eluting with EtOAc (300mL) providing the aldoxime 2 as a yellow solid.

Aldoxime 2 (1.001 g, 4.0 mmol) and copper (II) acetate monohydrate (84.6mg, 0.424 mmol) in anhydrous acetonitrile (180 mL) were stirred atreflux for 12 h. The completed reaction was cooled to rt, filtered andthe filter pad washed with H₂O to afford a brown solid. The crude solidwas purified over a short pad of silica gel (ca. 10 g) eluting with (DCM100 mL) to provide 5-bromoquinoline-8-carbonitrile, 3 (0.783 g, 3.4mmol, 79.3% yield over 2 steps) as a white-beige solid afterconcentration and drying in vacuo the eluted product. See: Frédériericde Montigny, Gilles Argouarch, Claude Lapinte, Synthesis, 2006, 293.

Compound 3—scheme 2

To a stirred solution of sodium acetate trihydrate (31.6 g, 0.232 mol)in EtOH (0.498 L) at 15° C. was added 5-bromoquinoline-8-carbaldehyde(49.84 g, 0.211 mol) followed by hydroxylamine hydrochloride (15.55 g,0.223 mol). The resultant mixture was heated to 70° C. for 3 h afterwhich time the reaction was cooled to 35° C. and then diluted with water(250 mL). The mixture was partially concentrated to approximately 250 mLafter which time water (250 mL), 2-methoxy-2-methylpropane (120 mL), andheptane (120 mL) were added followed by re-concentrated the mixture toapproximately 250 mL. The resultant slurry was diluted with water (250mL) and cooled to 0° C. after which time 1 M NaOH in water (211 mL) wasadded and the final mixture was stirred vigorously for 10 min. Thesuspension was filtered, rinsed with water (498 mL) and the filter cakedried at 30° C. for 18 h to afford aldoxime 2 (49.75 g, 0.198 mol, 93.9%yield) as tan powder.

To a stirred suspension of 2 (48.21 g, 0.192 mol) in acetonitrile (386mL) at 15° C. was added copper (II) acetate (0.523 g, 2.9 mmol) followedby acetic acid (13.1 mL, 0.229 mol). The resultant mixture was heated toreflux for 21 h after which time the completed reaction was cooled to50° C. Water (0.39 L) was added and the mixture was partiallyconcentrated followed by dilution with water (290 mL) and cooled to 5°C. 1 M NaOH in water (230 mL) was added and vigorous stirring wascontinued for 10 min. The suspension was filtered, the filter cakerinsed with water (500 mL) and dried to afford compound 3 (42.80 g,0.183 mol, 95.6% yield) as dark gray powder.

synthesis of ER-878952—scheme 3 & 15(Method 1)

3 (200.2 mg, 0.86 mmol) in NMP (1 mL) and commercially available cis-2,6dimethylmorpholine 69 (133.4 mg, 1.16 mmol—as a representative ofcompound 4 in Scheme 3) was microwaved at 150° C. for 1 h. The completedreaction was filtered and divided into several vials, diluted with NMPand purified by HPLC (C18 column, gradient 10/90-95/5 acetonitrile/waterwith 0.1% TFA, 15 min run, t=8.5-9 min) to yield ER-878952 (180 mg. 0.68mmol, 79.1% yield) after concentration and drying in vacuo the desiredcombined fractions.

ER-880369 (8.2 mg, 0.031 mmol, 48.4% yield) was produced in a similarmanner to ER-878952 using 3 (15 mg, 0.064 mmol) and 2-ethylmorpholine(22.2 mg, 0.191 mmol). The separation of the enantiomers was notperformed.

ER-885618 (385.2 mg, 1.032 mmol, 60.7% yield) was produced in a similarmanner to ER-878952 using 3 (400 mg, 1.716 mmol) and 11 (398.1 mg, 1.799mmol) from Scheme 4.

synthesis of compound ER-878952(Method 2, Scheme 3 & 15)

To a stirred suspension of Compound 3 (12.00 g, 0.0515 mol) in NMP (30.0mL) was added 69 (14.8 g, 0.129 mol) followed by heating at 120° C. for4 h. The completed reaction was cooled to 50° C., diluted with IPA (30mL), heptane (60 mL) and then further cooled to 0° C. After 30 min, theprecipitates were collected by filtration, rinsed with pre-chilled (at0° C.) IPA (18.0 mL)/heptane (36 mL) mixture and dried under N₂/vacuumfor 2 h to afford ER-878952 (11.00 g) as a yellow powdered. The filtratewas concentrated, partitioned between EtOAc (120 mL) and saturatedaqueous NaHCO₃ (60 mL). The organic layer was separated, washed withwater (60 mL) and passed through pre-conditioned (heptane-EtOAc 1:1)silica gel, eluted with EtOAc (120 mL) then concentrated. Brownish solidthus obtained was suspended in EtOAc (10 mL) heptane (10 mL) and heatedto 70° C. and then allowed to cool down to 20° C. Precipitates werecollected by filtration, rinsed with a mixture of EtOAc (5.0 mL) andheptane (5.0 mL), then dried under N₂/vacuum for 1 h, affording theadditional ER-878952 (0.649 g) as yellow powder. Overall the processprovided ER-878952 (11.64 g, 43.6 mmol, 89.6% yield).

ER-879484(Method 3, Scheme 3 and 16 )

To a stirred solution of 3 (15 mg, 64.4 mmol) and4-benzyl-2-(chloromethyl)morpholine, 70 (43.6 mg (0.193 mmol) in DMF(0.5 mL) was added TEA (0.27 uL, 0.194 mmol). The reaction mixture wasmicrowaved at 160° C. for 1 h after which time the completed reactionwas directly purified over a C-18 reverse phase preparative HPLC column(Water's X-Bridge C18 19×100 mm column; eluting with 0-40% gradient ofacetonitrile in water with 0.05% TFA). The fractions containing thedesired product were combined, concentrated and dried in vacuo toprovide ER-879484 (4.2 mg, 0.015 mmol, 22.7% yield). The enantiomers ofER-879484 (3.0 mg, 0.010 mmol) were separated using a chiral HPLC columnto providing ER-879569 (1.0 mg, 0.004 mmol) and ER-879570 (1.0 mg, 0.004mmol) after concentration the desired fractions and drying in vacuo. Theabsolute stereochemistry is unknown, but arbitrarily assigned.

ER-879739 (12 mg, 0.047 mmol, 73.6% yield) was produced in a similarmanner to ER-879484 starting using 3 (15 mg, 0.064 mmol) and2-methylmorpholine (19.5 mg, 0.195 mmol). Separation of the enantiomerswas not performed.

ER-880191 (9.5 mg, 0.036 mmol, 23.7% yield) was produced in a similarmanner to ER-879484 starting using 3 (35 mg, 0.150 mmol) and(2S,6S)-2,6-dimethylmorpholine (741 mg, 6.434 mmol). The cis-isomerER-878952 (15.2 mg, 0.057 mmol, 37.9% yield) was also isolated. TEA wasnot used in this preparation.

Additional Examples derived from ER-878952:

ER-885160: ER-878952 (85.6 mg, 0.320 mmol) was dissolved in1,2-ethanediol (1 mL) followed by the addition of potassium hydroxide(60 mg, 1.069 mmol). The reaction mixture was microwaved at 120° C. for10 h after which time, it was filtered then directly injected onto aC-18 reverse-phase preparative HPLC for purification (Water's X-BridgeC18 19×100 mm column, eluting with 10-100% acetonitrile in water with0.05% TFA). The desired fractions were concentrated to dry, dissolved inMeOH (3 mL) and eluted over a carbonate impregnated silica gel column(Biotage Isolute SPE, Si—CO₃, 1 g), washed with MeOH (3 mL),concentrated and dried in vacuo to provide ER-885160 (56.2 mg, 0.197mmol, 61.6% yield).

Preparation of Compound ER-890963 as an Example of Compound 15, Scheme 4

Compound 7: A 22 L reactor was charged with (2R)-benzyl 2-epoxypropylether (0.7692 kg, 4.684 mol) T-internal 18-19C. Allylamine (3800 mL, 51mol) was added at 18-19° C. and resultant mixture was heated to 50° C.After 20 h, the mixture was concentrated, azeotroped with MTBE (4 L×3)to give (R)-1-(allylamino)-3-(benzyloxy)propan-2-ol, 7 (ca. 1037 g,4.684 mol, 100% yield assumed) as colorless oil.

Compound 8: To a stirred suspension of sodium bicarbonate (1180 g, 14.0mol) in water (7.2 L) at 10-11° C. was added a solution ofo-nitrobenzenesulfonyl chloride (1038 g, 4.684 mol) in DCM (3100 mL)followed by warming the resultant biphasic mixture to 20° C. A solutionof 7 (ca. 1037 g, 4.684 mol assumed) in DCM (4100 mL) was added over 3 hwhile maintaining-T-internal between 20-23° C. and vigorous stirring wascontinued overnight. The mixture was diluted with water (4100 mL) withstifling followed by separation of the layers. The aqueous layer wasextracted with MTBE (4100 mL). The combined organic layers were dilutedwith n-heptane (4100 mL), sequentially washed with 1.0 M HCl (4700 mL),saturated NaHCO₃ (2.0 kg), water (4100 mL), concentrated, and azeotropedwith MTBE (5200 mL×3) to dry to provide(R)—N-allyl-N-(3-(benzyloxy)-2-hydroxypropyl)-2-nitrobenzenesulfonamide,8 (1.855 kg, 4.56 mol, 97% yield) as brownish green oil after drying for3 days in vacuo.

Compound 9: A stirred suspension of 8 (1.80 kg, 4.429 mol) in DMA (5.40L) was heated to 40° C. to achieve complete dissolution, then cooleddown to 25° C. after which time the mixture was added to a separatereactor was containing Cu(II) acetate (0.145 kg, 0.797 mol) followed byrinsing the original vessel with DMA (5.40 L). Palladium(II) chloride(0.063 kg, 0.354 mol) was added followed by was replacing internalatmosphere with oxygen (1 bar) and warming up 28-32° C. for 3 days. Thecompleted reaction mixture was split into equal 2 portions to facilitatework-up. Each portion was separately poured into a mixture of 0.1 M HCl(23 L) and MTBE (9.0 L) while controlling T-internal <25° C. The layerswere separated and the aqueous layer was extracted with MTBE (9.0 L &5.4 L). All organic layers were combined, sequentially washed with 0.1 MHCl (5.5 L), 8% NaHCO₃ (5.9 kg), 29% NaCl (6.3 kg). Celite 545 (270 g)was added to the organic layer, stirred for 30 min, filtered, and filtercake were rinsed with MTBE (2.7 L). All filtrates were combined andconcentrated. The reddish oil was re-dissolved in DCM (3.6 L) andtreated with 1,3,5-triazinane-2,4,6-trithione (79 g kg, 0.44 mol) at 25°C. for 1 h. The mixture was diluted with MTBE (18 L) and filteredthrough Celite 545 (270 g). The reactor and filter cake were rinsed withMTBE (3.6 L) and combined filtrate was concentrated to give(R)-2-((benzyloxy)methyl)-6-methyl-4-((2-nitrophenyl)sulfonyl)-3,4-dihydro-2H-1,4-oxazine,9 (1748 g, 4.322 mol, 97.6% yield) as yellow oil.

Compound 10: To a stirred suspension of 9 (1748 g, 4.322 mol) in DCM(3.5 L) was heated to 33-35° C. until a free-flowing suspension wasobtained after which time the mixture was cooled to 18-20° C. A separatereactor TFA (1.67 L, 21.6 mol) in DCM (2.62 L) was cooled to 5° C. withstirring after which time triethylsilane (1.04 L, 6.48 mol) was addedmaintaining the temperature at 5-6° C. followed by cooling to −5° C. Thesuspension of 9 in DCM was slowly added to the main reactor over 1.5 hwhile maintaining the temperature between −5 and −3° C. followed bystirring for 4 h continuing at −5 to −3° C. The completed reaction wasdiluted with pre-chilled n-heptane (8.74 L at −10° C.) then poured intopre-chilled NaOH solution (NaOH: 890 g, 22.3 mol in water: 8.7 L at 5°C.) while controlling T-internal <15° C. (over 1 h) followed by rinsingthe reactor rinsed with MTBE (3.5 L). The mixture was diluted with MTBE(5.2 L) and the layers separated. The organic layer was sequentiallywashed with: water (8.7 L), 30 wt % NaCl (3.5 kg) in water, water (5.2L), treated with Celite 545 (175 g) and filtered. The work-up vessel andfilter cake were rinsed with MTBE (1.75 L) and the combined filtrateswere concentrated under vacuum to approx. 3.5 L, azeotroped withn-heptane (8.7 L) and concentrated to approx. 5 L. The tan precipitateswere collected by filtration, rinsed with n-heptane (3.5 L) and driedunder N₂/vacuum for 1 h. 1.65 kg of the resultant solid was combinedwith 353 g solid obtained from a separate batch and suspended inn-heptane/EtOAc 1:1 (8.0 L). The mixture was heated to 61-63° C. toachieve complete dissolution, cooled down to 23-25° C. over 1 h, dilutedwith heptane (4 L) and further cooled down to 10-12° C. over 30 min.Stirring was continued at this temperature for 30 min. Light tanprecipitates were collected by filtration, rinsed with n-heptane/EtOAc6:1 (2 L) and then n-heptane (4 L) followed by drying under N₂/vacuumovernight, and then vacuum oven dried at 35° C. for 2 d to give(2R,6R)-2-((benzyloxy)methyl)-6-methyl-4-((2-nitrophenyl)sulfonyl)morpholine,10 (1616 g, 3.98 mol, 74% yield in 2 steps from 8) as a tan solid.

The minor product:(2R,6S)-2-((benzyloxy)methyl)-6-methyl-4-((2-nitrophenyl)-sulfonyl)morpholine,71 (diastereoisomer) isolated by purification of 10 mother liquor.

Compound 11: To a stirred solution of 1.0 M of t-BuOK in THF (0.650 L,0.650 mol). In THF (0.310 L) cooled to 5° C. was added benzenethiol(63.66 mL, 0.620 mol) while maintaining at <10° C. The mixture wasstirred at 10° C. for 30 min, then warmed up to 15° C. for 1 h afterwhich time a solution of 10 (240.00 g, 590.5 mmol) in THF (0.60 L) wasadded while maintaining the temperature 15-20° C. followed by andstirring 2 h. The completed reaction was slowly quenched with mixture of1.0 M HCl (1.30 L) in n-heptane (3.60 L, previously cooled to 10° C.)while maintaining the reaction mixture at <15° C. Resultant mixture wasvigorously stirred for 10 min followed by separation of the layers. Theorganic layer was extracted with water (0.24 L) with rinsing withn-heptane (0.24 L). All aqueous layers were combined and washed withn-heptane (3.60 L) followed by the addition of NaCl (240 g) withstifling. The aqueous mixture was rendered basic with 5.0 M of NaOH (165mL) followed by extraction two times with DCM (3.60 L & 2.40 L each).The combined organic layers were washed with 20 wt % NaCl in water (1400g), concentrated, azeotroped with MTBE (1400 mL), re-diluted with MTBE(960 mL) and filtered through a glass filter. The filtrate wasconcentrated to give (2R,6R)-2-((benzyloxy)methyl)-6-methylmorpholine,11 as brownish clear oil which was used for subsequent reaction withoutfurther purification.

Compound 12: To a stirred solution of 3 (137.6 g, 0.591 mol) in DMA (260mL) was added DIPEA (308 mL, 1.77 mol) followed by a solution of 11(130.67 g, 0.5905 mol) in DMA (260 ml) rinsing with DMA (130 mL). Thereaction mixture was heated at 125-130° C. for 2 h. The completedreaction mixture was cooled to 30° C. and diluted with EtOAc (1.96 L)and water (0.65 L) after which time it was poured into water (2.61 L)with vigorous stifling. The resulting mixture was filtered through a padof Celite 545 (260 g) and the layers separated. The aqueous layer wasextracted with EtOAc (1.31 L) followed by combining the organic layerswashing two times with 5% NaCl (1.0 kg, each) and concentrated to giveblack solid. The solid was dissolved in DCM (1 L), diluted withn-heptane (520 mL) followed by the addition of silica gel (196 g) andMgSO₄ (130 g). The resultant slurry was stirred at 20° C. for 30 min,filtered and eluted with isopropyl acetate (2.09 L). The combinedfiltrate was concentrated and resultant brownish solid was suspended ina mixture of EtOAc (196 mL) and n-heptane (523 mL). The mixture washeated to 70° C., followed by cooling to rt and stirred overnight. Theprecipitates were collected by filtration, washed with a mixture ofEtOAc/n-heptane 3:8 (220 mL), and dried under vacuum to provide5-((2R,6R)-2-((benzyloxy)methyl)-6-methylmorpholino)quinoline-8-carbonitrile,12 (178.44 g, 0.478 mol, 80% yield) as tan powder.

Compound 13: To a stirred suspension of 12 (167.3 g, 0.45 mol) inacetonitrile (500 mL) was added trimethylsilyl iodide (82.9 mL, 0.582mol) at rt. The resultant mixture was heated at 70° C. for 2 h afterwhich time it was cooled to rt, slowly quenched with water (167 g) andstirred at 25-30° C. for 1 h. The reaction mixture was cooled to 15° C.followed by the addition 28% aqueous ammonium hydroxide (500 g) afterwhich time the reaction was stirred at rt overnight. The mixture waspartially concentrated and then diluted with water (0.5 L), MTBE (0.04L) and n-heptane (0.3 L) followed by cooling to 0-5° C. Precipitateswere collected by filtration and rinsed with pre-chilled water (500 ml),then n-heptane/MTBE 7:1 (400 ml) followed by drying under vacuum (40°C.) overnight to5-((2R,6R)-2-(hydroxymethyl)-6-methylmorpholino)quinoline-8-carbonitrile,13 or ER-885493 (127.2 g, 0.45 mol, 100% yield) as tan powder.

Compound 14: To a stirred solution of 13 (24.8 g, 0.0875 mol) in DCM(200 mL) was added portion wise p-toluenesulfonyl chloride (17.95 g,94.17 mmol) followed by TEA (24.60 mL, 0.1765 mol) at rt. The reactionwas stirred for 3 h after which time the completed reaction was quenchedwith water (200 mL). The separated organic layer was washed with brine(50 mL), dried over Na₂SO₄, filtered and concentrated to a brownish tar.The crude product was purified over silica gel (SNAP 340×2 g, elutingwith heptane/EtOAc=5/1 to 3/1, TLC heptane/EtOAc=3/1, rf=0.6) to provide((2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl4-methylbenzenesulfonate, 14 (34.98 g. 79.95 mmol, 84.9% yield) as ayellow powder after concentration of the desired fractions and drying invacuo.

Compound 15 as Boc-Protected ER-890963

To a solution of 14 (13.9 g, 31.77 mmol) and TEA (8.86 mL, 63.541 mmol)in DMA (89 mL) at rt was added dropwise commercially available(S)-tert-butyl 2-ethylpiperazine-1-carboxylate (7.49 g, 34.95 mmol) over5-min period. The reaction mixture was stirred at 110° C. for 12 h tocompletion after which time the reaction was cooled to rt. The reactionwas concentrated to remove DMA followed by dilution with DCM (30 mL).The resultant organic solution was washed two times with water (30 mLeach), brine (30 mL), and dried over MgSO₄. The crude was filtered,concentrated in vacuo, and purified over silica gel (SNAP 340 g eluting10% to 30% EtOAc in heptene, TLC heptane/EtOAc=3/1, rt=0.6) gave5-((2S,6R)-2-(((S)-4-(3,3-dimethylbutanoyl)-3-ethylpiperazin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrileor Boc-protected ER-890963 (12.27 g, 24.15 mmol, 76% yield) as yellowpowder after concentration of the combined desired fractions and dryingin vacuo.

ER-890963 or Compound 15:

Boc-protected ER-890963 (23.55 g, 49.10 mmol) was dissolved withstifling in DCM (50 mL) followed by TFA (50 mL) at rt. The reaction wasstirred for 4 h at rt after which time the completed reaction wasconcentrated in vacuo. The crude dark orange material dissolved withstirring in DCM (50 mL) and neutralized with the addition of sat.aqueous NaHCO₃ at 20° C. until the solution became pH 5-6. The separatedaqueous layer was extracted two times with DCM (50 mL each) after whichtime the combined organic layers were washed with brine (20 mL), driedover Na₂SO₄, filtered, concentrated to dry. The crude residue wascrystallized from DCM/iPrOH/heptane/Et₂O=1/1/1/1 to provide ER-890963(17.89 g, 47.14 mmol, 96% yield) as a yellow powder.

ER-886604 (7.8 mg, 0.021 mmol, 73% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 1-amino-4-methylbenzene (0.030 mL, 0.290 mmol) using a microwave at180° C. for 15 min. ER-886604 was purified by reverse-phase HPLC(Water's X-Bridge C18 19×100 mm column, eluting with 10% acetonitrile inwater containing 0.05% TFA). The product fractions were combined andconcentrated to dry followed by dilution in MeOH (1 mL), passed throughas basic silica gel plug (Biotage SiCO₃, 1 g, eluting with MeOH (1 mL)),concentrated and dried in vacuo. Boc-deprotection was not required.

ER-886608 (8.2 mg, 0.019 mmol, 67% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 5-Amino-1,2-dimethylbenzimidazole dihydrochloride (30 mg, 0.128mmol) along with TEA (0.040 mL, 0.290 mmol).

ER-886609 (7.4 mg, 0.017 mmol, 59% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 5-amino-1-ethyl-2-methylbenzimidazole (30 mg, 0.171 mmol).

ER-886611 (9.2 mg, 0.027 mmol, 88% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 1-aminocyclohexane (30 mg, 0.171 mmol).

ER-886787 (4.5 mg, 0.012 mmol, 43.9% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 2-aminopyrimidine (24.7 mg, 0.263 mmol).

ER-886788 (5.2 mg, 0.014 mmol, 51% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 2-aminopyridine (24.4 mg, 0.263 mmol).

ER-886789 (4.5 mg, 0.012 mmol, 42% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 2-amino-6-methylpyridine (28.1 mg, 0.263 mmol).

ER-886790 (4.6 mg, 0.012 mmol, 43% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 2-amino-5-methylpyridine (28.1 mg, 0.263 mmol).

ER-886814 (4.2 mg, 0.012 mmol, 40.4% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and D-prolinol (26.2 mg, 0.263 mmol).

ER-886815 (4.0 mg, 0.011 mmol, 38.2% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 2,2-dimetylpyrrolidine (14.2 mg, 0.145 mmol).

ER-886816 (6.0 mg, 0.016 mmol, 60% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 2-isopropylpyrrolidine (29.4 mg, 0.263 mmol).

ER-886817 (4.2 mg, 0.012 mmol, 62% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and (R)-2-methylpyrrolidine (22.1 mg, 0.263 mmol).

ER-886818 (4.2 mg, 0.010 mmol, 35.2% yield) was prepared by a similarmethod described for ER-890604 starting with 14 (12.5 mg, 0.029 mmol)and (S) 3-phenylpyrrolidine (38.2 mg, 0.263 mmol).

ER-886819 (5.2 mg, 0.015 mmol, 52% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and (R)-3-methylpyrrolidine (22.1 mg, 0.263 mmol).

ER-886820 (6.2 mg, 0.018 mmol, 62% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and (S)-3-hydroxypyrrolidine (22.6 mg, 0.263 mmol).

ER-886853 (6.2 mg, 0.017 mmol, 58% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 2-amino-4-methylpyridine (28.1 mg, 0.263 mmol).

ER-886854 (2.9 mg, 0.007 mmol, 25% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 3-phenylpyrrolidine hydrochloride (47.7 mg, 0.263 mmol).

ER-886855 (4.9 mg, 0.013 mmol, 44% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 2-amino-5-methoxypyridine (32.2 mg, 0.263 mmol).

ER-886856 (7.8 mg, 0.022 mmol, 78% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and (S)-2-methylpyrrolidine (22.1 mg, 0.263 mmol).

ER-886857 (5.6 mg, 0.015 mmol, 54% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 2,5-dimethylpyrrolidine (25.7 mg, 0.263 mmol).

ER-886858 (3.6 mg, 0.009 mmol, 32% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 2-amino-4-methoxypyridine (32.2 mg, 0.263 mmol).

ER-886859 (2 mg, 0.005 mmol, 20% yield) was prepared by a similar methoddescribed for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and2-amino-6-methoxypyridine (32.2 mg, 0.263 mmol).

ER-886860 (2.5 mg, 0.006 mmol, 21% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 5-amino-1-phenylpyrazole (41.3 mg, 0.263 mmol).

ER-886866 (8.2 mg, 0.022 mmol, 78% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and L-prolinol (22.1 mg, 0.263 mmol).

ER-886867 (4.5 mg, 0.013 mmol, 45% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and (R)-3-hydroxypyrrolidine (22.6 mg, 0.263 mmol).

ER-886868 (6.5 mg, 0.019 mmol, 65% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and (S)-3-methylpyrrolidine (22.1 mg, 0.263 mmol).

ER-886869 (5.3 mg, 0.015 mmol, 51% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 3,3-dimethylpyrrolidine (25.7 mg, 0.263 mmol).

ER-886948 (6.2 mg, 0.016 mmol, 56% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 2-amino-3-methoxypyridine (32.2 mg, 0.263 mmol).

ER-886949 (4.8 mg, 0.013 mmol, 46% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and (R)-3-hydroxypiperidine (26.2 mg, 0.263 mmol).

ER-886950 (5.0 mg, 0.013 mmol, 46% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and (R,S)-2,6-dimethylpiperidine (29.4 mg, 0.263 mmol).

ER-886951 (3.2 mg, 0.009 mmol, 31% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and (S)-3-hydroxypiperidine (26.2 mg, 0.263 mmol).

ER-886953 (5.8 mg, 0.016 mmol, 55% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 4-hydroxypiperidine (26.2 mg, 0.263 mmol).

ER-886955 (7.5 mg, 0.020 mmol, 69% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 2-hydroxymethylpiperidine (29.9 mg, 0.263 mmol).

ER-887137 (4.5 mg, 0.012 mmol, 42% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 2,3 dimethylpiperazine (29.6 mg, 0.263 mmol).

ER-887138 (5.9 mg, 0.016 mmol, 57% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 3-aminopyridine (24.4 mg, 0.263 mmol).

ER-887139 (6.5 mg, 0.018 mmol, 63% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 3-aminopyridine (24.4 mg, 0.263 mmol).

ER-887141 (5.2 mg, 0.014 mmol, 50% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 4-methylpiperidine (25.7 mg, 0.263 mmol).

ER-887142 (4.5 mg, 0.012 mmol, 41% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 4,4-difluroropiperidine (31.4 mg, 0.263 mmol).

ER-887143 (4.7 mg, 0.011 mmol, 38% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 4-phenylpiperidine (41.8 mg, 0.263 mmol).

ER-887144 (6.2 mg, 0.017 mmol, 59% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 4-fluroropiperidine (26.8 mg, 0.263 mmol).

ER-887145 (6.5 mg, 0.019 mmol, 65% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 1-aminocyclopentane (22.1 mg, 0.263 mmol).

ER-887146 (7 mg, 0.018 mmol, 60% yield) was prepared by a similar methoddescribed for ER-886604 starting with 14 (12.5 mg, 0.029 mmol) and1-amino-3-methylcyclohexane (29.4 mg, 0.263 mmol).

ER-887177 (5.3 mg, 0.014 mmol, 49% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 2-amino-3-methylpyridine (20 mg, 0.145 mmol).

ER-887253 (10.2 mg, 0.029 mmol, 60% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (20 mg, 0.046 mmol) andpiperazine (40 mg, 0.460 mmol).

ER-887442 (6.2 mg, 0.016 mmol, 59% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.2 mg, 0.028 mmol)and 1-amino-4-methylcyclohexane (30 mg, 0.265 mmol).

ER-887443 (4.5 mg, 0.013 mmol, 47% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 1-amino-cyclobutane (10 mg, 0.141 mmol).

ER-887444 (7.7 mg, 0.020 mmol, 70.7% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 1-amino-cycloheptane (20 mg, 0.177 mmol).

ER-887526 (6.2 mg, 0.016 mmol, 57% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 1-amino-4-hydroxycyclohexane (30 mg, 0.260 mmol).

ER-887528 (5.4 mg, 0.015 mmol, 51.2% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 1-amino-2-hydroxycyclopentane (30 mg, 0.297 mmol).

ER-887539 (5.3 mg, 0.014 mmol, 49% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 1-amino-2-methylcyclohexane (30 mg, 0.265 mmol).

ER-887538 (6.5 mg, 0.014 mmol, 51.8% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 2-amino-5-phenylpyridine (50 mg, 0.294 mmol).

ER-887540 (6.1 mg, 0.014 mmol, 49% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 2-amino-3-phenylpyridine (50 mg, 0.294 mmol).

ER-887586 (6.2 mg, 0.017 mmol, 59% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and (S,R)-1-amino-2-hydroxypyrrolidine (10 mg, 0.099 mmol).

ER-887587 (7.5 mg, 0.019 mmol, 65% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 2-amino-3-ethoxylpyridine (40 mg, 0.290 mmol).

ER-887588 (5.6 mg, 0.013 mmol, 45% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 4-amino-2-phenylpyridine (20 mg, 0.118 mmol).

ER-887589 (2.4 mg, 0.006 mmol, 19% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 2-amino-6-phenylpyridine (20 mg, 0.118 mmol).

ER-887722 (3.5 mg, 0.009 mmol, 32% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 5-methylpiperazin-2-one (20 mg, 0.175 mmol).

ER-887723 (6.2 mg, 0.017 mmol, 59% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 1-N-methylpiperazine (10 mg, 0.100 mmol).

ER-887724 (6.2 mg, 0.016 mmol, 55% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 1-N-propylpiperazine (40 mg, 0.138 mmol).

ER-887725 (7.2 mg, 0.018 mmol, 64% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 4-(dimethylamino)-piperidine (20 mg, 0.156 mmol).

ER-887927 (10.2 mg, 0.024 mmol, 82.3% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 1,4′-bipiperidine (20 mg, 0.119 mmol).

ER-887928 (3.2 mg, 0.009 mmol, 31% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and (R)-tert-butyl piperidin-3-ylcarbamate (30 mg, 0.150 mmol).

ER-888070 (4.5 mg, 0.012 mmol, 43% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and tert-butyl piperidin-4-ylcarbamate (30 mg, 0.150 mmol).

ER-888202 (6.2 mg, 0.018 mmol, 62% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and piperidine (0.034 mL, 0.348 mmol).

ER-888203 (7.2 mg, 0.020 mmol, 58% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (15.5 mg, 0.035 mmol)and morpholine (0.030 mL, 0.350 mmol).

ER-888204 (6.2 mg, 0.016 mmol, 57% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and (2S,6R)-2,6-dimethylmorpholine (0.070 mL, 0.580 mmol).

ER-888205 (4.6 mg, 0.012 mmol, 41% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and ((2R,6R)-6-methylmorpholin-2-yl)methanol or ER-885491 (40 mg, 0.305mmol).

ER-885491: To a stirred suspension of 11 (890.2 mg, 4.023 mmol) in MeOH(8 mL) was added 5% palladium on carbon (270 mg) after which time themixture was purged with H₂ gas three times with vacuum evacuationbetween charges. The reaction was stirred under a H₂ atm at 40° C. for 8h. The incomplete reaction was degassed under vacuum with purging withN₂ gas, followed by 5% palladium on carbon (100 mg) and 2 drops conc.HCl after which time the reaction was placed under a H₂ atm as describedabove for 4 h at 40° C. The completed reaction was purged with N₂ gas,followed by filtering over Celite 545, eluting with MeOH (5 mL),concentrating and drying in vacuo. The crude product ER-885491 (378. 2mg, 2.883 mmol, 71.7% yield) was used in the previous step withoutfurther purification.

ER-888285 (8.6 mg, 0.020 mmol, 59% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (15 mg, 0.034 mmol) andN-(2-pyridyl)piperazine (30 mg, 0.184 mmol).

ER-888286 (10.2 mg, 0.020 mmol, 71.3% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (14.6 mg, 0.033 mmol)and N-(4-pyridyl)piperazine (30 mg, 0.184 mmol).

ER-888288 (7.2 mg, 0.016 mmol, 52% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (15 mg, 0.034 mmol) andN-(piperidin-4-yl)acetamide (20 mg, 0.141 mmol). The HCl salt is formedby procedures previously described.

ER-888289 (16.2 mg, 0.039 mmol, 21.6% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (80 mg, 0.183 mmol) and1,8-naphthyridin-2-amine (100 mg, 0.689 mmol).

ER-888320 (5.8 mg, 0.015 mmol, 42% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (15.5 mg, 0.035 mmol)and piperidine-4-carboxamide (20 mg, 0.156 mmol).

ER-888321 (6.2 mg, 0.013 mmol, 37% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (15.5 mg, 0.035 mmol)and N-(piperidin-4-yl)benzamide (40 mg, 0.196 mmol).

ER-888322 (10.5 mg, 0.027 mmol, 75.3% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (15.5 mg, 0.035 mmol)and 1-isopropylpiperazine (20 mg, 0.156 mmol).

ER-888330 (4.2 mg, 0.011 mmol, 30% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (15.5 mg, 0.035 mmol)and piperazine-1-carboxamide (20 mg, 0.155 mmol).

ER-888479 (7.6 mg, 0.018 mmol, 51% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and4-cyclohexylpiperidine (30 mg, 0.179 mmol).

ER-888480 (8.3 mg, 0.020 mmol, 58% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and4-(pyrrolidin-1-yl)piperidine (30 mg, 0.194 mmol).

ER-888838 (6.2 mg, 0.015 mmol, 45% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and3,5-dimethylpyridine-2,6-diamine (20 mg, 0.146 mmol).

ER-888977 (1.2 mg, 0.003 mmol, 11% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (12.5 mg, 0.029 mmol)and 1,3-dimethyl-1H-pyrazol-5-amine (28.8 mg, 0.259 mmol).

ER-889448 (8.2 mg, 0.022 mmol, 63% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and1-ethylpiperazine (0.020 mL, 0.136 mmol).

ER-889469 (6.5 mg, 0.018 mmol, 52% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and1-(azetidin-3-yl)pyrrolidine (20 mg, 0.158 mmol).

ER-889470 (7.2 mg, 0.017 mmol, 48% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and1-(azetidin-3-yl)piperidine (20 mg, 0.158 mmol).

ER-889557 (7.7 mg, 0.020 mmol, 58.6% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (15 mg, 0.034 mmol) andpiperidin-4-ylmethanol (20 mg, 0.174 mmol).

ER-889571 (3.2 mg, 0.008 mmol, 23% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and(R)-1,3′-bipyrrolidine (20 mg, 0.143 mmol).

ER-889572 (1.1 mg, 0.003 mmol, 7.7% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and(R)-1-(pyrrolidin-3-yl)piperidine (20 mg, 0.130 mmol).

ER-889601 (6.7 mg, 0.018 mmol, 51% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (15 mg, 0.034 mmol) and1-methyl-1,4-diazepane (20 mg, 0.175 mmol).

ER-889602 (10.2 mg, 0.022 mmol, 65.3% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (15 mg, 0.034 mmol) andphenyl(piperazin-1-yl)methanone (30 mg, 0.158 mmol).

ER-891084 (7.2 mg, 0.016 mmol, 47% yield) was prepared by a similarmethod described for ER-886608 starting with 14 (15 mg, 0.034 mmol) and1-(piperidin-4-yl)azepane (30 mg, 0.165 mmol).

ER-890108 (15.2 mg, 0.036 mmol, 58.6% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (27 mg, 0.062 mmol) and1-(azetidin-3-yl)-4-methylpiperazine (90.2 mg, 0.581 mmol).Triethylamine (0.008 mL, 0.062 mmol) was also added to the reaction.

ER-890112 (296.5 mg, 0.683 mmol, 74.7% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (400.6 mg, 0.916 mmol)and 4,4′-bipiperidine (290 mg, 1.723 mmol).

ER-894472 (53.9 mg, 0.143 mmol, 25% yield) and ER-894473 (51.2 mg, 0.135mmol, 23.6% yield) was prepared by a similar method described forER-886604 starting with 14 (250 mg, 0.571 mmol) and5-methylpiperazin-2-one (78.3 mg, 0.686 mmol). The stereochemistry ofeach diastereomeric methyl group is arbitrarily assigned.

ER-886507 (4.2 mg, 0.013 mmol, 51.9% yield) was prepared by a similarmethod described for ER-886604 starting with 14 (10.6 mg, 0.024 mmol)and pyrrolidine (0.022 mL, 0.257 mmol) using toluene (1 mL) instead ofDMA as solvent. Boc-deprotection was not required.

ER-886508 (3.3 mg, 0.010 mmol, 38.9% yield) was prepared by a similarmethod described for ER-890507 starting with 14 (10.8 mg, 0.025 mmol)and N,N-diethylamine (0.027 mL, 0.262 mmol).

ER-886509 (4.8 mg, 0.013 mmol, 44.9% yield) was prepared by a similarmethod described for ER-890507 starting with 14 (12.5 mg, 0.029 mmol)and benzylamine (0.028 mL, 0.263 mmol).

ER-886601 (6.6 mg, 0.018 mmol, 64.2% yield) was prepared by a similarmethod described for ER-890507 starting with 14 (12.5 mg, 0.029 mmol)and phenylamine (0.008 mL, 0.087 mmol).

ER-886602 (6.4 mg, 0.017 mmol, 60.1% yield) was prepared by a similarmethod described for ER-890507 starting with 14 (12.5 mg, 0.029 mmol)and 1-amino-3-methylbenzene (0.028 mL, 0.263 mmol).

ER-887104 (2.1 mg, 0.005 mmol, 17.9% yield) was prepared by a similarmethod described for ER-890507 starting with 14 (12.5 mg, 0.029 mmol)and (S)-2-(trifluoromethyl)pyrrolidine (36.1 mg, 0.260 mmol).

ER-886603 (7.6 mg, 0.020 mmol, 71% yield) was prepared by a similarmethod described for ER-890507 starting with 14 (12.5 mg, 0.029 mmol)and 1-amino-2-methylbenzene (0.030 mL, 0.290 mmol) using NMP(1 mL)instead of toluene as a solvent.

ER-886957 (4.7 mg, 0.013 mmol, 45% yield) was prepared by a similarmethod described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol)and 2-methylpiperidine (25.7 mg, 0.263 mmol).

ER-886958 (6.2 mg, 0.016 mmol, 57% yield) was prepared by a similarmethod described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol)and 2-ethylpiperidine (29.3 mg, 0.263 mmol).

ER-887139 (2.1 mg, 0.005 mmol, 18% yield) was prepared by a similarmethod described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol)and (S)-2-trifluoromethypyrrolidine (36.1 mg, 0.263 mmol).

ER-887252 (2.6 mg, 0.006 mmol, 21% yield) was prepared by a similarmethod described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol)and 2-amino-4-phenylpyridine (20 mg, 0.145 mmol).

ER-887258 (4.2 mg, 0.010 mmol, 34% yield) was prepared by a similarmethod described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol)and N-phenyl piperazine (0.040 mL, 0.290 mmol) in toluene (0.5 mL).

ER-887259 (3.2 mg, 0.009 mmol, 30% yield) was prepared by a similarmethod described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol)and 2,6-dimethylpyridine (30 mg, 0.290 mmol).

ER-887260 (3.3 mg, 0.009 mmol, 30.1% yield) was prepared by a similarmethod described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol)and (S,S)-2,5-dimethylpiperazine (29.6 mg, 0.263 mmol).

ER-887261 (4.2 mg, 0.011 mmol, 39% yield) was prepared by a similarmethod described for ER-886507 starting with 14 (12 mg, 0.027 mmol) andN-acetyl piperazine (40 mg, 0.274 mmol).

ER-887262 (2.4 mg, 0.006 mmol, 22% yield) was prepared by a similarmethod described for ER-886507 starting with 14 (12.5 mg, 0.029 mmol)and 4-(R)-hydroxy-2-(S)-hydroxymethylpyrrolidine (30.4 mg, 0.263 mmol).

ER-887268 (9.3 mg, 0.017 mmol, 10% yield) was prepared by a similarmethod described for ER-886608 starting with 14 (50 mg, 0.114 mmol) and(R)-tert-butyl 3-methylpiperazine-1-carboxylate (100 mg, 0.570 mmol)using toluene (1 mL). Boc-deprotection was required as described forBoc-protected ER-890963 above. ER-887268 was purified by reverse-phaseHPLC (Water's X-Bridge C18 19×100 mm column, eluting with 10-40%acetonitrile in water with 0.05% TFA) followed by neutralization asdescribed for ER-886608.

ER-887269 (6.2 mg, 0.025 mmol, 21.4% yield) was prepared by a similarmethod described for ER-887268 starting with 14 (51.8 mg, 0.118 mmol)and (R)-tert-butyl 2-methylpiperazine-1-carboxylate (100 mg, 0.570mmol).

ER-887270 (12.2 mg, 0.033 mmol, 30% yield) was prepared by a similarmethod described for ER-887268 starting with 14 (50 mg, 0.114 mmol) and(S)-tert-butyl 2-methylpiperazine-1-carboxylate (200 mg, 1.14 mmol).

ER-887271 (2.3 mg, 0.006 mmol, 5.5% yield) was prepared by a similarmethod described for ER-887268 starting with 14 (48.2 mg, 0.110 mmol)and (R,R)-tert-butyl 2,5-dimethylpiperazine-1-carboxylate hydrochloride(100 mg, 0.399 mmol) and DIPEA (0.10 mL, 0.55 mmol).

ER-887272 (3.2 mg, 0.008 mmol, 7.1% yield) was prepared by a similarmethod described for ER-887268 starting with 14 (52.7 mg, 0.120 mmol)and (S,R)-tert-butyl 2,5-dimethylpiperazine-1-carboxylate (100 mg, 0.467mmol).

ER-890119 (256.2 mg, 0.630 mmol, 58.6% yield) was prepared by a similarmethod described for ER-890963 starting with 14 (450 mg, 1.029 mmol) andtert-butyl 4-(azetidin-3-yl)piperazine-1-carboxylate (314.2 mg, 1.302mmol). Triethylamine (0.172 mL, 1.23 mmol) was also added to thereaction. Dioxane (2 mL) was used instead of DMA. Deprotection of aBoc-group with TFA was required followed by neutralization of the finalproduct as described previously.

ER-892253 (152.3 mg, 0.362 mmol, 4.0% overall yield) was prepared by asimilar method described for ER-890119 starting with 14 (4.0 g, 9.1mmol) and tert-butyl(1-(azetidin-3-yl)piperidin-4-yl)carbamate (2.52 g,9.9 mmol).

ER-888605 (7.6 mg, 0.017 mmol, 5.0% yield) was prepared by a similarmethod described for ER-890119 starting with 14 (150 mg, 0.343 mmol) and[1,4′-bipiperidin]-2-one hydrochloride (82.5 mg, 0.377 mmol). Boc-groupdeprotection was not required.

ER-888605 (7.6 mg, 0.017 mmol, 5.0% yield) was prepared by a similarmethod described for ER-890119 starting with 14 (150 mg, 0.343 mmol) and[1,4′-bipiperidin]-2-one hydrochloride (82.5 mg, 0.377 mmol). Boc-groupdeprotection was not required.

ER-890093 (15.2 mg, 0.035 mmol, 45.4% yield) was prepared by a similarmethod described for ER-890119 starting with 14 (33.6 mg, 0.077 mmol)and 4-(piperidin-4-yl)morpholine (52 mg, 0.305 mmol). Boc-groupdeprotection was not required.

ER-890104 (569 mg, 1.06 mmol, 42.6% yield) was prepared by a similarmethod described for ER-890119 starting with 14 (1.08 g, 2.5 mmol) andtert-butyl 4-(piperidin-4-yl)piperazine-1-carboxylate (1.00 g, 3.7mmol). Boc-group deprotection of ER-890104 (21 mg, 0.039 mmol) wasperformed as described above to provide ER-890106 (12.4 mg, 0.029 mmol,73.2% yield).

ER-890105 (65 mg, 0.122 mmol, 11.3% yield) was prepared by a similarmethod described for ER-890119 starting with 14 (1.08 g, 2.5 mmol) andtert-butyl 4-(piperidin-4-yl)piperazine-1-carboxylate (1.00 g, 3.7mmol). DIPEA (0.65 mL, 3.7 mmol) was also added to the reaction mixture.Boc-group deprotection of ER-890105 (60 mg, 0.112 mmol) was performed asdescribed above to provide ER-890107 (11.3 mg, 0.026 mmol, 23.2% yield).

ER-890311 (4.5 mg, 0.011 mmol, 31% yield) was prepared by a similarmethod described for ER-886608 starting with 14 (15 mg, 0.034 mmol) and(S)-1-(pyrrolidin-3-yl)piperidine dihydrochloride (30 mg, 0.108 mmol)replacing DMA with acetonitrile (1 mL). Triethylamine (0.014 mL, 0.102mmol) was also added to the reaction. The dihydrochloride salt of theproduct was produced according to processes described previously.

ER-890342 (41.3 mg, 0.101 mmol, 11% yield) was prepared by a similarmethod described for ER-890311 starting with 14 (150.2 mg, 0.916 mmol)and 4-(azetidin-3-yl)morpholine (221.6 mg, 1.030 mmol).

ER-890343 (25.2 mg, 0.062 mmol, 77.2% yield yield) was prepared by asimilar method described for ER-890311 starting with 14 (35.2 mg, 0.080mmol) and 1-(azetidin-3-yl)-4-methylpiperazine (40.3 mg, 0.0201 mmol).

ER-890344 (21.4 mg, 0.059 mmol, 73.8%) was prepared by a similar methoddescribed for ER-890311 starting with 14 (35.2 mg, 0.080 mmol) and(S)-tert-butyl 3-methylpiperazine-1-carboxylate (28.2 mg, 0.201 mmol).Deprotection of the Boc-group with TFA followed by neutralization wasperformed.

ER-890963 (685.2 mg, 1.806 mmol, 86%) was prepared by a similar methoddescribed for ER-890344 starting with 14 (919 mg, 2.101 mmol) and(S)-tert-butyl 2-ethylpiperazine-1-carboxylate (500 mg, 2.333 mmol). Thedihydrochloride salt of the product was produced according to processesdescribed previously.

ER-891090 (54.2 mg, 0.133 mmol, 46.8% yield) was prepared by a similarmethod described for ER-890311 starting with 14 (137.5 mg, 0.314 mmol)and (S)-1,3′-bipyrrolidine dihydrochloride (30 mg, 0.165 mmol).Boc-group deprotection was not required.

ER-895204 (35.2 mg, 0.084 mmol, 73.1% yield) was prepared by a similarmethod described for ER-890311 starting with 14 (50 mg, 0.114 mmol) andN-ethylpiperidine-4-carboxamide (21.4 mg, 0.137 mmol). The hydrochloridesalt of the product was produced according to processes describedpreviously.

Preparation of ER-887612 as a Modified Example of Compound 15 fromScheme 4

A mixture of Compound 3 (201 mg, 0.862 mmol) and (R)-2-hydroxymethylmorpholine hydrochloride (132, 0.856 mmol) in NMP(3 mL) was heated to170° C. for 16 h. The completed reaction was cooled, filtered, elutedwith MeOH (2 mL) then purified directly by HPLC using a C-18 columneluting with a 10-100% acetonitrile in water containing 0.1% TFA. Thedesired product was collected and concentrated to dry. The resultingproduct was dissolved in MeOH (2 mL) and passed over a basic silica plug(Biotage, 1 g, SiCO₃) eluting with MeOH (5 mL) to provide(R)-5-(2-(hydroxymethyl)morpholino)quinoline-8-carbonitrile or ER-886849(108 mg, 0.401 mmol, 46.9% yield).

To a stirred solution of ER-886849 (101 mg, 0.375 mmol) in DCM (2 mL)was added p-toluenesulfonyl chloride (78.5 mg, 0.412 mmol) followed byDIPEA (0.13 mL, 0.746 mmol) and DMAP (2.3 mg, 0.019 mmol). The reactionmixture was stirred at rt for 2 h after which time additionalp-toluenesulfonyl chloride (78.7 mg, 0.413 mmol) was added followed bystirring at rt for 4 h. Water (1.2 mL) and DCM (5.9 mL) were added tothe completed reaction with stirring followed separation of the layers.The organic layer was washed with brine (1.2 mL), dried over MgSO₄,filtered and concentrated to dry. The crude product was purified oversilica gel (Biotage SP4, Interchim 25 g, eluting with 20-100% EtOAc inheptane gradient), the desired fractions collected, concentrated anddried in vacuo to provide(R)-(4-(8-cyanoquinolin-5-yl)morpholin-2-yl)methyl4-methylbenzenesulfonate (85 mg, 0.201 mmol, 53.6% yield).

A solution of (R)-(4-(8-cyanoquinolin-5-yl)morpholin-2-yl)methyl4-methylbenzene-sulfonate (27 mg, 0.064 mmol) and 2-aminopyridine (90mg, 0.956 mmol) in NMP (1 mL) was microwaved at 150° C. for 15 min. Thecooled reaction was diluted with NMP (3 mL) and purified directly byHPLC using a C-18 column eluting with a 10-100% acetonitrile in watercontaining 0.1% TFA. The desired product was collected and concentratedto dry. The resulting product was dissolved in MeOH (2 mL) and passedover a basic silica plug (Biotage, 1 g, SiCO₃) eluting with MeOH (5 mL)to provide ER-887612 (16 mg, 0.046 mmol, 71.9% yield).

ER-885211 (4 mg, 0.016 mmol, 24.7% yield) was prepared in a similarmanner to ER-886849 starting with Compound 3 (15 mg, 0.064 mmol) and(R)-2-methylmorpholine (22 mg, 0.160 mmol). TEA (0.05 mL, 0.359 mmol)was added to the reaction.

Alternative Synthesis of Compound 10—scheme 5

Compound 16: To a stirred solution of compound 8 (2.869 g, 7.06 mmol) inacetonitrile (14.4 ml) cooled to 5-6° C. was added TFA (0.163 ml, 2.12mmol) followed by NBS (1.385 g, 7.78 mmol). The reaction mixture wasstirred for 1 h after which time 9% NaHCO₃ (6.6 g, 7.1 mmol) was addedfollowed by sodium sulfite (Na₂SO₃; 0.27 g, 2.1 mmol) and then stirredfor 5 min. The mixture was diluted with water (5.7 ml) and toluene (29ml), stirred for an additional 5 min followed by separation of thelayers. The aqueous layer was extracted with toluene (14.4 ml) afterwhich time the combined organic layers were washed with 20% NaCl (7.20ml), concentrated to approx. 5 ml, and then diluted with MTBE (29 ml). 2M NaOH (7.1 ml) was added and resultant biphasic mixture was vigorouslystirred for 10 min. The organic layer was separated and sequentiallywashed two times with 20% NaCl (14 ml each), water (5.7 ml),concentrated to approx. 5 ml, and diluted with toluene (14.4 ml). Theresultant solution containing(2R)-2-((benzyloxy)methyl)-6-(bromomethyl)-4-((2-nitrophenyl)-sulfonyl)morpholine,16, was used directly in the next reaction.

Compound 17: To the stirred solution of 16 (ca. 3.43 g, 7.06 mmol fromabove) in toluene was added DBU (2.66 ml, 17.648 mmol) followed byheating at 100° C. for 4 h. The completed reaction was cooled to 15° C.followed by the addition of MTBE (60 ml) and 1 M HCl (21.2 ml) withstirring. The layers were separated after which time the aqueous layerwas extracted with MTBE (20 ml). The combined organic layers were washedwith water (10 ml), 9 wt % NaHCO₃ in water (10 g, 10.713 mmol), 20 wt %NaCl (10 ml), concentrated to dry. The give crude yellow oil with saltswas diluted with DCM (10 ml), filtered and concentrated to give crude(R)-2-((benzyloxy)methyl)-6-methylene-4-((2-nitrophenyl)sulfonyl)morpholine,17 (3.2 g) as orange-colored oil.

Compound 10: To a stirred solution triethylsilane (1.69 ml, 10.6 mmol)in DCM (4 ml) at 0° C. was added TFA (2.72 ml, 35.3 mmol) followed bycooling to −15° C. Crude 17 (ca. 2.86 g, 7.06 mmol) in DCM (4 ml) wasadded while maintaining the temperature at −5° C. followed by adding therinsed residuals with DCM (4 ml). The resultant mixture was stirred at−10 to −5° C. for 1 h then warmed to 2-3° C. for an additional 1 h. Thecompleted reaction was cooled to −10° C., poured into pre-chilled (2°C.) 2 M NaOH (21.2 ml, 42.4 mmol) rinsing the reactor with DCM (2 ml).The final mixture was extracted with MTBE (50 ml) and the organic layerwas washed with water (10 ml), 20 wt % NaCl (10 ml) and concentrated togive orange-colored oil. Crude product was purified over silica gel(n-heptane/MTBE 1:2) to provide(2R,6R)-2-((benzyloxy)methyl)-6-methyl-4-((2-nitrophenyl)sulfonyl)morpholine,10 (1.437 g, 3.54 mmol, 50% yield in 3 steps from 8) as light yellowsolid after combining and concentration of the desired fractions thendrying in vacuo.

Alternative Synthesis of Compound 11—scheme 6

Compounds 18 & 19: To a stirred suspension of glycine (85.86 g, 1.144mol) was in 1,4-dioxane (660 mL) was added 1.0 M aqueous NaOH (1144 mL,1.114 mol) followed by heating to 80° C. after which time a solution of(2R)-benzyl 2-epoxypropyl ether 6 (93.90 g, 0.5718 mol) in 1,4-dioxane(94 mL) was added slowly while maintaining T-internal between 77-82° C.over a 2-h period. The completed reaction mixture was cooled to 18° C.followed by the addition of di-tert-butyl dicarbonate (262.1 g, 1.201mol) maintaining the temperature between 18 and 21° C. The mixture wasstirred at rt overnight after which time the completed mixture waswashed two times with heptane (2000 mL). The aqueous layer was acidifiedwith 20 wt % citric acid (270 g) and extracted three times with EtOAc(2000 mL & 2×1000 mL). The combined organic layers were washed twicewith 20 wt % NaCl (460 g each), concentrated, dissolved in EtOAc (560mL), filtered, concentrated and diluted with DCM (280 mL) to give(R)-2-((3-(benzyloxy)-2-hydroxypropyl)(tert-butoxycarbonyl)amino)aceticacid, 18 in a solution.

To a stirred solution of EDC (120.6 g, 0.6290 mol) and DMAP (2.10 g,0.0172 mol) were suspended in DCM (380 mL) at 15° C. was added the above18 solution over a 30-min period while maintaining the temperature below20° C. The reaction mixture was stirred at 18-20° C. for 3 h after whichtime it was cooled to 10° C. and then quenched with of 20 wt % citricacid (820 g) with stifling. The layers were separated and the aqueouslayer was extracted with MTBE (1.4 L). The combined organic layers werewashed with saturated aqueous NaHCO₃ (480 g), 30% NaCl (470 g) andconcentrated. The crude product thus obtained was purified over silicagel (eluting with n-heptane/EtOAc 4:1 to 3:1) to provide (R)-tert-butyl2-((benzyloxy)methyl)-6-oxomorpholine-4-carboxylate, 19 (96 g, 0.298mol, 26.1% yield in two steps) as clear yellow oil after combining thedesired fractions, concentration and drying in vacuo.

Compounds 22 & 23: To a stirred solution of 19 (134.29 g, 0.418 mol) inTHF (1100 mL) cooled to −75° C. was added 1.5 M of MeLi—LiBr complex indiethyl ether (334 mL, 0.501 mol)) was dropwise over 1 h whilemaintaining the temperature at <−65° C. The mixture was cooled to −75°C. and stirred for 1.5 h after which time the reaction was slowlyquenched over a 10-min period with 20 wt % aqueous NH₄Cl (270 g) whilemaintaining the temperature at <−55° C. The mixture was warmed to 0° C.over 1 h, partitioned between water (270 g) and MTBE (1340 mL. Theaqueous layer was extracted with MTBE (1100 mL) followed by combiningthe organic layers and washing them with 20 wt % NaCl (270 g) andconcentrated to dry. The residue was dissolved in toluene (1100 mL),filtered, concentrated, azeotroped to dry with toluene (1100 mL), andthen dissolved in DCM (1200 ml). The mixture was cooled to −72° C. andtriethylsilane (0.200 L, 1.25 mol) was added followed by trimethylsilyltrifluoromethanesulfonate (151 mL, 0.836 mol) over 45-min period whilemaintaining the temperature at <−68° C. TFA (129 mL, 1.67 mol) in DCM(336 mL, 5.24 mol) was added over 20-min period to the completedreaction while maintaining the temperature at <−65° C. The mixture waswarmed up to −10° C. followed by the addition of saturated aqueousNaHCO₃ (0.70 kg) with stifling. The layers were separated and theaqueous layer was extracted two times with DCM (940 mL each). Thecombined organic layers were washed with saturated aqueous NaHCO₃ (0.70kg), concentrated, dissolved in acetonitrile (400 mL), treated withdi-tert-butyl dicarbonate (91.2 g, 0.418 mol) at 20-25° C., and stirredfor 1 h. The completed reaction azeotroped to dry with toluene (800 ml)and purified over silica gel (eluted with n-heptane/EtOAc 9:1 to 4:1) toprovide (2R,6R)-tert-butyl2-((benzyloxy)methyl)-6-methylmorpholine-4-carboxylate, 22 (61.90 g,0.193 mol, 46% yield from 19) as white solid after combining the desiredfractions, concentration and drying in vacuo. The minor stereoisomer(2R,6S)-tert-butyl2-((benzyloxy)methyl)-6-methylmorpholine-4-carboxylate, 23, wasseparable by silica gel column chromatography.

Compound 11: To a stirred solution of 22 (27 mg, 0.084 mol) in DCM (0.60mL) was added TFA (0.30 mL, 0.0039 mol) at rt followed by stirring for30 min. The completed reaction was concentrated, azeotroped twice todryness with toluene (1.8 mL×2) and dissolved in DCM (3.0 mL). Theorganic solution was washed with saturated aqueous NaHCO₃ (0.50 g),concentrated, and dried in vacuo to provide(2R,6R)-2-((benzyloxy)methyl)-6-methylmorpholine, 11 (19 mg, 100% yield)as colorless film.

2^(nd) Alternative Synthesis of Compound 11—scheme 7

Compound 23: A solution of (2R)-benzyl 2-epoxypropyl ether, 6 (21.0 g,0.128 mol) in EtOH (100 mL) was added slowly to a solution of 7.0 Mammonia in MeOH (100 mL) and 28% aq. ammonium hydroxide (210 mL) at rt.The reaction vessel was tightly capped and stirred at rt for 23 h. Thecompleted reaction was concentrated in vacuo, and the crude product wasazeotroped to dry twice with toluene (100 mL) to provide(R)-1-amino-3-(benzyloxy)propan-2-ol, 23 (23 g) as waxy solid containingapproximately 15% of dimer. The crude was used for next reaction withoutfurther purification.

Compound 25: To the solution of 23 (12.0 g, 49.7 mmol) in EtOH (15 mL)was added commercially available methyl(S)-(−)-2-chloropropionate, 24(6.69 g, 54.6 mol). The mixture was heated to 70° C. and stirred for 14h after which time the completed reaction was concentrated in vacuo. Thecrude product was diluted with EtOAc (50 mL), washed with 1N HCl (20mL), brine (20 mL), and then the organic phase was dried over anhydrousNa₂SO₄, filtered and concentrated to dry. Purification over silica gel(SNAP 10 g, heptane/EtOAc=5/1 to 1/5, then EtOAc only, TLChep/EtOAc=1/3, rf=0.45) provided the colorless syrup(S)—N—((R)-3-(benzyloxy)-2-hydroxypropyl)-2-chloropropanamide, 25 (9.86g, 36.2 mmol, 73% yield) after the desired collected fractions wereconcentrated and dried in vacuo.

Compound 26: To the stirred suspension of 60% sodium hydride (5.82 g,0.0728 mol) in THF (440 mL) cooled to 0° C. was added 25 (9.89 g, 36.4mmol) in THF (100 mL) dropwise over a 15 min period. The reactionmixture was stirred at 0° C. an additional 30 min after which time itwas allowed to warm to rt for 1 h. The completed reaction completioncooled to 0° C. upon which time isopropyl alcohol (100 mL) was addedslowly. The crude solution was neutralized with Dowex H⁺ followed byfiltering off the resin, washing with isopropanol two times (20 mL each)and concentrating the filtrate to dry. The crude product was purifiedover silica gel (SNAP 100 g, hep/EtOAc=1/1 to EtOAc only, TLChep/EtOAc=1/3, rf=0.4)) to provide(2R,6R)-6-((benzyloxy)methyl)-2-methylmorpholin-3-one, 26 (6.42 g, 27.3mmol, 75% yield) after the desired collected fractions were collected,concentrated and dried in vacuo.

Compound 11

To a stirred solution of 26 (6.67 g, 28.3 mmol) in THF (20 mL) solutionwas added to 1 M of lithium tetrahydroaluminate in THF (40.0 mL) at rtdropwise. The reaction was stirred at rt for 2.5 h after which time thecompleted reaction was cooled to 0° C. followed by a slow dropwiseaddition of water (13 mL), then 1 M of NaOH in water (0.8 mL). Thequenched reaction was stirred at rt until a free flowing whiteprecipitate formed. The precipitate was filtered over a Celite 545 padand washed with EtOAc, DCM, and Et₂O (10 mL each). The filtrate wasconcentrated and purified over silica gel (SNAP 100 g, DCM only toDCM/MeOH=97/3, TLC CHCl₃/MeOH=9/1, rf_(trans)=0.5, rf_(cis)=0.4).Obtained the cis/trans diastereomer mixture of 11 (4.42 g, 20.0 mmol,70.6% yield) of which pure 11 (0.93 g, 4.2 mmol, 15% yield) wasobtained.

Alternative Preparation of Compound 12—scheme 8

Compound 28: To a suspension of sodium carbonate (31 g, 0.37 mol) inwater (50 ml) was added a solution of 1-amino-3,3-diethoxypropane (10.00mL, 61.81 mmol) in DCM (50 mL) followed by cooling to 0° C.benzenesulfonyl chloride (7.65 mL, 60.0 mmol) was added at 0° C. withvigorous stirring followed by warming to 20° C. and continued stirringfor 2 h after which time MTBE (150 mL) was added. Organic layer wasseparated, washed with 1.0 M of HCl (50 mL), saturated NaHCO₃ (50 g),water (50 g), concentrated and azeotroped to dry two times with MTBE(150 mL×2) to provide N-(3,3-diethoxypropyl)benzenesulfonamide, 28(17.34 g, 60.34 mmol, 97% yield) as light yellow clear oil.

Compound 30: To a stirred solution of 2-fluoro-4-hydroxybenzonitrile, 29(15.00 g, 0.1094 mol) in DMF (45.0 mL) cooled to 0° C. was addedpotassium carbonate (37.8 g, 0.274 mol) followed by stifling at 0-5° C.for 30 min. Benzyl bromide (13.7 mL, 0.115 mol) was added to thereaction mixture at <5° C., stirred at 5° C. for 1 h followed by warmingto 20° C. and stirring for additional 2.5 h. The completed reaction waspartitioned between water (180 ml) and MTBE (220 mL), the layersseparated and the organic layer was washed with water (90 mL),concentrated and azeotroped to dry two times with EtOAc (150 mL each) toprovide 4-(benzyloxy)-2-fluorobenzonitrile, 30 (24.64 g, 0.1084 mol, 99%yield) as white solid.

Compounds 32: To a stirred solution of 28 (13.28 g, 46.21 mmol) in NMP(30.0 mL) was added 30 (10.00 g, 44.01 mmol) at rt followed by Cs₂CO₃(21.5 g, 66.0 mmol). Resultant mixture was heated at 110° C. for 16 hfollowed cooling to rt. The mixture was partitioned between water (120g) and MTBE (120 mL) and the aqueous layer was extracted with MTBE (120mL). The combined organic layers were washed with water (60 g)concentrated and azeotroped to dry two times with EtOAc (100 mL each) togiveN-(5-(benzyloxy)-2-cyanophenyl)-N-(3,3-diethoxypropyl)benzenesulfonamide,31, as a brownish oil. The crude product was subjected to hydrogenolysiswith 10 wt % Pd—C(1.40 g) in EtOAc (100 mL) under a hydrogen gasatmosphere (balloon pressure) for 3 h, after which time the purgedreaction mixture was filtered through a pad of Celite, rinsed with EtOAc(100 mL) and concentrated. The crude product thus obtained was purifiedover silica gel (eluting with n-heptane/MTBE 2:3) to provideN-(2-cyano-5-hydroxyphenyl)-N-(3,3-diethoxypropyl)benzenesulfonamide, 32(16.38 g, 40.50 mmol, 92% yield) as yellow viscous oil.

Compound 33: To a stirred solution of 32 (5.45 g, 13.5 mmol) in THF (40mL) cooled to 0° C. was added water (5.4 mL) followed by TFA (11 mL,0.14 mol). The resultant mixture was allowed to warm to 20° C. andstirred overnight. The completed reaction was azeotroped to dry twotimes with toluene (54 mL each) to provideN-(2-cyano-5-hydroxyphenyl)-N-(3-oxopropyl)benzenesulfonamide, 33 (4.55g, 13.8 mmol, 100% yield. as viscous oil.

Compound 34: To a stirred suspension of 33 (1.64 g, 4.96 mmol) in amixture of toluene (29.5 mL) and NMP (1.2 mL) heated at 70° C. was addedD-(+)-10-camphorsulfonic acid (1.15 g, 4.96 mmol) followed by heating at100° C. for 14 h. The completed reaction was cooled to rt, diluted withEtOAc (60 mL), washed with water (6.3 mL), and concentrated to give darkbrownish oil. Crude product was purified over silica gel (eluting withn-heptane/EtOAc 1:1) to provide5-hydroxy-1-(phenylsulfonyl)-1,2-dihydroquinoline-8-carbonitrile, 34(685 mg, 2.19 mmol, 44% yield) as yellow solid.

Compounds 35 and 12: To a stirred suspension of 34 (0.393 g, 1.26 mmol)in DCM (3.0 ml) was added 2,6-lutidine (0.437 ml, 3.78 mmol) followed bycooling to 1-2° C. A solution of trifluoromethanesulfonic anhydride(0.275 ml, 1.64 mmol) in DCM (1.0 ml) was added while maintaining thetemperature below 4° C. The reaction mixture was stirred at 2-3° C. for1 h, poured into a pre-chilled (5° C.) mixture of MTBE (20 ml) and 1 MHCl (6.3 ml). The resultant, separated organic layer was washed with 9wt % NaHCO₃ (3 g), 20 wt % NaCl (5 g), dried over Na₂SO₄ (2 g) for 1 h,filtered and concentrated to give crude8-cyano-1-(phenylsulfonyl)-1,2-dihydroquinolin-5-yltrifluoromethane-sulfonate, 35 as a yellow oil. 35 was dissolved in NMP(2.5 ml) and DIPEA (1.75 ml, 10.1 mmol) followed by 11 (0.446 g, 2.02mmol) and resultant mixture was heated at 125° C. overnight. Thecompleted reaction was cooled to rt and partitioned between EtOAc (30ml) and water (10 ml). The organic layer was washed with water (10 ml),concentrated and purified over a silica gel plug column (eluting withn-heptane/EtOAc 1:1) to provide5-((2R,6R)-2-((benzyloxy)methyl)-6-methylmorpholino)-quinoline-8-carbonitrile,12 (80.2 mg, 0.215 mmol, 17% yield) as brownish solid.

synthesis of Compound 36—scheme 9: To a stirred suspension of 13 (10.97g, 38.72 mmol) in DCM (44 mL) was added 2,6-lutidine (5.38 mL, 46.5mmol) followed by cooling to 0° C. A solution oftrifluoromethanesulfonic anhydride (Tf₂O; 6.84 mL, 40.7 mmol) in DCM (22mL) was added while maintaining the temperature at <5° C. and stirringfor 1 h. The completed reaction was quenched with saturated sodiumbicarbonate (65 g) and the mixture was warmed up to 15° C. The layerswere separated and the aqueous layer was extracted with DCM (55 mL). Thecombined organic layers were washed with 20 wt % NaCl (33 g) and stirredover Florisil (11 g) for 1.5 h after which time the mixture wasfiltered, eluted with MTBE (55 mL) and concentrated. The tan solid wassuspended in DCM (11 ml), diluted with n-heptane (110 ml), filtered,rinsed with n-heptane/DCM 10:1 (121 ml), and dried under vacuum toprovide ((2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyltrifluoromethanesulfonate, 36 (15.20 g, 36.6 mmol, 94% yield) as lighttan solid.

synthesis of ER-887927 using Schemes 9 and 17:

To a stirred suspension of 36 (1.002 g, 2.412 mmol) in acetonitrile (6.0mL) was added potassium carbonate (1.33 g, 9.65 mmol) followed bycommercially available 1,4′-bipiperidine, 72 (609 mg, 3.62 mmol). Thereaction mixture was heated at reflux for 5 h after which time thecompleted reaction was cooled to rt, diluted with water (12 mL) andpartially concentrated. N-Heptane (10 mL) and MTBE (10 mL) were addedand the mixture was partially concentrated upon which time a brownishsolid thus formed was collected by filtration, rinsed with: (1) water(15 mL) and (2) n-heptane (15 mL), and dried under vacuum overnight. Thedried solid was dissolved in n-heptane (10 mL, 0.2 mol), diluted withacetonitrile (5.0 mL, 0.096 mol) then treated with Florisil (0.50 g) atrt for 10 min. The mixture was filtered, eluted with acetonitrile (10mL) and concentrated to give tan solid, which was triturated withMTBE/n-heptane 1:2 (15 ml), filtered, rinsed with MTBE/n-heptane 1:3 (10ml) and dried under N₂/vacuum to give ER-887927 as light tan powder(1.001 g, 2.31 mmol, 95% yield).

ER-893881 (15.2 mg, 0.037 mmol, 51.6% yield) was prepared by a similarmethod described for ER-887927 starting with 36 (30 mg, 0.072 mmol) and(S)-1,3′-bipyrrolidine dihydrochloride (20.5 mg, 0.144 mmol) using TEA(0.020 mL, 0.141 mmol) instead of K₂CO₃.

ER-894483 (30 mg, 0.079 mmol, 32.8% yield) was prepared by a similarmethod described for ER-893881 starting with 36 (100 mg, 0.241 mmol) and(R)-3-methylpiperazin-2-one (54.9 mg, 0.481 mmol).

ER-894484 (30 mg, 0.079 mmol, 32.8% yield) was prepared by a similarmethod described for ER-893881 starting with 36 (100 mg, 0.241 mmol) and(S)-3-methylpiperazin-2-one (54.9 mg, 0.481 mmol).

ER-894504 (30 mg, 0.076 mmol, 31.5% yield) was prepared by a similarmethod described for ER-893881 starting with 36 (100 mg, 0.241 mmol) and(2S,5R)-2,5-dimethylpiperazine (54.9 mg, 0.481 mmol).

ER-894505 (30 mg, 0.076 mmol, 31.5% yield) was prepared by a similarmethod described for ER-893881 starting with 36 (100 mg, 0.241 mmol) and2,3-dimethylpiperazine (54.9 mg, 0.481 mmol).

ER-894655 (140 mg, 0.309 mmol, 64.2% yield) was prepared by a similarmethod described for ER-893881 starting with 36 (200 mg, 0.482 mmol) andtert-butyl 2,2-dimethylpiperazine-1-carboxylate (206 mg, 0.961 mmol).The Boc-protecting group was hydrolyzed using 4 N HCl dioxane followedby isolation of the desired product by azeotroping to dry with tolueneand drying under vacuo.

ER-894151 (1.066 g, 3.16 mmol, 65.4% yield) was prepared by a similarmethod described for ER-893881 starting with 36 (2.0 g, 4.81 mmol) andtert-butyl azetidin-3-ylcarbamate (0.995 g, 5.78 mmol). TheBoc-protected intermediate was deprotected using TFA (3 mL) in DCM (3mL). The reaction was allowed to stir for 30 m, after which time thereaction was concentrated to dry with azeotroping three times withtoluene (5 mL each). The residue was diluted with DCM (10 mL), washedtwo times with sat. NaHCO₃ (5 mL), water (5 mL), brine (5 mL), driedover MgSO₄, filtered, concentrated and dried in vacuo to provide thedesired product.

ER-890250: To a cooled stirring solution of ER-887927 (50 mg, 0.115mmol) in THF (1 mL) at −78° C. was added 1.6 M methyl lithium-lithiumbromide complex in ethyl ether (0.15 mL, 0.24 mmol) whereupon the paleyellow solution was changed to bright red/orange. The reaction mixturewas stirred for 1.5 h at −78° C. after which time it was quenched withaqueous ammonium hydroxide (2 mL) followed by slowly warming to rt. Thereaction was extracted three times with DCM (5 mL) and the combinedorganic layers were dried over, filtered and concentrated to dry.

The crude intermediate was dissolved in acetone (1 mL) followed by asolution of ceric ammonium nitrate (300 mg, 0.547 mmol) in water (1.5mL). The reaction mixture was stirred for 30 min after which time thereaction mixture was concentrated to a crude solid. The solid wassuspended in acetone 5 mL, stirred for 5 min, filtered and the solidfilter pad eluted three times with acetone (5 mL each). The combinedfiltrates were concentrated in then purified by reverse-phase HPLC(X-Bridge C18 19×100 mm column using a acetonitrile/water gradientcontaining 0.1% formic acid). The desired fractions were combined,concentrated, dissolved in MeOH (2 mL), passed over a SiCO₃ column,eluted two times with MeOH, concentrated and dried in vacuo to provideER-890250 (4.4 mg, 0.010 mmol, 8.5% yield).

synthesis of ER-884884 from Scheme 10:

Compound 37: To a stirred solution of 22 from Scheme 6 (1.003 g, 3.121mmol) in EtOH (5 mL) was added 5% Pd on carbon (100 mg) followed bycharging the flask several times with hydrogen gas. The reaction washeated to 40° C. maintaining a hydrogen atmosphere (balloon pressure)and stirred overnight, after which time the reaction was purged withnitrogen gas several times while evacuating the system with house vacuumbetween purges. The completed reaction was filtered over Celite 545, thefilter pad washed two times with EtOH (5 mL each), followed byconcentration of the combined filtrates were concentrated and dried invacuo. The crude product, (3R,5S)-tert-butyl3-(hydroxymethyl)-5-methylpiperidine-1-carboxylate (0.720 g, 3.114 mmol,99.8% yield) was used in the next step without further purification.

To a stirred solution of (3R,5S)-tert-butyl3-(hydroxymethyl)-5-methylpiperidine-1-carboxylate (0.783 g, 3.385 mmol)in DCM (5 mL) was added p-toluenesulfonyl chloride (0.968 g, 5.078 mmol)followed by DMAP (40 mg, 0.33 mmol) and DIPEA (1.18 mL, 6.77 mmol) atrt. The reaction mixture was stirred at rt for 3 h after which timewater (5 mL) was added followed by stifling an additional 15 min. Theresultant organic layer was washed with 0.1 N HCl (5 mL), brine (3 mL),dried over MgSO₄, filtered and concentrated to dryness. The crudeproduct was purified over silica gel (Biotage, eluting with 3:1heptanes: EtOAc) to provide (3S,5R)-tert-butyl3-methyl-5-((tosyloxy)methyl)piperidine-1-carboxylate (0.8602 g, 2.232mmol, 65.9% yield).

To a stirred solution of (3S,5R)-tert-butyl3-methyl-5-((tosyloxy)methyl)piperidine-1-carboxylate (0.860 g, 2.232mmol) in DMF (7 mL) at rt was added sodium azide (0.218 g, 3.347 mmol)after which time the reaction was warmed to 80° C. and stirred anadditional 3 h. The completed reaction was cooled to rt, diluted withEtOAc (25 mL) and washed three times with water (5 mL each). Theresultant organic layer was dried over anhydrous Na₂SO₄, filtered,concentrated after which time the crude product was purified over silicagel (Biotage eluting with 0 to 15% EtOAc in heptane gradient) to provide(2R,6R)-tert-butyl 2-(azidomethyl)-6-methylmorpholine-4-carboxylate, 37(0.545 g, 2.126 mmol, 95.3% yield) as a colorless crystalline solidafter concentration of the desired combined fractions and drying invacuo.

ER-884884: To a stirred solution of 37 (0.545 g, 2.126 mmol) in MeOH (5mL) was added 5% palladium on activated carbon (250 mg) followed bycharging the flask several times with hydrogen gas. The reaction wasmaintaining under a hydrogen atmosphere (balloon pressure) at rt andstirred for 12 h, after which time the reaction was purged with nitrogengas several times while evacuating the system with house vacuum betweenpurges. The completed reaction was filtered over Celite 545, the filterpad washed two times with EtOH (2 mL each), followed by concentration ofthe combined filtrates were concentrated and dried in vacuo. The crudeproduct, (2S,6R)-tert-butyl2-(aminomethyl)-6-methylmorpholine-4-carboxylate (0.489 g, 2.10 mmol,99.9% yield) was used in the next step without further purification.

To a stirred solution of (2S,6R)-tert-butyl2-(aminomethyl)-6-methylmorpholine-4-carboxylate (50.2 mg, 0.218 mmol)in DCM (0.5 mL) was added TFA (0.25 mL, 3.4 mmol) at rt. The reactionmixture was stirred for 1 h after which time it was concentrated andazeotroped to dry two times with toluene (2 mL each) and dried in vacuo.The crude deprotected morpholine was dissolved with stirring in DMA (1mL) followed by TEA (2 mL) and compound 3 (50 mg, 0.214 mmol). Thereaction mixture was warmed to 140° C. and stirred for 1 h after whichtime the completed reaction was cooled to rt and directly injected ontoa preparative reverse-phase HPLC column (after filtering) to provideER-884884 (12.1 mg, 0.043 mmol, 19.7% yield) after concentration of thedesired combined fractions and drying under vacuo.

substituted Compound 15, Scheme 10 or ER-879713: To a stirred solutionof ER-884884 (30.2 mg, 0.107 mmol) in DCM (0.5 mL) was added TEA (30 uL,0.20 mmol) followed by 2,2-dimethylpropanoyl chloride (20 uL, 0.162mmol). The reaction mixture was stirred at rt for 3 h after which timethe completed reaction was concentrated, filtered, and purified directlyvia preparative reverse-phase HPLC (Water's X-Bridge C18 19×100 mmcolumn; eluted with a gradient of acetonitrile in water containing 0.05%TFA) to provide ER-879713 (20.5 mg, 0.056 mmol, 52.3% yield) afterconcentration of the desired combined fractions and drying under vacuo.

ER-886432 (10.2 mg, 0.023 mmol, 52.7% yield) was obtained using asimilar process to ER-879713 starting with ER-884884 (50 mg, 0.177 mmol)and 1-phenylcyclobutanecarbonyl chloride (8.5 mg, 0.044 mmol).

ER-886563 (3.6 mg, 0.023 mmol, 20.3% yield) was obtained using a similarprocess to ER-879713 starting with ER-884884 (12.4 mg, 0.044 mmol) andbenzeneacetyl chloride (0.007 mL, 0.053 mmol).

ER-888137: To a stirred solution of ER-884884 (30.2 mg, 0.107 mmol) inNMP(0.5 mL) was added 2-chloro-5-fluoropyrimidine (140 mg, 1.056 mmol).The reaction mixture was microwaved at 150° C. for 5 min, after whichtime the cooled reaction was purified over a C-18 reverse-phase HPLCpreparative column eluting with a 10 to 40% acetonitrile in watergradient. The desired fractions were concentrated and dried under vacuoto provide ER-888137 (6.5 mg, 0.017 mmol, 9.7% yield).

ER-888701 (12.2 mg, 0.031 mmol, 17.7% yield) was prepared in a similarmanner to ER-888137 starting with ER-884884 (50 mg, 0.177 mmol) and2-chloro-5-ethylpyrimidine (150 mg, 1.052 mmol).

ER-888896 (3.0 mg, 0.008 mmol, 23.1% yield) was prepared in a similarmanner to ER-888137 starting with ER-884884 (10.1 mg, 0.036 mmol) and2-chloropyrazine (30 mg, 0.261 mmol).

ER-879713 or Compound 76 using Scheme 18:

Compound 73: To a stirred solution of 37 (0.545 g, 2.126 mmol) in MeOH(5 mL) was added 5% palladium on activated carbon (250 mg) followed bycharging the flask several times with hydrogen gas. The reaction wasmaintaining under a hydrogen atmosphere (balloon pressure) at rt andstirred for 12 h, after which time the reaction was purged with nitrogengas several times while evacuating the system with house vacuum betweenpurges. The completed reaction was filtered over Celite 545, the filterpad washed two times with EtOH (2 mL each), followed by concentration ofthe combined filtrates were concentrated and dried in vacuo. The crudeproduct, (2S,6R)-tert-butyl2-(aminomethyl)-6-methylmorpholine-4-carboxylate, 73 (0.489 g, 2.10mmol, 99.9% yield) was used in the next step without furtherpurification.

Compound 74: To a stirred solution of 73 (50.2 mg, 0.218 mmol) in DCM(0.5 mL)) was added TEA (36.5 uL, 0.268 mmol) followed by2,2-dimethylpropanoyl chloride (29.5 uL, 0.235 mmol). The reactionmixture was stirred at rt for 1 h after which time the completedreaction was poured over water, extract three times with DCM (3 mL each)and the combined organic layers were dried over MgSO₄, filtered,concentrated, and dried under vacuo to provide crude (2R,6S)-tert-butyl2-methyl-6-(pivalamidomethyl)morpholine-4-carboxylate, 74 (R=tBu).

ER-879713: To as stirred solution of crude 74 in DCM (5 mL) was addedTFA (0.25 mL, 3.4 mmol) followed by stirring at rt for 1 h. Thecompleted reaction was concentrated and azeotroped two times withtoluene and then dried in vacuo for 30 min, after which time the crude,advanced intermediate, 75, was dissolved in DMA (1 mL) followed by TEA(2 mL) and compound 3 (50 mg, 0.214 mmol). The reaction mixture waswarmed to 140° C. and stirred for 1 h after which time the completedreaction was cooled to rt and directly injected onto a preparativereverse-phase HPLC column (after filtering) to provide an example of 76or ER-879713 (9.3 mg, 0.025 mmol, 11.6% yield, R=tBu) afterconcentration of the desired combined fractions and drying under vacuo.

ER-879689 (4.3 mg, 0.013 mmol, 6.0% yield, R=Me) was obtain using asimilar process to ER-879713 starting with 73 (50.2 mg, 0.218 mmol,R=Me) and 3 (50 mg, 0.215 mmol).

ER-886360 (14.3 mg, 0.035 mmol, 15.8% yield, R═CH(Me)Ph) was obtainusing a similar process to ER-879713 starting with 73 (50.2 mg, 0.218mmol, R═CH(Me)Ph) and 3 (50 mg, 0.215 mmol).

Additional examples of substituted Compound 15:

ER-888603: To stirred solution of 37 (58.1 mg, 0.227 mmol) andcyclohexylacetylene (0.026 mL, 0.200 mmol) in tert-butyl alcohol (0.08mL) and water (0.07 mL) was added sodium bicarbonate (2.5 mg, 0.030mmol) followed by copper(II) sulfate pentahydrate (2.5 mg, 0.010 mmol)and sodium ascorbate (7.8 mg, 0.039 mmol). The reaction mixture wasstirred at rt for 14 h after which time DCM (5 mL) and saturated sodiumbicarbonate (5 mL) was added and stirred an additional 10 min. Thelayers were separated and the aqueous layer was extracted two times withDCM (3 mL each). The combined organic layers were dried over anhydrousMgSO₄, filtered and concentrated to dry. The crude Boc-protectedintermediate was dissolved with stirring in DCM (3 mL) followed by TFA(0.8 mL). The reaction was stirred at rt for 1 h after which time thecompleted reaction was concentrated and azeotroped to dryness usingtoluene (2 times @ 5 mL each). The crude product was purified via HPLC(Water's X-Bridge C18 19×100 mm column; eluted with a gradient ofacetonitrile in water containing 0.05% TFA) to provide(2R,6R)-2-((4-cyclohexyl-1H-1,2,3-triazol-1-yl)methyl)-6-methylmorpholine(8.9 mg, 0.034 mmol, 16.8% yield)

To a stirred solution of(2R,6R)-2-((4-cyclohexyl-1H-1,2,3-triazol-1-yl)methyl)-6-methylmorpholine(8.9 mg, 0.034 mmol) in DMA (0.3 mL) and TEA (0.005 mL, 0.036 mmol) wasadded 3 (7.85 mg, 0.034 mmol). The mixture was microwaved at 150° C. for30 min after which time the cooled reaction was directly injected onto apreparative, C-18 reverse phase HPLC column (Water's X-Bridge C18 19×100mm column; eluting with a gradient of 10-40% acetonitrile in watercontaining 0.05% TFA). The desired collected fractions were concentratedand dried in vacuo to provide ER-888603 (3.3 mg, 0.008 mmol, 23.3% yieldor a 3.9% overall yield).

ER-888604 (5.2 mg, 0.013 mmol, 6.5% overall yield) was prepared in asimilar manner to ER-888603 starting with 37 (58.1 mg, 0.227 mmol),phenylacetylene (0.022 mL, 0.200 mmol) and 3 (7.85 mg, 0.034 mmol).

ER-889556: To a stirred suspension of ER-887268 (140.3 mg, 0.384 mmol)in water (1.5 mL) was added formaldehyde (1 mL) and formic acid (0.55mL) after which time the reaction mixture was microwaved at 110° C. for1.5 h. The completed reaction was cooled and directly injected onto apreparative, C-18 reverse phase HPLC column eluting with a gradient of10-40% acetonitrile in water containing 0.1% TFA. The desired collectedfractions were concentrated, dissolved in MeOH (5 mL), passed over aplug of SiCO₃ eluting with MeOH (10 mL), concentrated and dried in vacuoto provide ER-889556 (75 mg, 0.197 mmol, 51.5% yield).

ER-890114 (75.9 mg, 0.170 mmol, 40.5% yield) was prepared in a similarmanner to ER-889556 starting with ER-890112 (182 mg, 0.420 mmol).

ER-890108 (72.1 mg, 0.171 mmol, 40.7% yield) was prepared in a similarmanner to ER-889556 starting with ER-890119 (170.6 mg, 0.420 mmol).

ER-890345 (43.5 mg, 0.115 mmol, 38% yield) was prepared in a similarmanner to ER-889556 starting with ER-890344 (110.2 mg, 0.302 mmol).

ER-890346 (52.6 mg, 0.139 mmol, 73.3% yield) was prepared in a similarmanner to ER-889556 starting with ER-887269 (69 mg, 0.189 mmol).

ER-890831 (85.2 mg, 0.225 mmol, 74.5% yield) was prepared in a similarmanner to ER-889556 starting with ER-887270 (110.2 mg, 0.302 mmol).

ER-890964 (506.2 mg, 1.286 mmol, 71.2% yield) was prepared in a similarmanner to ER-889556 starting with ER-890963 (685.2 mg, 1.806 mmol).

ER-890186 (10.2 mg, 0.023 mmol, 20.7% yield) was prepared in a similarmanner to ER-889556 starting with ER-890107 (48 mg, 0.111 mmol).

ER-890223 (35 mg, 0.078 mmol, 42.9% yield) was prepared in a similarmanner to ER-889556 starting with ER-890106 (100 mg, 0.182 mmol) as theTFA salt.

ER-894656 (31.7 mg, 0.068 mmol, 61.5% yield) was prepared in a similarmanner to ER-889556 starting with ER-894655 (50 mg, 0.111 mmol) as thedihydrochloride salt.

ER-889728: To a stirred solution of ER-888070 (12.5 mg, 0.034 mmol) inDCM (0.5 mL) was added TEA (0.01 mL, 0.072 mmol) followed by nicotinoylchloride (10 mg, 0.071 mmol). The reaction mixture was stirred at rt for1 h after which time the reaction was diluted with DCM (5 mL), washedwith water (2 mL), brine (2 mL), dried over MgSO₄, filtered andconcentrated to dry. The crude product was purified over a preparative,C-18 reverse phase HPLC column eluting with a gradient of 10-25%acetonitrile in water containing 0.1% TFA. The desired collectedfractions were concentrated, dissolved in MeOH (5 mL), passed over aplug of SiCO₃ eluting with MeOH (10 mL), concentrated and dried in vacuoto provide ER-889728 (7.2 mg, 0.015 mmol, 45% yield).

ER-889729 (8.2 mg, 0.017 mmol, 51.3% yield) was prepared in a similarmanner to ER-889728 starting with ER-888070 (12.5 mg, 0.034 mmol) andisonicotinoyl chloride (10 mg, 0.071 mmol).

ER-889734 (8.6 mg, 0.018 mmol, 52.9% yield) was prepared in a similarmanner to ER-889728 starting with ER-888070 (12.5 mg, 0.034 mmol) andpicolinoyl chloride (10 mg, 0.071 mmol).

ER-889744 (12 mg, 0.028 mmol, 80.8% yield) was prepared in a similarmanner to ER-889728 starting with ER-888070 (12.5 mg, 0.034 mmol) andhexanoyl chloride (9 mg, 0.067 mmol).

ER-889745 (8 mg, 0.018 mmol, 54% yield) was prepared in a similar mannerto ER-889728 starting with ER-888070 (12.5 mg, 0.034 mmol) andisobutyryl chloride (7 mg, 0.066 mmol).

ER-889746 (7.6 mg, 0.017 mmol, 50% yield) was prepared in a similarmanner to ER-889728 starting with ER-888070 (12.5 mg, 0.034 mmol) and2,2-dimethylpropanoyl chloride (8 mg, 0.066 mmol).

ER-890113 (25.6 mg, 0.054 mmol, 66.7% yield) was prepared in a similarmanner to ER-889728 starting with ER-890112 (35.2 mg, 0.081 mmol) andacetic anhydride (0.093 mL, 0.984 mmol).

ER-890120 (20.3 mg, 0.045 mmol, 54.2% yield) was prepared in a similarmanner to ER-889728 starting with ER-890119 (33.7 mg, 0.083 mmol) andacetic anhydride (0.012 mL, 0.127 mmol).

ER-890122 (35.2 mg, 0.069 mmol, 43.1% yield) was prepared in a similarmanner to ER-889728 starting with ER-890119 (65.2 mg, 0.160 mmol) andbenzoyl chloride (0.037 mL, 0.318 mmol).

ER-890142 (45.2 mg, 0.084 mmol, 53.1% yield) was prepared in a similarmanner to ER-889728 starting with ER-890112 (68.5 mg, 0.158 mmol) andbenzoyl chloride (0.037 mL, 0.318 mmol).

ER-890187 (9.4 mg, 0.020 mmol, 18.0% yield) was prepared in a similarmanner to ER-889728 starting with ER-890107 (48 mg, 0.111 mmol) andacetic anhydride (0.125 mL, 1.3 mmol).

ER-890188 (8.9 mg, 0.018 mmol, 16.0% yield) was prepared in a similarmanner to ER-889728 starting with ER-890107 (48 mg, 0.111 mmol) andisobutyryl chloride (0.051 mL, 0.487 mmol).

ER-890189 (10 mg, 0.019 mmol, 16.7% yield) was prepared in a similarmanner to ER-889728 starting with ER-890107 (48 mg, 0.111 mmol) andbenzoyl chloride (0.056 mL, 0.482 mmol).

ER-890190 (6.5 mg, 0.014 mmol, 36.8% yield) was prepared in a similarmanner to ER-889728 starting with ER-890119 (15.6 mg, 0.038 mmol) andisobutyryl chloride (0.006 mL, 0.058 mmol).

ER-890219 (32.0 mg, 0.067 mmol, 91.8% yield) was prepared in a similarmanner to ER-889728 starting with ER-890106 (40.2 mg, 0.073 mmol) as theTFA salt, TEA (0.20 mL, 1.43 mmol) and acetic anhydride (0.10 mL, 1.06mmol).

ER-890221 (28.2 mg, 0.056 mmol, 76.7% yield) was prepared in a similarmanner to ER-890219 starting with ER-890106 (40.2 mg, 0.073 mmol) as theTFA salt and isobutyryl chloride (0.080 mL, 0.764 mmol).

ER-890222 (30.1 mg, 0.056 mmol, 76.7% yield) was prepared in a similarmanner to ER-890219 starting with ER-890106 (40.5 mg, 0.074 mmol) as theTFA salt and benzoyl chloride (0.20 mL, 1.723 mmol).

ER-892254 (24.2 mg, 0.0.52 mmol, 67.5% yield) was prepared in a similarmanner to ER-889728 starting with ER-892253 (32.2 mg, 0.077 mmol) andacetic anhydride (0.015 mL, 0.151 mmol). Acetonitrile (0.5 mL) was addedto the reaction mixture.

ER-892256 (25.2 mg, 0.052 mmol, 41.9% yield) was prepared in a similarmanner to ER-889728 starting with ER-890119 (50.2 mg, 0.124 mmol) andmethanesulfonyl chloride (0.011 mL, 0.142 mmol).

ER-893926 (124.2 mg, 0.255 mmol, 51.7% yield) was prepared in a similarmanner to ER-889728 starting with ER-888070 (180.2 mg, 0.493 mmol) and1,3-dimethyl-1H-pyrazole-4-carbonyl chloride (93.8 mg, 0.592 mmol).

ER-893927 (45.2 mg, 0.0.83 mmol, 57.8% yield) was prepared in a similarmanner to ER-889728 starting with ER-892253 (60.5 mg, 0.144 mmol) and1,3-dimethyl-1H-pyrazole-4-carbonyl chloride (27.4 mg, 0.173 mmol).

ER-893948 (65.3 mg, 0.147 mmol, 29.9% yield) was prepared in a similarmanner to ER-889728 starting with ER-888070 (180.2 mg, 0.493 mmol) andmethanesulfonyl chloride (68 mg, 0.593 mmol).

ER-894149 (67.2 mg, 0.133 mmol, 80.6% yield) was prepared in a similarmanner to ER-889728 starting with ER-888070 (60.2 mg, 0.165 mmol) andbenzenesulfonyl chloride (0.023 mL, 0.180 mmol).

ER-894150 (58.2 mg, 0.111 mmol, 69.9% yield) was prepared in a similarmanner to ER-889728 starting with ER-888070 (58.2 mg, 0.159 mmol) and4-fluorobenzenesulfonyl chloride (0.025 mL, 0.188 mmol).

ER-894152 (36.2 mg, 0.095 mmol, 63.6% yield) was prepared in a similarmanner to ER-889728 starting with ER-894151 (50.6 mg, 0.150 mmol) andacetic anhydride (0.014 mL, 0.135 mmol).

ER-894153 (5.4 mg, 0.012 mmol, 7.4% yield) was prepared in a similarmanner to ER-889728 starting with ER-894151 (52.2 mg, 0.155 mmol) and4-fluorobenzenzoyl chloride (25 mg, 0.158 mmol).

ER-894154 (38.5 mg, 0.093 mmol, 62.4% yield) was prepared in a similarmanner to ER-889728 starting with ER-894151 (50.4 mg, 0.149 mmol) andmethanesulfonyl chloride (0.012 mL, 0.146 mmol).

ER-894155 (42.1 mg, 0.085 mmol, 57.1% yield) was prepared in a similarmanner to ER-889728 starting with ER-894151 (50.3 mg, 0.149 mmol) and4-fluorobenzenesulfonyl chloride (29 mg, 0.149 mmol).

ER-894159 (20.4 mg, 0.041 mmol, 27.4% yield) was prepared in a similarmanner to ER-889728 starting with ER-894151 (50.5 mg, 0.150 mmol) and1,3-dimethyl-1H-pyrazole-4-sulfonyl chloride (29 mg, 0.149 mmol).

ER-894160 (47.2 mg, 0.0.90 mmol, 65.8% yield) was prepared in a similarmanner to ER-889728 starting with ER-888070 (50.1 mg, 0.137 mmol) and1,3-dimethyl-1H-pyrazole-4-sulfonyl chloride (27 mg, 0.139 mmol).

ER-894206 (11.3 mg, 0.029 mmol, 19% yield) was prepared in a similarmanner to ER-889728 starting with ER-894151 (50.6 mg, 0.150 mmol) andisobutyryl chloride (16. mg, 0.150 mmol).

ER-894594 (215 mg, 0.487 mmol, 46.4% yield) was prepared in a similarmanner to ER-889728 starting with ER-894151 (354 mg, 1.049 mmol) andbenzoic anhydride (407 mg, 1.81 mmol). Acetonitrile (2 mL) was usedinstead of DCM.

Preparation of ER-890252: To a stirred solution of 36 (2.0 g, 4.8 mmol)from Scheme 9 in acetonitrile (15 mL) was added (R)-tert-butylpyrrolidin-2-ylcarbamate (1.10 g, 5.9 mmol) followed by TEA (1.6 mL,11.5 mmol). The reaction was stirred at 70° C. for 3 h after which timethe completed reaction was concentrated to a crude syrup, diluted withDCM (20 mL), washed with water (5 mL), dried over, filtered andconcentrated to dryness. The crude product was purified over silica gel(Biotage SP4, 40+M, eluting with a gradient of 5% MeOH in 1:1 EtOAc:DCMto 10% MeOH in 1:1 EtOAc:DCM over a 10 column volume cycle. The productcontaining fractions were combined, concentrated and dried under vacuoto providetert-butyl((R)-1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)pyrrolidin-3-yl)carbamate(1.35 g, 3.0 mmol, 62% yield).

To a stirred solution oftert-butyl((R)-1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)-pyrrolidin-3-yl)carbamate(1.35 g, 3.0 mmol) in DCM (10 mL) was added TFA (8.1 mL). The reactionwas stirred at rt after which time it was concentrated and azeotroped todryness three times with toluene (10 mL each) and then dried under vacuoto provide crude5-((2S,6R)-2-(((R)-3-aminopyrrolidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile(1.39 g, 3.0 mmol, 100% yield) as the TFA salt.

ER-890252 (120.3 mg, 0.306 mmol, 71.2% yield) was prepared in a similarmanner to ER-890222 starting with5-((2S,6R)-2-(((R)-3-aminopyrrolidin-1-yl)methyl)-6-methylmorpholino)-quinoline-8-carbonitrile(200 mg, 0.430 mmol) as the TFA salt and acetic anhydride (0.80 mL, 8.46mmol).

ER-890253 (146.5 mg, 0.348 mmol, 80.8% yield) was prepared in a similarmanner to ER-890122 starting with5-((2S,6R)-2-(((R)-3-aminopyrrolidin-1-yl)methyl)-6-methylmorpholino)-quinoline-8-carbonitrile(200 mg, 0.430 mmol) as the TFA salt and isobutyryl chloride (0.50 mL,4.77 mmol).

ER-894544 (103.6 mg, 0.227 mmol, 52.9% yield) was prepared in a similarmanner to ER-890122 starting with5-((2S,6R)-2-(((R)-3-aminopyrrolidin-1-yl)methyl)-6-methylmorpholino)-quinoline-8-carbonitrile(200 mg, 0.430 mmol) as the TFA salt and benzoyl chloride (0.50 mL, 4.31mmol).

ER-894546 (96.7 mg, 0.214 mmol, 49.8% yield) was prepared in a similarmanner to ER-890222 starting with5-((2S,6R)-2-(((S)-3-aminopyrrolidin-1-yl)methyl)-6-methylmorpholino)-quinoline-8-carbonitrile(200 mg, 0.430 mmol) as the TFA salt and acetic anhydride (0.80 mL, 8.46mmol).5-((2S,6R)-2-(((S)-3-aminopyrrolidin-1-yl)methyl)-6-methylmorpholino)-quinoline-8-carbonitrilewas prepared in a similar manner to5-((2S,6R)-2-(((R)-3-aminopyrrolidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrileusing (S)-tert-butyl pyrrolidin-2-ylcarbamate as the starting materialin the first step described above for the preparation of ER-890252.

ER-894547 (120.8 mg, 0.287 mmol, 66.7% yield) was prepared in a similarmanner to ER-894546 starting with5-((2S,6R)-2-(((S)-3-aminopyrrolidin-1-yl)methyl)-6-methylmorpholino)-quinoline-8-carbonitrile(200 mg, 0.430 mmol) as the TFA salt and isobutyric anhydride (0.70 mL,4.22 mmol).

ER-894548 (110.4 mg, 0.242 mmol, 56.4% yield) was prepared in a similarmanner to ER-894546 starting with5-((2S,6R)-2-(((S)-3-aminopyrrolidin-1-yl)methyl)-6-methylmorpholino)-quinoline-8-carbonitrile(200 mg, 0.430 mmol) as the TFA salt and benzoic anhydride (0.50 g, 2.21mmol).

ER-894545 (32 mg, 0.084 mmol, 19.6% yield) was prepared in a similarmanner to ER-889556 starting with5-((2S,6R)-2-(((R)-3-aminopyrrolidin-1-yl)methyl)-6-methylmorpholino)-quinoline-8-carbonitrile(200 mg, 0.430 mmol) as the TFA.

ER-894549 (103.8 mg, 0.274 mmol, 63.6% yield) was prepared in a similarmanner to ER-889556 starting with5-((2S,6R)-2-(((S)-3-aminopyrrolidin-1-yl)methyl)-6-methylmorpholino)-quinoline-8-carbonitrile(200 mg, 0.430 mmol) as the TFA.

Preparation of 886355 using modifications to Scheme 7 and Scheme 4: To astirred solution of (R)-1-amino-3-(benzyloxy)propan-2-ol, Compound 22 inScheme 7 (8.0 g, 44.1 mmol) in DMF (60 mL) was added(S)-2-chlorobutanoic acid (5.0 g, 40.8 mmol) followed by TEA (10.5 g.103.8 mmol), DMAP (0.4 g, 3.3 mmol) and finally EDC (9.52 g, 49.7 mmol).The reaction mixture was stirred at rt for 5 d after which time thecompleted reaction was concentrated to a crude syrup. Purification oversilica gel (Biotage, eluting with a gradient of 20-100% EtOAc inheptanes) followed by collection of the desired fractions, concentrationand drying in vacuo provided(S)—N—((R)-3-(benzyloxy)-2-hydroxypropyl)-2-chlorobutanamide (683.5 mg,2.392 mmol, 5.9% yield).

To stirred suspension of sodium hydride (203.1 mg, 5.1 mmol as a 60% oildispersion) in THF (18 mL) cooled to 0° C. was added dropwise(S)—N—((R)-3-(benzyloxy)-2-hydroxypropyl)-2-chlorobutanamide (362.8 mg,1.270 mmol) in THF (3.8 mL) over a 5-min period after which the reactionwas stirred at 0° C. for 30 min followed by stirring at rt for 5 h. Thecompleted reaction was quenched with the slow addition of IPA (1 mL)followed by adding Dowex 50, H+ form, until a neutral to acidic pH wasobserved. The final suspension was filtered and the solid was rinsed twotimes with EtOAc. The combined filtrated were concentrated and theresultant crude product was purified over silica gel (Biotage, elutingwith 1:1 EtOAc:heptane). The desired fractions were combined,concentrated and dried in vacuo to provide(2R,6R)-6-((benzyloxy)methyl)-2-ethylmorpholin-3-one (314 mg, 1.260mmol, 99.2% yield).

To a stirred solution of(2R,6R)-6-((benzyloxy)methyl)-2-ethylmorpholin-3-one (362.2 mg, 1.453mmol) in THF (2 mL) was added 1 M lithium tetrahydroaluminate in THF (2mL, 2 mmol) dropwise at rt over a 2-min period. The reaction was stirredat rt for 2.5 h after which time it was cooled to 0° C. followed by adropwise addition of water (0.6 mL) and then 1 M sodium hydroxide inwater (0.04 mL). The quenched reaction was warmed to rt, stirred until agranular solid was formed and filtered over a Celite 545 pad rinsingwith EtOAc (5 mL), DCM (5 mL) and ethyl ether (5 mL). The filtrate wasconcentrated and the resultant crude product was purified over silicagel (Biotage, eluting with a gradient of 5-10% MeOH in DCM) followed bycombining the desired fractions, concentration and drying in vacuo toprovide (2R,6R)-2-((benzyloxy)methyl)-6-ethylmorpholine (50.2 mg, 0.213mmol, 14.6% yield).

To a stirred solution of (2R,6R)-2-((benzyloxy)methyl)-6-ethylmorpholine(12.4 mg, 0.053 mmol) and Compound 3 (10.2 mg, 0.044 mmol) in DMA (2 mL)was added DIPEA (0.015 mL, 0.086 mmol) followed by microwaving at 150°C. for 7 h. The cooled completed reaction was directly injected onto aC-18 reverse phase HPLC (Water's X-Bridge C18, 19×100 mm column, elutingwith a linear gradient of 10%-90% acetonitrile in water with 0.1% formicacid) and concentrating the desired peak followed by high vacuum todryness to provide ER-886355 (6.2 mg 0.016 mmol, 36.4% yield).

Preparation of ER-887199: To a stirred solution of(2R,6R)-2-((benzyloxy)methyl)-6-ethylmorpholine (552.2 mg, 2.347 mmol)in MeOH (10 mL) was cycled over 10% Pd(OH)₂ column with H₂ gas at 1atmosphere over 16 h using a H-Qube hydrogenation instrument. Thecompleted reaction solution was concentrated and dried in vacuo toprovide crude product, ((2R,6R)-6-ethylmorpholin-2-yl)methanol (320 mg,2.204 mmol, 93.9% yield) that was used in the next step without furtherpurification.

((2R,6R)-6-ethylmorpholin-2-yl)methanol (145.2 mg, 1.00 mmol) andCompound 3 (266.4 mg, 1.143 mmol) in 1-methylpyrrolidin-2-one (2 mL) wasmicrowaved at 180° C. for 15 minutes after which time it was cooled toroom temperature and directly injected onto a C-18 reverse phase HPLC(Water's X-Bridge C18, 19×100 mm column, eluting with a linear gradientof 10%-90% acetonitrile in water with 0.1% formic acid) andconcentrating the desired peak followed by high vacuum to dryness toprovide ER-887199 (92.3 mg 0.313 mmol, 31.3% yield).

Preparation of example ER-899742 using Scheme 11 and 19

ER-895194 or 38: To a stirred solution of 13 (231.0 g, 815.3 mmol) inDCM (3.93 L) at 0-5° C. was added iodobenzene diacetate (525 g, 1630.6mmol) while maintaining the temperature at <5° C. TEMPO (25.4 g, 162.8mmol) was added followed by water (151 mL) after which time theresulting reaction mixture was warmed to 10° C., stirred for 30 minutesand then allowed to warm to rt and stirred for 15 h. The completedreaction was cooled to <15° C. and quenched by the slow addition of 1.34L of a 10% (w/v) solution of sodium thiosulfate in water whilemaintaining the reaction temperature ≦15° C. followed by additionalstifling at rt for 45 min. The pH of the quenched reaction was adjustedto pH 9 by the slow addition of 1M sodium hydroxide in water whilemaintaining the temperature at ≦25° C. The stirring layers wereseparated and the organic layer was washed with water (560 mL).1-Butanol (2.31 L) was added to the combined aqueous layers after whichtime the mixture was cooled to 10-15° C. followed by the slow additionof 5 M sulfuric acid (231 mL) maintaining the temperature at ≦25° C. toobtain an approximate pH 5. The resultant layers were separated and theaqueous layer was extracted 3 times with 1-butanol (2.31 L) whilemaintaining the pH of the aqueous layer approximately pH 5 betweenextractions. The combined aqueous layers were concentrated while warmingto 50-55° C. after which time the resultant yellow solid-slurry wasconcentrated via azeotroping three times with n-heptane (693 mL each) toa volume of 1.5 L followed by the addition of DCM (2.31 L). The yellowsolid suspension was stirred at rt for 1 h followed by filtration,washing the filter pad two times with DCM (462 mL). The collected yellowcake was dried under vacuum) overnight at 40° C. followed by suspendingin toluene (1.16 L) and concentrated to complete dryness at 45° C. invacuo to provide 38 or ER-895194 (187 g, 629 mmol, 77% yield) as ayellow solid.

To a stirred solution of 38 (300 mg, 1.01 mmol) in DCM (2 mL) was addedthe mixture of (3S,4R)-tert-butyl3-amino-4-fluoropyrrolidine-1-carboxylate and (3R,4S)-tert-butyl3-amino-4-fluoropyrrolidine-1-carboxylate, 77 (205.3 mg, 1.005 mmol),HBTU (247 mg, 1.211 mmol) and DIEA (0.70 mL, 4.04 mmol) followed bystifling at rt for 16 h. The was found complete and concentrated todryness followed by dissolving in EtOAc (20 mL), washed 1 time withwater (10 mL), 2 N citric acid in water (10 mL), saturated NaHCO₃ (10mL), and brine (10 mL). The combined aqueous layers were extracted 3times with EtOAc (10 mL ea.) after which time the combined organicfractions were dried over MgSO4, filtered and concentrated to dry. Thecrude product was purified over a 25 g Biotage silica gel column elutingwith 0-10% MeOH in DCM (200 mL total) to provide the diastereomericmixture of 78 and 79.

78 and 79 were separated using Chiral Technologies' 5 uM Chiralpak IAcolumn of appropriate size eluting with a Heptane:EtOH:MeOH:DEA(70:15:15:0.1) solvent system. Obtained after concentration and bringingto a dry solid via house vacuum: 72 (95 mg, 0.196 mmol, 19.5% yield) asthe first eluted fraction; and 73 (75 mg, 0.155 mmol, 15.4% yield) asthe second eluted fraction.

78 (95 mg, 0.196 mmol) was dissolved with stifling in dioxane (17 uL)followed by a dropwise addition of 4 N HCl in dioxane (0.49 mL 1.97mmol, 10 equivalents) over a 3-minute period at rt. The reaction wasstirred for an additional 4 h after which time the completed reactionwas concentrated and azeotroped 3 times using toluene (10 mL each) todryness and then high vacuumed dried to obtain ER-899742-HCl (69 mg,0.164 mmol, 84% yield) as the HCl salt that did not require furtherpurification.

Indirect determination of the absolute stereochemistry of ER-899742

An indirect method was used to determine the absolute stereochemistry ofER-899742 using the confirmed chiral starting material that described byTsuzuki, et. al., in Tetrahedron Asymmetry 2001, 12, 29891 to providethe chiral compound 81 in Scheme 20.

To a stirred solution of (3S,4S)-tert-butyl3-(benzylamino)-4-hydroxypyrrolidine-1-carboxylate, 80 (3.091 g, 10.57mmol) and imidazole (3.60 g, 52.9 mmol) in DCM (185 ml) was addedtriethylamine (4.42 ml, 31.7 mmol). The resultant mixture was cooled to1-2° C., and then a solution of thionyl chloride (1.16 ml, 15.9 mmol) inDCM (46 ml) was added dropwise over 30-min period. The mixture wasstirred at 1-2° C. for 6 h, warm up to rt and stirred overnight afterwhich time the reaction was quenched with water (46 ml). The organiclayer was separated, concentrated to give crude product as whitesolid/foam, which was subjected to silica gel column chromatography(n-heptane/EtOAc 2:1) to give (3S,6S)-tert-butyl3-benzyltetrahydropyrrolo[3,4-d][1,2,3]oxathiazole-5(3H)-carboxylate2-oxide (2.10 g, 6.21 mmol, 58.7% yield) as white solid.

To stirred solution of (3S,6S)-tert-butyl3-benzyltetrahydropyrrolo[3,4-d][1,2,3]oxathiazole-5(3H)-carboxylate2-oxide (2.10 g, 6.21 mmol) in 1,2-dichloroethane (10 ml) diluted withacetonitrile (10 ml) and water (10 ml) cooled down to 2-3° C. was addedruthenium(III) chloride hydrate (14 mg) followed by sodium periodate(1.39 g, 6.50 mmol). The resultant mixture was stirred at 2-3° C. for 1h, warmed up to 17-18° C. over 1 h, and stirred at this temperature for16 h. 20 wt % Na₂SO₄ (5 g) was added followed by EtOAc (30 ml) afterwhich time the resultant mixture was stirred vigorously for 10 min andfiltered through a pad of Celite (2 g). Organic layer was separated,washed with 20 wt % sodium sulfite (5 g), 20 wt % NaCl (5 g) andconcentrated to give light purple/gray oil. The crude oil was passedover silica gel plug (10 g) eluting with EtOAc (120 ml) and concentratedto dryness to provide (3S,6S)-tert-butyl3-benzyltetrahydropyrrolo[3,4-d][1,2,3]oxathiazole-5(3H)-carboxylate2,2-dioxide (1.54 g, 4.35 mmol, 70.0% yield) as white solid.

(3S,6S)-tert-butyl 3-benzyltetrahydropyrrolo[3,4-d][1,2,3]oxathiazole-5(3H)-carboxylate 2,2-dioxide (20 mg, 0.056 mmol) was dissolved in TBAF(1 M solution in THF, 1.0 ml) and heated at reflux overnight, afterwhich time the reaction was cooled to room temperature and acidifiedwith HCl (1 M solution, 2 ml). After 2 h, the mixture was neutralizedwith NaHCO₃ (9% aqueous solution, 2.5 g) and extracted with EtOAc (10ml). Organic layer was separated, concentrated and combined with twoadditional batches using 100 mg (0.282 mmol ea.) of starting oxathiazolefor each batch. The combined crude products were purified over silicagel column chromatography (n-heptane/EtOAc 1:1) to provide(3S,4S)-tert-butyl 3-(benzylamino)-4-fluoropyrrolidine-1-carboxylate, 82(29 mg, 0.099 mmol, 15.9% yield) as a light brown oil and being lesspolar via TLC (silica gel), and (3S,4R)-tert-butyl3-(benzylamino)-4-fluoropyrrolidine-1-carboxylate, 81 (20 mg, 0.068mmol, 11.0% yield) as a light brown oil and being more polar via TLC(silica gel).

(3S,4R)-tert-butyl 3-(benzylamino)-4-fluoropyrrolidine-1-carboxylate, 81(16 mg, 0.054 mmol) was subjected to hydrogenolysis with 10 wt % Pd—C(10mg) in ethanol (3 ml). The completed reaction mixture was filtered,concentrated and azeotroped with CDCl₃ to provide (3S,4R)-tert-butyl3-amino-4-fluoropyrrolidine-1-carboxylate, 83 (8.3 mg, 0.041 mmol, 75.9%yield).

To a stirred solution of (3S,4R)-tert-butyl3-amino-4-fluoropyrrolidine-1-carboxylate and 38 or ER-895194 (15 mg,0.050 mmol) in DMF (0.2 ml) was added propylphosphonic anhydride (0.2 gof a 50% solution in EtOAc) at 40° C. for 2 h. The reaction mixture waspassed over a silica gel plug (3 g, eluting with heptane-EtOAc 1:3), andthen further purified by preparative TLC (n-heptane/EtOAc 1:4) to givecorresponding amide, 78, as yellow/green oil (11.2 mg, 0.023 mmol, 56%yield in 2 steps). The 1H-NMR & HPLC matched with Compound 78 asdescribed earlier thus the absolute stereochemistry of ER-899742 wasconfirmed indirectly.

Absolute stereochemistry of ER-899742 was also confirmed by X-Raydiffraction. Crystallization process: 5.3 mg of ER-899742-01 (lot.MC2-1130-120-1) was dissolved in 0.5 mL IPA and 0.3 mL H₂O. The vialcontaining the solution was capped and stored at room temperature for aday. The next day the cap was opened and IPA was evaporated slowly for aday at room temperature. The next day the cap was closed and the vialwas stored at room temperature for 2 weeks, after which colorless needlecrystals of ER-899742-01 appeared from which a single crystal wasselected for X-ray analysis. X-ray diffraction analysis: Equipment:R-AXIS RAPID II (RIGAKU); X-ray source: CuKa (1=1.54187A); Temperature:297 K; Measurement: oscillation method along the ω axis; Crystal size:0.1×0.1×0.4 mm. The crystal structure was solved with a final R-factorof 0.0606 and a Flack parameter of −0.01. The structure of ER-899742-01was determined as(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-[(3S,4R)-4-fluoropyrrolidin-3-yl]-6-methylmorpholine-2-carboxamidehydrochloride. See FIG. 8 for ORTEP drawing.

(3S,4S)-tert-butyl 3-(benzylamino)-4-fluoropyrrolidine-1-carboxylate, 82(24 mg, 0.082 mmol) was subjected to hydrogenolysis with 10 wt % Pd—C(10mg) in ethanol (3 ml). The reaction mixture was filtered, concentratedand azeotroped dry with CHCl₃ to provide (3S,4S)-tert-butyl3-amino-4-fluoropyrrolidine-1-carboxylate (16.6 mg, 0.081 mmol, 99.2%yield) that was used in the next step without purification.

To a stirred solution of (3S,4S)-tert-butyl3-amino-4-fluoropyrrolidine-1-carboxylate (12.5 mg, 0.061 mmol) and 38,or ER-895194 (18 mg, 0.061 mmol) in DMF (0.2 ml) was treated withpropylphosphonic anhydride (50% solution in EtOAc; 0.2 g,) at 40° C. for2 h. The reaction mixture was passed over silica gel plug (3 g, elutingwith heptane-EtOAc 1:3), and then further purified by preparative TLC(n-heptane/EtOAc 1:4) to provide (3S,4S)-tert-butyl3-((2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamido)-4-fluoropyrrolidine-1-carboxylate,85 (14.2 mg, 0.029 mmol, 47% yield in 2 steps) as yellow/green oil.

ER-899745-HCL (62.3 mg, 0.148 mmol, 96% yield) was obtained using thesame equivalents of reagents as for ER-899742-HCl, starting withcompound 79 (75 mg, 0.155 mmol). ER-894550 (5.3 mg, 0.016 mmol, 18.4%yield) was prepared in a similar manner to ER-899742 starting with 38(25.9 mg, 0.087 mmol) and ethyl amine hydrochloride (206 mg, 0.962mmol). DMF (0.5 mL) was used instead of DCM. The ER-894550 was purifiedby reverse-phase HPLC (X-Bridge C18 19×100 mm column; eluting with agradient of increasing acetonitrile in water containing 0.1% formicacid) followed by combining the desired fractions, concentration anddrying in vacuo. The product fractions were combined and concentrated todry followed by dilution in MeOH (1 mL), passed through as basic silicagel plug (Biotage SiCO₃, 1 g, eluting with MeOH (1 mL)), concentratedand dried in vacuo.

ER-895473 (103 mg, 0.261 mmol, 27.1% yield) was prepared in a similarmanner to ER-899742 starting with 38 (286 mg, 0.962 mmol) and(S)-tert-butyl 2-ethylpiperazine-1-carboxylate (206 mg, 0.962 mmol). DMF(3 mL) was used instead of DCM for the amide forming reaction and 2.0 MHCl in ethyl ether (1.3 mL, 2.6 mmol) was used in the Boc-deprotectionprocess using acetonitrile (1 mL) as a solvent. ER-895473 was purifiedby reverse-phase HPLC (X-Bridge C18 19×100 mm column; eluting with agradient of increasing acetonitrile in water containing 0.1% formicacid). The product fractions were combined and concentrated to dryfollowed by dilution in MeOH (1 mL), passed through as basic silica gelplug (Biotage SiCO₃, 1 g, eluting with MeOH (1 mL)), concentrated anddried in vacuo.

ER-895474 (6.3 mg, 0.015 mmol, 19.6% yield) was prepared in a similarmanner to ER-899742 starting with 38 (22.5 mg, 0.076 mmol) and(3,4-difluorophenyl)methanamine (10.83 mg, 0.076 mmol). Boc-deprotectionwas not required.

ER-895475 (16.2 mg, 0.044 mmol, 71.5% yield) was prepared in a similarto ER-895473 starting with 38 (18.3 mg, 0.062 mmol) and (R)-tert-butylpyrrolidin-3-ylcarbamate (11.46 mg, 0.062 mmol).

ER-895476 (14.0 mg, 0.042 mmol, 28.8% yield) was prepared in a similarmanner to ER-895474 starting with 38 (43.0 mg, 0.145 mmol) and azetidinehydrochloride (13.53 mg, 0.145 mmol).

ER-895477 (26.1 mg, 0.058 mmol, 32.1% yield) was prepared in a similarmanner to ER-895474 starting with 38 (54.0 mg, 0.182 mmol) and1,4′-bipiperidine (30.6 mg, 0.182 mmol).

ER-895478 (15.9 mg, 0.047 mmol, 29.0% yield) was prepared in a similarmanner to ER-895474 starting with 38 (48.4 mg, 0.163 mmol) andcyclopropanamine (11.42 μl, 0.163 mmol).

ER-895479 (14.9 mg, 0.042 mmol, 23.7% yield) was prepared in a similarmanner to ER-895473 starting with 38 (53.2 mg, 0.179 mmol) andtert-butyl azetidin-3-ylcarbamate (30.8 mg, 0.179 mmol).

ER-897922 (15.1 mg, 0.041 mmol, 48.7% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and1-aminobutan-2-ol (13.0 mg, 0.146 mmol).

ER-897923 (13.9 mg, 0.038 mmol, 44.9% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and2-ethoxyethanamine (13.0 mg, 0.146 mmol).

ER-897924 (17.0 mg, 0.046 mmol, 54.9% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and(R)-2-aminobutan-1-ol (14.0 mg, 0.157 mmol).

ER-897925 (4.5 mg, 0.012 mmol, 14.5% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and2-aminopropane-1,3-diol (14.0 mg, 0.154 mmol).

ER-897926 (7.6 mg, 0.021 mmol, 24.4% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and3-aminopropane-1,2-diol (15.0 mg, 0.165 mmol).

ER-897927 (15.0 mg, 0.039 mmol, 46.9% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and(R)-(tetrahydrofuran-2-yl)methanamine (15.0 mg, 0.148 mmol).

ER-897928 (14.9 mg, 0.039 mmol, 46.6% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and(tetrahydrofuran-2-yl)methanamine (16.0 mg, 0.158 mmol).

ER-897929 (10.3 mg, 0.027 mmol, 32.0% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and2-propoxyethanamine (16.0 mg, 0.155 mmol).

ER-897930 (12.8 mg, 0.033 mmol, 39.8% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and(R)-2-aminopentan-1-ol (16.0 mg, 0.155 mmol).

ER-897931 (11.1 mg, 0.029 mmol, 34.5% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and2-isopropoxyethanamine (15.0 mg, 0.145 mmol).

ER-897932 (10.0 mg, 0.026 mmol, 31.1% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and1-methoxybutan-2-amine (0.0160 g, 0.155 mmol).

ER-897933 (9.0 mg, 0.021 mmol, 24.6% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and2-amino-1-(2-fluorophenyl)ethanol (23.0 mg, 0.148 mmol).

ER-897934 (13.3 mg, 0.035 mmol, 41.1% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and(S)-2-amino-3-methylbutan-1-ol (15.0 mg, 0.145 mmol).

ER-897935 (15.7 mg, 0.041 mmol, 48.6% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and2,2-dimethoxyethanamine (15.0 mg, 0.143 mmol).

ER-897936 (10.4 mg, 0.027 mmol, 32.2% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and2-(2-aminoethoxyl)ethanol (16.0 mg, 0.152 mmol).

ER-897937 (12.1 mg, 0.031 mmol, 36.5% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and(1S,2S)-2-aminocyclohexanol (23.0 mg, 0.200 mmol).

ER-897938 (8.5 mg, 0.022 mmol, 25.6% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and2-aminocyclohexanol (17.0 mg, 0.148 mmol).

ER-897939 (10.1 mg, 0.025 mmol, 30.3% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and2-aminohexan-1-ol (18.3 mg, 0.156 mmol).

ER-897940 (10.3 mg, 0.026 mmol, 30.9% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and(S)-2-amino-3,3-dimethylbutan-1-ol (19.0 mg, 0.162 mmol).

ER-897941 (14.0 mg, 0.035 mmol, 42.0% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and(S)-2-aminohexan-1-ol (19.0 mg, 0.162 mmol).

ER-897942 (9.9 mg, 0.025 mmol, 29.7% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and(2S,3S)-2-amino-3-methylpentan-1-ol (18.0 mg, 0.154 mmol).

ER-897943 (11.1 mg, 0.028 mmol, 33.3% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and(S)-2-amino-4-methylpentan-1-ol (18.0 mg, 0.154 mmol).

ER-897944 (10.9 mg, 0.027 mmol, 32.7% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and(R)-2-amino-4-methylpentan-1-ol (18.0 mg, 0.154 mmol).

ER-897945 (13.2 mg, 0.032 mmol, 38.3% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and(4-methylmorpholin-2-yl)methanamine (20.0 mg, 0.154 mmol).

ER-897946 (16.1 mg, 0.035 mmol, 42.0% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and(S)-2-amino-4-(methylthio)butan-1-ol (20.0 mg, 0.148 mmol).

ER-897947 (12.0 mg, 0.029 mmol, 34.3% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and2-phenoxyethanamine (21.0 mg, 0.153 mmol).

ER-897948 (12.0 mg, 0.028 mmol, 33.1% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and(S)-2-amino-3-phenylpropan-1-ol (24.0 mg, 0.159 mmol).

ER-897949 (11.7 mg, 0.027 mmol, 32.3% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and2-phenoxypropan-1-amine (29.0 mg, 0.192 mmol).

ER-897950 (11.7 mg, 0.027 mmol, 32.3% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and1-amino-3-phenylpropan-2-ol (23.0 mg, 0.152 mmol).

ER-897952 (14.0 mg, 0.032 mmol, 38.6% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and2-(pyridin-3-yloxy)propan-1-amine (24.0 mg, 0.158 mmol).

ER-897955 (8.2 mg, 0.019 mmol, 22.5% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and2-(4-fluorophenoxyl)ethanamine (23.0 mg, 0.148 mmol).

ER-897956 (11.2 mg, 0.026 mmol, 26% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and2-amino-1-(3-fluorophenyl)ethanol (24.0 mg, 0.155 mmol).

ER-897957 (9.8 mg, 0.022 mmol, 26.7% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and(S)-2-amino-3-cyclohexylpropan-1-ol (30.0 mg, 0.191 mmol).

ER-897958 (13.6 mg, 0.031 mmol, 36.5% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) andisochroman-1-ylmethanamine (24.0 mg, 0.147 mmol).

ER-897960 (13.0 mg, 0.029 mmol, 34.6% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and1-amino-3-phenoxypropan-2-ol (25.0 mg, 0.150 mmol).

ER-897961 (9.7 mg, 0.022 mmol, 25.8% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and4-((1S,2R)-2-amino-1-hydroxypropyl)phenol (32.0 mg, 0.191 mmol).

ER-897962 (17.8 mg, 0.040 mmol, 47.4% yield) was prepared in a similarmanner to ER-895474 starting with 38 (25 mg, 0.084 mmol) and(1S,2S)-2-amino-1-phenylpropane-1,3-diol (26.0 mg, 0.155 mmol).

ER-897963 (3.1 mg, 0.007 mmol, 8.4% yield) was prepared in a similarmanner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and tert-butyl4-(3-amino-2-hydroxypropyl)piperazine-1-carboxylate (40.0 mg, 0.154mmol).

ER-897964 (12.7 mg, 0.036 mmol, 21.5% yield) was prepared in a similarmanner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and tert-butyl3-aminoazetidine-1-carboxylate (27.0 mg, 0.157 mmol).

ER-897965 (0.4 mg, 0.001 mmol, 1.3% yield) was prepared in a similarmanner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and(S)-tert-butyl 3-aminopyrrolidine-1-carboxylate (29.0 mg, 0.156 mmol).

ER-897966 (0.4 mg, 0.001 mmol, 1.3% yield) was prepared in a similarmanner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and(R)-tert-butyl 3-aminopyrrolidine-1-carboxylate (29.0 mg, 0.156 mmol).

ER-897967 (0.3 mg, 0.001 mmol, 0.9% yield) was prepared in a similarmanner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and(S)-tert-butyl 3-aminopiperidine-1-carboxylate (30.0 mg, 0.150 mmol).

ER-897968 (0.4 mg, 0.001 mmol, 1.3% yield) was prepared in a similarmanner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and(R)-tert-butyl 3-aminopiperidine-1-carboxylate (30.0 mg, 0.150 mmol).

ER-897969 (0.2 mg, 0.001 mmol, 0.6% yield) was prepared in a similarmanner to ER-895473 starting with 38 (25 mg, 0.084 mmol) and(S)-tert-butyl 2-(aminomethyl)pyrrolidine-1-carboxylate (30.0 mg, 0.150mmol).

ER-897970 (3.4 mg, 0.008 mmol, 9.4% yield) was prepared in a similarmanner to ER-895473 starting with 38 (25 mg, 0.084 mmol) andtert-butyl(2-aminoethyl)(benzyl)carbamate (38.0 mg, 0.152 mmol).

ER-898560 (11.2 mg, 0.030 mmol, 30.9% yield) was prepared in a similarmanner to ER-895473 starting with 38 (28.8 mg, 0.097 mmol) andpyridin-2-amine (9.12 mg, 0.097 mmol).

ER-898561 (12.8 mg, 0.033 mmol, 44.6% yield) was prepared in a similarmanner to ER-895474 starting with 38 (22.1 mg, 0.074 mmol) and6-methylpyridin-2-amine (8.04 mg, 0.074 mmol).

ER-898562 (7.4 mg, 0.020 mmol, 18.7% yield) was prepared in a similarmanner to ER-895474 starting with 38 (31.2 mg, 0.105 mmol) and5-methylisoxazol-3-amine (10.30 mg, 0.105 mmol).

ER-898563 (6.5 mg, 0.017 mmol, 16.7% yield) was prepared in a similarmanner to ER-895474 starting with 38 (30.7 mg, 0.103 mmol) and2,2,2-trifluoroethanamine hydrochloride (13.99 mg, 0.103 mmol).

ER-898564 (1.4 mg, 0.004 mmol, 3.8% yield) was prepared in a similarmanner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and2,2-difluoroethanamine (8.18 mg, 0.101 mmol).

ER-898565 (3.0 mg, 0.008 mmol, 7.5% yield) was prepared in a similarmanner to ER-895474 starting with 38 (30.2 mg, 0.102 mmol) and3,3,3-trifluoropropan-1-amine (11.49 mg, 0.102 mmol).

ER-898566 (14.6 mg, 0.037 mmol, 20.4% yield) was prepared in a similarmanner to ER-895474 starting with 38 (53.7 mg, 0.181 mmol) andN2,N2,2-trimethylpropane-1,2-diamine (20.99 mg, 0.181 mmol).

ER-898914 (31.6 mg, 0.092 mmol, 28.8% yield) was prepared in a similarmanner to ER-895474 starting with 38 (95.2 mg, 0.320 mmol) and2-fluoroethanamine hydrochloride (31.9 mg, 0.32 mmol).

ER-898915 (19.1 mg, 0.054 mmol, 19.3% yield) was prepared in a similarmanner to ER-895474 starting with 38 (82.3 mg, 0.277 mmol) and3-fluoropropan-1-amine hydrochloride (31.4 mg, 0.277 mmol).

ER-898916 (14.6 mg, 0.037 mmol, 21.5% yield) was prepared in a similarmanner to ER-895474 starting with 38 (51.4 mg, 0.173 mmol) and(R)-1,1,1-trifluoropropan-2-amine (20 mg, 0.177 mmol).

ER-898917 (27.6 mg, 0.066 mmol, 20.4% yield) was prepared in a similarmanner to ER-895474 starting with 38 (95.7 mg, 0.322 mmol) and(R)-1,1,1-trifluoro-3-methylbutan-2-amine (45.4 mg, 0.322 mmol).

ER-898918 (15.0 mg, 0.038 mmol, 19.3% yield) was prepared in a similarmanner to ER-895474 starting with 38 (59.2 mg, 0.199 mmol) and1,3-dimethyl-1H-pyrazol-5-amine (22.13 mg, 0.199 mmol).

ER-898919 (13.1 mg, 0.035 mmol, 10.5% yield) was prepared in a similarmanner to ER-895474 starting with 38 (98.1 mg, 0.33 mmol) and1-methyl-1H-pyrazol-5-amine (32.0 mg, 0.33 mmol).

ER-898920 (20.1 mg, 0.060 mmol, 21.4% yield) was prepared in a similarmanner to ER-895474 starting with 38 (83.3 mg, 0.280 mmol) and2-aminoacetonitrile hydrochloride (25.9 mg, 0.28 mmol).

ER-898921 (11.4 mg, 0.032 mmol, 12.8% yield) was prepared in a similarmanner to ER-895474 starting with 38 (73.1 mg, 0.246 mmol) andcyclopropanecarbonitrile hydrochloride (25.5 mg, 0.246 mmol).

ER-898922 (25.4 mg, 0.067 mmol, 33.7% yield) was prepared in a similarmanner to ER-895474 starting with 38 (59.0 mg, 0.198 mmol) and1,2,4-thiadiazol-5-amine (20.07 mg, 0.198 mmol).

ER-898923 (12.6 mg, 0.032 mmol, 16.5% yield) was prepared in a similarmanner to ER-895474 starting with 38 (57.6 mg, 0.194 mmol) and3-methyl-1,2,4-thiadiazol-5-amine (22.31 mg, 0.194 mmol).

ER-899017-HCl (328 mg, 0.769 mmol, 65.3% yield) was prepared in asimilar manner to ER-899742-HCl starting with 38 (350 mg, 1.177 mmol)and tert-butyl 2,6-diazaspiro[3.4]octane-6-carboxylate (250 mg, 1.177mmol).

ER-899019-HCl (26 mg, 0.059 mmol, 58.2% yield) was prepared in a similarmanner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) andtert-butyl 4-(aminomethyl)-4-fluoropiperidine-1-carboxylate (23.4 mg,0.101 mmol).

ER-899020-HCl (25 mg, 0.062 mmol, 61.4% yield) was prepared in a similarmanner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) tert-butyl3-(aminomethyl)azetidine-1-carboxylate (18.8 mg, 0.101 mmol).

ER-899023-HCl (25.5 mg, 0.060 mmol, 59.4% yield) was prepared in asimilar manner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) andtert-butyl 1,6-diazaspiro[3.4]octane-6-carboxylate (21.4 mg, 0.101mmol).

ER-899024-HCl (30.1 mg, 0.068 mmol, 67.5% yield) was prepared in asimilar manner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) andtert-butyl 1,7-diazaspiro[4.4]nonane-1-carboxylate (22.8 mg, 0.101mmol).

ER-899025-HCl (32.1 mg, 0.077 mmol, 76% yield) was prepared in a similarmanner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) and4-amino-1-methyl-1H-pyrazole-3-carboxamide (14.1 mg, 0.101 mmol).Boc-deprotection was not required.

ER-899031-HCl (30.1 mg, 0.079 mmol, 78% yield) was prepared in a similarmanner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) and(3-methyloxetan-3-yl)methanamine (10.2 mg, 0.101 mmol). Boc-deprotectionwas not required.

ER-899032-HCl (28.7 mg, 0.079 mmol, 78% yield) was prepared in a similarmanner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) and2-oxo-6-azasprio[3.3]helptane (10.0 mg, 0.101 mmol). Boc-deprotectionwas not required.

ER-899033-HCl (32.8 mg, 0.093 mmol, 92% yield) was prepared in a similarmanner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) andoxetane-3-amine (7.4 mg, 0.101 mmol). Boc-deprotection was not required.

ER-899034-HCl (26.4 mg, 0.067 mmol, 66.2% yield) was prepared in asimilar manner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) andoxetane-3,3-diyldimethanamine dihydrochloride (19.1 mg, 0.101 mmol).Boc-deprotection was not required.

ER-899035-HCl (25.9 mg, 0.071 mmol, 70.1% yield) was prepared in asimilar manner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) andoxetan-2-ylmethanamine (8.8 mg, 0.101 mmol). Boc-deprotection was notrequired.

ER-899036-HCl (33.1 mg, 0.082 mmol, 82% yield) was prepared in a similarmanner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) andtert-butyl piperazine-1-carboxylate (18.8 mg, 0.101 mmol).

ER-899191-HCl (30.7 mg, 0.081 mmol, 80% yield) was prepared in a similarmanner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) andazetidine-3-carboxamide (10.1 mg, 0.101 mmol). Boc-deprotection was notrequired.

ER-899192-HCl (34.4 mg, 0.078 mmol, 77% yield) was prepared in a similarmanner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) andtert-butyl 2,7-diazaspiro[4.4]nonane-2-carboxylate (22.8 mg, 0.101mmol).

ER-899193-HCl (38.1 mg, 0.081 mmol, 80% yield) was prepared in a similarmanner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) andtert-butyl 3,9-diazaspiro[5.5]undecane-3-carboxylate (25.7 mg, 0.101mmol).

ER-899196-HCl (23.7 mg, 0.057 mmol, 56.4% yield) was prepared in asimilar manner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) and4-aminonicotinamide (13.84 mg, 0.101 mmol). Boc-deprotection was notrequired.

ER-899282-HCl (29.6 mg, 0.079 mmol, 79% yield) was prepared in a similarmanner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) andpyridin-4-amine (9.5 mg, 0.101 mmol). Boc-deprotection was not required.

ER-899283-HCl (31.1 mg, 0.083 mmol, 83% yield) was prepared in a similarmanner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) andpyridin-3-amine (9.5 mg, 0.101 mmol). Boc-deprotection was not required.

ER-899285-HCl (28.5 mg, 0.059 mmol, 58.6% yield) was prepared in asimilar manner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) andtert-butyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate (26.9 mg,0.101 mmol).

ER-899286-HCl (31.7 mg, 0.070 mmol, 69.2% yield) was prepared in asimilar manner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) andtert-butyl 3-(4-amino-1H-pyrazol-1-yl)azetidine-1-carboxylate (24.0 mg,0.101 mmol).

ER-899287 (29.7 mg, 0.079 mmol, 78% yield) was prepared in a similarmanner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and(1H-pyrazol-5-yl)methanamine (9.80 mg, 0.101 mmol).

ER-899288 (20.7 mg, 0.057 mmol, 56.6% yield) was prepared in a similarmanner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and1H-pyrazol-4-amine (8.38 mg, 0.101 mmol).

ER-899289 (35.5 mg, 0.078 mmol, 77% yield) was prepared in a similarmanner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and(3-(trifluoromethyl)pyridin-2-yl)methanamine (17.77 mg, 0.101 mmol).

ER-899290 (15.0 mg, 0.034 mmol, 33.9% yield) was prepared in a similarmanner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and1-(pyridin-2-yl)ethanamine (12.33 mg, 0.101 mmol).

ER-899291 (26.1 mg, 0.067 mmol, 66.7% yield) was prepared in a similarmanner to ER-895474 starting with 38 (30 mg, 0.101 mmol) andpyridin-2-ylmethanamine (10.91 mg, 0.101 mmol).

ER-899292 (31.0 mg, 0.077.2 mmol, 76.4% yield) was prepared in a similarmanner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and(6-methylpyridin-2-yl)methanamine (12.3 mg, 0.101 mmol).

ER-899293 (32.0 mg, 0.079 mmol, 77.7% yield) was prepared in a similarmanner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and(1-methylpiperidin-2-yl)methanamine (12.9 mg, 0.101 mmol).

ER-899294 (32.2 mg, 0.080 mmol, 79% yield) was prepared in a similarmanner to ER-895474 starting with 38 (30 mg, 0.101 mmol) and(3-methylpyridin-2-yl)methanamine (12.3 mg, 0.101 mmol).

ER-899334 (51.3 mg, 0.140 mmol, 11.7% yield) was prepared in a similarmanner to ER-895473 starting with 38 (357.2 mg, 1.201 mmol) and(R)-tert-butyl 2-(aminomethyl)pyrrolidine-1-carboxylate (224 mg, 1.201mmol).

ER-899414-HCl (31.1 mg, 0.075 mmol, 74.1% yield) was prepared in asimilar manner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) and(R)-tert-butyl 2-(aminomethyl)pyrrolidine-1-carboxylate (20.2 mg, 0.101mmol).

ER-899415-HCl (30.5 mg, 0.071 mmol, 70.3% yield) was prepared in asimilar manner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) and(S)-tert-butyl 2-(aminomethyl)piperidine-1-carboxylate (21.6 mg, 0.101mmol).

ER-899416-HCl (24.2 mg, 0.055 mmol, 54.3% yield) was prepared in asimilar manner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) andtert-butyl 3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate (22.84 mg,0.101 mmol).

ER-899417-HCl (32.8 mg, 0.076 mmol, 76% yield) was prepared in a similarmanner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) andtert-butyl 4-aminoazepane-1-carboxylate (21.62 mg, 0.101 mmol).

ER-899418-HCl (29.6 mg, 0.072 mmol, 70.9% yield) was prepared in asimilar manner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) and(1R,5S,6S)-tert-butyl 6-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate(20.0 mg, 0.101 mmol).

ER-899476-HCl (31.0 mg, 0.068 mmol, 67.4% yield) or the diastereomericmixture of ER-899742 and ER-899745 was prepared in a similar manner toER-899742-HCl starting with 38 (30 mg, 0.101 mmol) and a 1:1 mixture of(3R,4S)-tert-butyl 3-amino-4-fluoropyrrolidine-1-carboxylate and(3S,4R)-tert-butyl 3-amino-4-fluoropyrrolidine-1-carboxylate (20.6 mg,0.101 mmol).

ER-899477-HCl (25.5 mg, 0.059 mmol, 58.2% yield) as a diastereomermixture was prepared in a similar manner to ER-899742-HCl starting with38 (30 mg, 0.101 mmol) and a 1:1 mixture of (3R,4S)-tert-butyl3-amino-4-fluoropiperidine-1-carboxylate and (3S,4R)-tert-butyl3-amino-4-fluoropiperidine-1-carboxylate (22.02 mg, 0.101 mmol).

ER-899479-HCl (30.5 mg, 0.071 mmol, 70.6% yield) was prepared in asimilar manner to ER-899742-HCl starting with 38 (30 mg, 0.101 mmol) andtert-butyl 6-amino-2-azaspiro[3.3]heptane-2-carboxylate (21.42 mg, 0.101mmol).

ER-897383 (14.2 mg, 0.017 mmol, 14.1% yield) was prepared in a similarmanner to ER-895474 starting with 38 (35.2 mg, 0.118 mmol) and2-aminoethanol (10.9 mg, 0.178 mmol). DMF (1 mL) was used instead ofDMAC.

ER-897385 (14.2 mg, 0.017 mmol, 14.1% yield) was prepared in a similarmanner to ER-897383 starting with 38 (35 mg, 0.118 mmol) and2-methoxyethanamine (13.7 mg, 0.178 mmol).

ER-897445 (87 mg, 0.245 mmol, 72.9% overall yield) was prepared in asimilar manner to ER-897383 starting with 38 (100 mg, 0.336 mmol) and(R)-2-((tert-butyldiphenylsilyl)oxy)propan-1-amine (158 mg, 0.505 mmol)followed by the removal of the tert-butyldiphenylsilyl-protecting groupusing 1 M TBAF in THF (0.43 mL, 0.43 mmol) in DCM (1.1 mL) stirring for1 h at rt. The desired product was purified over silica gel (eluted with80-100% EtOAc in heptane).

ER-897446 (67 mg, 0.189 mmol, 75% overall yield) was prepared in asimilar manner to ER-897445 starting with 38 (75 mg, 0.252 mmol) and(S)-1-((tert-butyldiphenylsilyl)oxy)propan-2-amine (103 mg, 0.329 mmol).

ER-897447 (78 mg, 0.220 mmol, 65.5% overall yield) was prepared in asimilar manner to ER-897445 starting with 38 (100 mg, 0.336 mmol) and(R)-1-((tert-butyldiphenylsilyl)oxy)propan-2-amine (158 mg, 0.505 mmol).

ER-897827 (48.2 mg, 0.131 mmol, 64.9% overall yield) was prepared in asimilar manner to ER-897445 starting with 38 (60 mg, 0.202 mmol) and(S)-1-((tert-butyldiphenylsilyl)oxy)butan-2-amine (90 mg, 0.303 mmol).

ER-897828 (49.4 mg, 0.129 mmol, 64% overall yield) was prepared in asimilar manner to ER-897445 starting with 38 (60 mg, 0.202 mmol) and(S)-1-((tert-butyldiphenylsilyl)oxy)-3-methylbutan-2-amine (103 mg,0.303 mmol).

ER-897829 (65.2 mg, 0.157 mmol, 77.7% overall yield) was prepared in asimilar manner to ER-897445 starting with 38 (60 mg, 0.202 mmol) and(S)-2-((tert-butyldiphenylsilyl)oxy)-1-phenylethanamine (114 mg, 0.303mmol).

ER-897830 (60.2 mg, 0.145 mmol, 71.8% overall yield) was prepared in asimilar manner to ER-897445 starting with 38 (60 mg, 0.202 mmol) and(R)-2-((tert-butyldiphenylsilyl)oxy)-1-phenylethanamine (114 mg, 0.303mmol).

ER-899722 (79 mg, 0.215 mmol, 25.6% yield) was prepared in a similarmanner to ER-895474 starting with 38 (250 mg, 0.841 mmol) and2-methylpropane-1,2-diamine (0.09 mL, 0.841 mmol). DCM (2 mL) was usedinstead of DMAC.

ER-899295 (27.5 mg, 0.0.71 mmol, 70.4% yield) was prepared in a similarmanner to ER-899722 starting with 38 (30 mg, 0.101 mmol) and3-amino-1H-pyrazole-4-carbonitrile (10.9 mg, 0.101 mmol).

ER-898946: 38 (50 mg, 0.168 mmol), HATU (128 mg, 0.336 mmol) and DIEA(0.176 ml, 1.009 mmol) was dissolved in DCM:DMF (5 mL: 2 mL) followed bytert-butyl 4-aminopiperidine-1-carboxylate (67.4 mg, 0.336 mmol). Theresulting reaction mixture was stirred at rt for 16 h after which timeadditional HATU (128 mg, 0.336 mmol), and by tert-butyl4-aminopiperidine-1-carboxylate (67.4 mg, 0.336 mmol) was added followedby stifling for an additional 3 h. The completed reaction wasconcentrated to dry and the crude product was purified by chromatography(25 g Silica gel) eluting with 10% acetonitrile in DCM to give pure Bocprotected product. The Boc-protected product was dissolved in DCM(4ml)/TFA (0.5 ml) and stirred at rt for 3 h after which time the solventwas removed under reduced pressure, the residue was dissolved in MeOH(10 mL) and 0.3 g of MP-carbonate was added (pH>7). The resultingsuspension was stirred at rt for 30 min after which time the polymerbeads were filtered, washed with MeOH (10 mL) and the solvent wasconcentrated and high vacuum to dry to give ER-898946 (12 mg, 0.027mmol, 16.0% yield).

ER-898694-2 HCl (67 mg, 0.155 mmol, 46.1% yield) was prepared in asimilar manner to ER-898946 starting with 38 (100 mg, 0.336 mmol) and(S)-tert-butyl 2-(aminomethyl)morpholine-4-carboxylate (95 mg, 0.437mmol) followed by the addition of 3N HCl in dioxane (31 uL) to providethe dihydrochloride salt after concentration and high vacuum to dryness.

Alternative method for the preparation of ER-899742 & ER-899745: To astirred solution 38 (2.91 g, 9.79 mmol and TEA (1.706 ml, 12.24 mmol) inDCM (50.0 ml) was added 77 (2.000 g, 9.792 mmol) and HOBT (2.65 g, 19.59mmol). The reaction mixture was cooled to 0° C. followed by the portionwise addition of EDC (3.75 g, 19.59 mmol) after which time mixture waswarmed to 40° C. and stirred for 3 hours. DCM (50 mL) was added, thelayers separated after which time the organic layer was washed with sat.ammonium chloride (20 mL), sat. NaHCO₃ (20 mL), brine (20 mL), driedover Na₂SO₄, filtered and concentrated to dry. The crude product waspurified over silica gel (Biotage SP4, eluting with 10% MeOH:DCM). Thediastereomers were separated as described above to obtain 78 (1.65 g,3.41 mmol, 34.8% yield) and 79 (1.49 g, 3.08 mmol, 31.5% yield).

78 (470 mg, 0.97 mmol) was dissolved in a stifling solution of DCM (5.0mL) followed by the addition of TFA (2.5 mL, 32.45 mmol) after whichtime the reaction was warmed to 49° C. and stirred for 2 h. Thecompleted reaction was azeotroped to dryness three times with toluene (2mL each) and then dried in vacuo to provide ER-899742-TFA (543 mg, 0.97mmol, 100% yield—the product contained 1.5 molecules of TFA to onemolecule of ER-899742 via mass spectrum) as an orange solid.

ER-899742 free base can be obtained by dissolving the TFA salt in MeOHand adding Amberlite IRA 400 hydroxide form and stifling for 10 min oronce a neutral pH is obtained. The resultant suspension is filtered,washed with MeOH two times with MeOH of equal volumes, and concentrationof the combined filtrates to paste. The paste is azeotroped two timeswith toluene to provide ER-899742 in the free base form in quantitativeyield. The HCl salt form can be then be generated as described above.

ER-899742-HCl salt may be obtained directly from 78 by treatment with5.5 N HCL in isopropanol to provide desired product in quantitativeyield after stifling for 2 h at rt followed by azeotroping to dry 3times with toluene and high vacuum drying as 1.5 molecules of HCl to onemolecule of ER-899742 demonstrated by mass spectra analyses.

ER-899464-HCl: To a stirred solution of 38 (50 g, 168.2 mmol) in DMF(250 mL) was added TEA (29.3 mL, 210.2 mmol) followed by4-amino-1-methylpiperidine (28.8 g, 252.3 mmol) and HOBT (45.4 g, 336.4mmol). The reaction mixture was cooled to 0° C. followed by a portionwise addition of EDC (64.5 g, 336.4 mmol). The reaction mixture waswarmed to 40° C. and stirred for an additional 6 h. The completedreaction was slowly poured into a flask containing water (1.5 L) withstifling after which time DCM (1.5 L) was added, stirred an additional10 min. The two layers were separated and the aqueous layer wasextracted three times with DCM (600 mL each). The combined organiclayers were concentrated to a DMF solution followed by concentration at50° C. under vacuum. The resultant yellow slurry was diluted with ethylether (1 L) and stirred for 15 min, after which time the solid wascollected by filtration followed by rinsing the filter pad with ethylether (0.5 L) and dried in vacuo to provide ER-899464 (44.9 g, 114 mmol,67.9% yield). The HCl salt is obtained by dissolving ER-899464 (22.8 g,57.9 mmol) in 10 volumes of isopropanol and 1 volume of water followedby the addition of 1 equivalent of 5.5 N HCl in isopropanol to provide awhite precipitate. The solid is filtered and washed with isopropanol (2vol) followed by drying in a vacuo to provide ER-899464.HCl (20.3 g,47.2 mmol, 81.5%).

ER-899477 (78 mg, 0.196 mmol, 58.3% yield) was prepared in a similarmanner to ER-899464 starting with 38 (100 mg, 0.336 mmol) and(3S,4R)-tert-butyl 3-amino-4-fluoropiperidine-1-carboxylate (220 mg,1.009 mmol).

ER-897968 (475 mg, 1.252 mmol, 37.2% yield) was prepared in a similarmanner to ER-899464 starting with 38 (1.00 g, 3.364 mmol) and(R)-tert-butyl 3-aminopiperidine-1-carboxylate (2.021 g, 10.091 mmol).

ER-899018 (370 mg, 0.975 mmol, 58.0% yield) was prepared in a similarmanner to ER-899464 starting with 38 (500 mg, 1.682 mmol) andtert-butyl(azetidin-3-ylmethyl)(methyl)carbamate (500 mg, 2.497 mmol).

ER-899819 (62 mg, 0.158 mmol, 31.3% yield) was prepared in a similarmanner to ER-899464 starting with 38 (150 mg, 0.505 mmol) and tert-butyl3-aminoazepane-1-carboxylate (324 mg, 1.514 mmol).

ER-899416-HCl (53 mg, 0.120 mmol, 35.7% yield) was prepared in a similarmanner to ER-899464-HCl starting with 38 (100 mg, 0.336 mmol) and(1R,3S,5S)-tert-butyl 3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate(76 mg, 0.336 mmol).

ER-899417-HCl (56 mg, 0.130 mmol, 38.7% yield) was prepared in a similarmanner to ER-899464-HCl starting with 38 (100 mg, 0.336 mmol) andtert-butyl 4-aminoazepane-1-carboxylate (144 mg, 0.673 mmol).

ER-899285-HCl (52 mg, 0.108 mmol, 32.1% yield) was prepared in a similarmanner to ER-899464-HCl starting with 38 (100 mg, 0.336 mmol) andtert-butyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate (179 mg,0.673 mmol)

ER-899021-HCl (62 mg, 0.140 mmol, 41.7% yield) was prepared in a similarmanner to ER-899464-HCl starting with 38 (100 mg, 0.336 mmol) andtert-butyl 2,6-diazaspiro[3.5]nonane-6-carboxylate (152 mg, 0.673 mmol).

ER-899619-HCl (36 mg, 0.084 mmol, % yield) was in a similar manner toER-899464-HCl starting with 38 (100 mg, 0.336 mmol) and (S)-tert-butyl3-(methylamino)piperidine-1-carboxylate (216 mg, 1.009 mmol).

ER-899616-HCl (21 mg, 0.049 mmol, % yield) was prepared in a similarmanner to ER-899464-HCl starting with 38 (100 mg, 0.336 mmol) and(R)-tert-butyl 3-(methylamino)piperidine-1-carboxylate (216 mg, 1.009mmol).

ER-898566-HCl (272 mg, 0.630 mmol, 37.5% yield) was prepared in asimilar manner to ER-899464-HCl starting with 38 (500 mg, 1.682 mmol)and N2,N2,2-trimethylpropane-1,2-diamine (586 mg, 5.045 mmol).

ER-899618-HCl (4.8 mg, 0.011 mmol, 3.2% yield) was prepared in a similarmanner to ER-899464-HCl starting with 38 (500 mg, 1.682 mmol) and4-aminopicolinamide (138 mg, 1.009 mmol).

ER-899477 (78 mg, 0.196 mmol, 58.3% yield as a diastereomeric mixture)was prepared in a similar manner to ER-899464 starting with 38 (100 mg,0.336 mmol) and a racemic mixture of (3S,4R)-tert-butyl3-amino-4-fluoropiperidine-1-carboxylate and (3R,4S)-tert-butyl3-amino-4-fluoropiperidine-1-carboxylate (220 mg, 1.009 mmol).

ER-895415 as an example for Compound 41 in Scheme 11: To a stirredsolution of 38 (1.10 g, 3.70 mmol) in DCM (5 mL) at 0° C. was addedoxalyl chloride (1.0 mL, 11.42 mmol) dropwise over 2 min. The reactionmixture was allowed to warm to rt and stir for 1 h after which time thereaction was concentrated and dried in vacuo. The dried syrup was cooledto 0° C. followed by the slow addition of MeOH (5 mL) with stirring. Thecompleted reaction was concentrated to dry, diluted with DCM (10 mL),washed with saturated sodium sulfite (3 mL), brine (3 mL) and then driedover Na₂SO₄, filtered and concentrated to dry. The crude product waspurified over silica gel (eluting w a 0-50% EtOAc in heptane gradient)to provide ER-895415 (894 mg, 2.81 mmol, 76% yield) after combining thedesired fractions, concentrating and drying in vacuo.

Preparation of Example ER-899332 Following Scheme 21:

The solution of ER-899472-HCl (49.8 mg, 0.119 mmol) and paraformaldehyde(8.90 mg, 0.297 mmol) in DCM (0.5 mL) was stirred at room for 1 hr.Sodium triacetoxyborohydride (62.8 mg, 0.297 mmol) was added andresulting solution was stirred at rt for 2 days. After the solvents wereremoved, the crude was chromatographied on silica (15% MeOH in DCM) togive ER-899332 (8.16 mg, 0.021 mmol, 18.3% yield).

ER-899457 (50 mg, 0.117 mmol, 97% yield) was prepared in a similarmanner to ER-899332 starting with ER-899336 (50 mg, 0.122 mmol).

ER-899836: A stirred solution of ER-899477 (76 mg, 0.191 mmol) insolution of 37% formaldehyde in water (0.5 g, 16.652 mmol) and formicacid (0.5 ml, 13.036 mmol) was warmed to 80° C. for 3 h after which timethe completed reaction is cooled to rt. The mixture was azeotroped todryness four times with toluene (2 mL each) and the resultant residuewas dissolved in MeOH (5 mL) followed by the addition of AmberliteIRA400 hydroxide form (2 g) and stirred for 10 min. Additional AmberliteIRA400 is added with stifling until a neutral pH is obtained after whichtime the suspension was filtered, concentrated, and azeotroped two timeswith toluene (2 mL each). The crude material was then purified oversilica gel (Biotage SNAP Ultra, 25 g, eluting with a 1-40% MeOH in DCM)to provide ER-899836 (55 mg, 0.134 mmol, 69.9% yield) after combiningthe desired fractions, concentrating and drying in vacuo.

ER-899836 (50 mg, 0.124 mmol) was dissolved in acetonitrile (1 mL)followed by the addition of 2 M HCl in diethyl ether (0.062 ml, 0.124mmol) and stirred at rt for 30 min. The resultant orange solution wasconcentrated to dryness and placed under high vacuum overnight toprovide ER-899836-HCl in quantitative yield.

ER-899688-HCl (381 mg, 0.886 mmol, 88.4% yield) was prepared in asimilar manner to ER-899836-HCl starting with ER-897968 (600 mg, 1.58mmol).

ER-899820-HCl (45 mg, 0.110 mmol, 69.9% yield) was prepared in a similarmanner to ER-899836-HCl starting with ER-899819 (62 mg, 0.158 mmol).

ER-899337 (35.6 mg, 0.087 mmol, 24. % yield) was similarly prepared in asimilar manner to ER-899836 starting with ER-897968 (142 mg, 0.361 mmol)as a free base.

ER-899835 (29 mg, 0.071 mmol, 81. % yield) was similarly prepared in asimilar manner to ER-899836 starting with ER-899718 (34 mg, 0.086 mmol)as a free base.

ER-899837 (35.6 mg, 0.087 mmol, 24.2% yield) was similarly prepared in asimilar manner to ER-899836 starting with ER-899417 (142 mg, 0.361 mmol)as a free base.

ER-898707-formate (17 mg, 0.0.36 mmol, 78. % yield) was prepared in asimilar manner to ER-899836 starting with ER-898694 (20 mg, 0.046 mmol)maintaining as the formate salt instead of conversion to the HCl salt asabove.

Other Examples Depicted by General Structure 39 or 40 in Scheme 11

ER-895472: To a cooled solution of 38 (22.7 mg, 0.076 mmol) and TEA(12.8 μl, 0.092 mmol) in THF at−15° C. was added ethyl chloroformate(8.1 μl, 0.084 mmol). After stifling 1.5 hr, ammonium hydroxide (6.0 μl,0.153 mmol) was added after which time stifling continued for anadditional 2 hr at −10° C. The reaction was allowed to warm to rt andstirred an additional 2 h. The completed reaction was quenched byaddition of sat. NaHCO₃ (5 mL) followed by the extraction of the aqueousphase 3 times with EtOAc (5 mL each). The combined organic layers weredried over anhydrous Na₂SO₄, filtered and concentrated to give a paleyellow oil. The crude product was purified using reverse phase HPLC C-18(Water's X-Bridge C18 19×100 mm column; gradient usingacetonitrile/water containing 0.1% formic acid) to provide ER-895472(6.2 mg, 0.021 mmol, 27.5% yield).

ER-899122: To a cooled solution of 38 (80 mg, 0.24 mmol) and4-methylmorpholine (32 μl, 0.288 mmol) in THF (4 mL) at 0° C. was addedisopropyl chloroformate (38 μl, 0.084 mmol). After stifling 30 min,Tetrahydro-pyran-4-ylamine (29.1 mg, 0.288 mmol) was added after whichtime stifling continued for an additional 2 hr at −10° C. The reactionwas allowed to warm to rt and stirred an additional 16 h. The completedreaction was quenched by addition of sat. NaHCO₃ (5 mL) followed by theextraction of the aqueous phase 3 times with EtOAc (5 mL each). Thecombined organic layers were dried over anhydrous Na₂SO₄, filtered andconcentrated to give a pale yellow oil. The crude product was purifiedover silica gel (25 g) eluting with a linear gradient of 80-100% EtOAcin heptane to provide ER-899122 (40 mg, 0.100 mmol, 41.7% yield) afterconcentration of the desired fractions to dry and placing the productunder high vacuum.

ER-899121 (40 mg, 0.104 mmol, 43.3% yield) was prepared in a similarmanner to ER-899122 starting with 38 (80 mg, 0.24 mmol) and3-aminomethyl-oxetane (25.06 mg, 0.288 mmol).

ER-899123 (40 mg, 0.109 mmol, 45.5% yield) was prepared in a similarmanner to ER-899122 starting with 38 (80 mg, 0.24 mmol) and3-aminotetrahydrofuran (25.06 mg, 0.288 mmol).

ER-899140 (20 mg, 0.051 mmol, 21.3% yield) was prepared in a similarmanner to ER-899122 starting with 38 (80 mg, 0.24 mmol) andtert-butyl(2-aminoethyl)(methyl)carbamate (50.1 mg, 0.288 mmol) afterremoval of the Boc group using TFA and neutralizing with MP-carbonate asdescribed.

ER-899151 (15 mg, 0.035 mmol, 14.6% yield) and ER-899152 (15 mg, 0.035mmol, 14.6% yield) were prepared in a similar manner to ER-899122starting with 38 (80 mg, 0.24 mmol) and3-Amino-1,1,1-trifluoro-2-propanol (37.1 mg, 0.288 mmol) as a mixture ofstereoisomers. The two products were separated using the chromatographymethod described for ER-899122. The stereocenters were arbitrarilyassigned and have not been definitively determined.

ER-899153 (32 mg, 0.083 mmol, 34.4% yield) was prepared in a similarmanner to ER-899122 starting with 38 (80 mg, 0.24 mmol) and glycinemethyl ester hydrochloride (36.1 mg, 0.288 mmol).

ER-899154 (16 mg, 0.041 mmol, 17.3% yield) was prepared in a similarmanner to ER-899122 starting with 38 (80 mg, 0.24 mmol) anddimethylethylenediamine (31.6 μl, 0.288 mmol).

ER-899159 (14 mg, 0.033 mmol, 13.8% yield) and ER-899160 (13 mg, 0.031mmol, 12.8% yield) were prepared in a similar manner to ER-899122starting with 38 (80 mg, 0.24 mmol) and4-amino-1,1,1-trifluorobutan-2-ol hydrochloride (51.6 mg, 0.288 mmol) asa mixture of stereoisomers. The two products were separated using thechromatography method described for ER-899122. The stereocenters werearbitrarily assigned and have not been definitively determined.

ER-899161 (13 mg, 0.031 mmol, 12.9% yield) was prepared in a similarmanner to ER-899122 starting with 38 (80 mg, 0.24 mmol) and4,4,4-trifluorobutane-1,3-diamine dihydrochloride (61.9 mg, 0.288 mmol)as a diastereomeric mixture.

ER-899152 (9 mg, 0.024 mmol, 37.0% yield) was prepared by dissolvingER-899153 (24 mg, 0.65 mmol) in MeOH (2 mL) and water (0.5 mL) followedby the addition of lithium hydroxide (3.12 mg, 13.0 mmol). The reactionwas stirred for 16 h at rt after which time the completed reaction wasacidified with 3 N HCl to pH 3 followed by extraction 3 times with EtOAc(10 mL each), combining the organic layers, drying over anhydrousNa₂SO₄, filtering and concentrating to dryness. The crude product waspurified over a C-18 reverse phase HPLC column eluting with a lineargradient of 10%-90% acetonitrile in water with 0.1% formic acid andconcentrating the desired peak followed by high vacuum to dryness.

ER-899278 (20 mg, 0.051 mmol, 33.8% yield) was prepared in a similarmanner to ER-899140 starting with 38 (50 mg, 0.15 mmol) and(R)-tert-butyl 2-(aminomethyl)morpholine-4-carboxylate (48.6 mg, 0.225mmol).

ER-899366 (70 mg, 0.171 mmol, 42.4% yield) was prepared in a similarmanner to ER-899140 starting with 38 (120 mg, 0.404 mmol) and(2S,6R)-tert-butyl 2-(aminomethyl)-6-methylmorpholine-4-carboxylate (112mg, 0.484 mmol).

ER-899367 (40 mg, 0.102 mmol, 38% yield) was prepared in a similarmanner to ER-899140 starting with 38 (80 mg, 0.269 mmol) and tert-butylhexahydropyrrolo[3,4-c]pyrrole-2(M)-carboxylate (68.5 mg, 0.373 mmol).

ER-899459 (30 mg, 0.074 mmol, 31.3% yield) was prepared in a similarmanner to ER-899122 starting with 38 (70 mg, 0.235 mmol) andN,N-dimethylpiperidin-4-amine (36.2 mg, 0.283 mmol).

ER-899464 (20 mg, 0.051 mmol, 18.9% yield) was prepared in a similarmanner to ER-899122 starting with 38 (80 mg, 0.269 mmol) and1-methylpiperidin-4-amine (36.9 mg, 0.323 mmol).

ER-899588 (40 mg, 0.105 mmol, 44.8% yield) was prepared in a similarmanner to ER-899140 starting with 38 (70 mg, 0.235 mmol) and tert-butylpiperidin-4-ylcarbamate (56.6 mg, 0.283 mmol).

ER-899608 (40 mg, 0.102 mmol, 37.8% yield) was prepared in a similarmanner to ER-899140 starting with 38 (70 mg, 0.235 mmol) andtert-butyl(4-methylpiperidin-4-yl)carbamate (63.4 mg, 0.296 mmol).

ER-899680 (40 mg, 0.098 mmol, 19.2% yield) was prepared in a similarmanner to ER-899122 starting with 38 (100 mg, 0.336 mmol) and1-ethylpiperidin-3-amine (43.1 mg, 0.336 mmol).

ER-899431 (53 mg, 0.103 mmol, 51.3% yield) was prepared in a similarmanner to ER-899122 starting with 38 (99 mg, 0.333 mmol) and methylamine(2M in THF) (1.50 mL, 3.00 mmol).

ER-899626 (29 mg, 0.071 mmol, 35.3% yield) was prepared in a similarmanner to ER-899122 starting with 38 (60 mg, 0.202 mmol) and4-amino-1-ethyl piperidine (25.9 mg, 0.202 mmol).

ER-899718 (32 mg, 0.081 mmol, 40.1% yield) was prepared in a similarmanner to ER-899140 starting with 38 (60 mg, 0.202 mmol) and tert-butyl4-amino-4-methylpiperidine-1-carboxylate (47.6 mg, 0.222 mmol).

Additional Examples: Modification of general structure 39, Scheme 11:

ER-899333-HCl: To a stirred solution of 38 (58.2 mg, 0.196 mmol) andHBTU (89 mg, 0.235 mmol) in DCM (1.94 mL) was added DIEA (137 μl, 0.783mmol) followed by (3R,4S)-tert-butyl3-amino-4-fluoropiperidine-1-carboxylate (42.7 mg, 0.196 mmol). Thereaction was stirred overnight after which time the completed reactionwas concentrated and diluted with EtOAc (10 mL). The organic solutionwas washed with 2N aqueous citric acid, saturated NaHCO₃, dried overanhydrous Na₂SO₄, filtered and concentrated to dryness. The crudeproduct was purified over silica gel (50 g, eluting with a 40-100% EtOAcin heptane, 20 column volumes) to provide 86 (58.5 mg, 0.118 mmol, 56.2%yield) as a pale yellow solid.

To a stirred solution of 86 (58.8 mg, 0.118 mmol) and methyl iodide(7.39 μL, 0.118 mmol) in DMF (1 mL) cooled to 0° C. was added NaH (5.20mg, 0.13 mmol, oil dispersion). The reaction was warmed to rt andstirred for 3.5 h. The completed reaction was cooled with ice/water bathand quenched by the slow addition of saturated ammonium chloride (5 mL)followed by water (5 mL) and extraction two times with EtOAc (10 mLeach). The combined organic phases were dried over anhydrous Na₂SO₄,filtered and concentrated to dryness. The crude product was purifiedover silica gel (25 g, eluting with a 40-100% gradient of EtOAc inheptane, 20 column volumes) to provide 87 (42.9 mg, 0.084 mmol, 71.0%)as a pale yellow solid.

To a stirred solution of 87 (42.9 mg, 0.084 mmol) in EtOAc (1 mL) wasadded 4.0 N HCl in 1,4-Dioxane (0.419 mL, 1.677 mmol) followed bystifling at rt for 1 hr, after which time the completed reaction wasconcentrated and dried in vacuo to provide ER-89933-HCL (23.4 mg, 0.054mmol, 62.3%).

ER-8999335: To a stirred solution 38 (357.2 mg, 1.201 mmol) and HBTU(547 mg, 1.442 mmol) in DCM (10 mL) was added DIEA (0.84 mL, 4.806 mmol)and tert-butyl(azetidin-3-ylmethyl)carbamate (224 mg, 1.201 mmol). Thereaction mixture was stirred for 3 h after which time the completedreaction concentrated, dissolved in EtOAc (25 mL) and washed with 2Naqueous citric acid (20 mL), saturated NaHCO₃ (20 mL), and dried overanhydrous Na₂SO₄, filtered and concentrated to dry. The crude productwas purified over silica gel (40 g, eluting with a 50-100%EtOAc/heptane, 20 column volumes) to provide 88 (181.6 mg, 0.390 mmol,32.5% yield) of pale yellow solid.

To a stirred solution 88 (52.6 mg, 0.113 mmol) and ethyl iodide (10.50μL, 0.13 mmol) in DMF (1.0 mL, 12.915 mmol) at 0° C. was added 60%sodium hydride (5.87 mg, 0.147 mmol) after which time the reaction wasallowed to warm to rt and stirred for 6 h. The completed reaction wascooled to 0° C. and quenched by the slow addition of saturated NH₄Cl (5mL) followed by dilution with water (5 mL) and extraction two times withEtOAc (10 mL each). The combined organic phases were dried overanhydrous Na₂SO₄, filtered and concentrated to dryness. The crudeproduct was purified over silica gel (25 g, eluting with 70-100% EtOAcin heptane, 20 column volumes) to provide the Boc-protected intermediatewhich was used in the next step. The Boc was removed by dissolving theintermediate in EtOAc (1 mL) and adding TFA (0.5 mL) followed bystifling for 1 h. The completed reaction was concentrated to dry,dissolved in DCM (10 mL), washed 2 times with saturated NaHCO₃, driedover anhydrous Na₂SO₄, filtered, concentrated, and high vacuum to dry toprovide ER-899335 (4.1 mg, 0.010, mmol, 9.3%) as a pale yellow solid.

ER-899336: To a stirred solution of ER-899334 (35.4 mg, 0.097 mmol) andiodomethane (0.013 mL, 0.213 mmol) in DMF (1 mL) at 0° C. was added 60%sodium hydride (9.69 mg, 0.242 mmol) after which time the reaction waswarmed to rt and stirred overnight. The completed reaction was cooled to0° C. and quenched by the slow addition of saturated NH₄Cl (5 mL)followed by dilution with water (5 mL) and extraction two times withEtOAc (10 mL each). The combined organic phases were dried overanhydrous Na₂SO₄, filtered and concentrated to dryness. The crudeproduct was purified over silica gel (25 g, eluting with 70-100% EtOAcin heptane, 20 column volumes) to provide ER-899336 (5.2 mg, 0.013 mmol,13.6% yield) after collection of the desired material, concentration andhigh vacuo.

ER-899481: To a stirred solution of ER-898946 (60 mg, 0.158 mmol) inacetonitrile (10 mL) was added K₂CO₃ (87 mg, 0.632 mmol) and2-bromoacetamide (43.6 mg, 0.316 mmol). The reaction mixture was warmedto 60° C. and stirred for 16 h, after which time the completed reactionwas filtered. The resultant solution was concentrated and the crudeproduct was purified over a C-18 HPLC column (eluting with 10% to 50%acetonitrile in water with 0.1% formic acid) to provide ER-899481 (43mg, 0.099 mmol, 62.3% yield) after collection of the desired material,concentration and high vacuo.

ER-885612 as an Example of Compound 42, Scheme 12: To a cooled, stirredsolution of 13 (25 mg, 0.088 mmol) in DMF (0.5 mL) at 0° C. was addedNaH (3.5 mg, 0.088 mmol, 60% oil dispersion) followed by methyl iodide(16.5 uL, 0.265 mmol). The reaction was stirred an additional 20 minafter which time water (1 mL) was slowly added. The quenched reactionwas extracted two times with DCM (2 mL each), dried over MgSO₄, filteredand concentrated to dry. Purification over a reverse-phase preparativeHPLC column (X-Bridge C18 19×100 mm column; eluting with 0-50%acetonitrile in water containing 0.05% TFA) provided ER-885612 (16.9 mg,0.057 mmol, 64.6% yield) after combining the desired collectedfractions, concentration and drying in vacuo.

ER-885807 (15.2 mg, 0.049 mmol, 55.7% yield) was prepared in a similarmanner to ER-885612 starting with 13 (25 mg, 0.088 mmol) and iodoethane(20.6 mg, 0.132 mmol).

ER-885808 (8.2 mg, 0.025 mmol, 28.6% yield) was prepared in a similarmanner to ER-885612 starting with 13 (25 mg, 0.088 mmol) and isopropyliodide (22.5 mg, 0.132 mmol).

ER-885892 (3.1 mg, 0.009 mmol, 10.4% yield) was prepared in a similarmanner to ER-885612 starting with 13 (25 mg, 0.088 mmol) and1-iodo-2-methylpropane (15.2 uL, 0.132 mmol).

ER-885929 (17.5 mg, 0.048 mmol, 54.6% yield) was prepared in a similarmanner to ER-885612 starting with 13 (25 mg, 0.088 mmol) and1-iodohexane (37.4 mg, 0.176 mmol).

ER-885930 (7.9 mg, 0.021 mmol, 23.7% yield) was prepared in a similarmanner to ER-885612 starting with 13 (25 mg, 0.088 mmol) andcyclohexylmethyl bromide (31.3 mg, 0.177 mmol).

ER-895324 (35.2 mg, 0.098 mmol, 54.7% yield) was prepared in a similarmanner to ER-885612 starting with 13 (50.6 mg, 0.179 mmol) and2-bromopyridine (20.4 uL, 0.214 mmol). THF (1 mL) was used instead ofDMF.

ER-895325 (54.2 mg, 0.150 mmol, 83.8% yield) was prepared in a similarmanner to ER-893324 starting with 13 (50.6 mg, 0.179 mmol) and2-bromopyrimidine (57 mg, 0.359 mmol).

ER-894552 (5 mg, 0.014 mmol, 19.2% yield) was prepared in a similarmanner to ER-893324 starting with 13 (20.4 mg, 0.072 mmol) and2-chloropyrazine (8.3 mg, 0.0.072 mmol).

ER-886137: In a dry microwave reaction vessel was added cesium carbonate(172.5 mg, 0.529 mmol), copper (I) iodide (33.6 mg, 0.176 mmol),1,1′-binaphthyl-2,2′-diamine (50.2 mg, 0.177 mmol,2-iodo-1,3-dimethylbenzene (123 mg, 0.53 mmol) in DMSO (0.3 mL) followedby 13 (50 mg, 0.177 mmol). The reaction mixture was microwaved at 110°C. for 12 h after which time the mixture was directly injected on areverse-phase preparative HPLC column (Water's X-Bridge C18 19×100 mmcolumn; gradient using 0-50% acetonitrile in water containing 0.05% TFA)for purification eluting with, providing a crude product. The crudeproduct was purified over silica gel (Biotage eluting with a gradientfrom 25% EtOAc in heptane to 100% EtOAc) to provide ER-886137 (12.1 mg,0.031 mmol, 17.6% yield) after combining the desired collectedfractions, concentration and drying in vacuo.

ER-886514: To a stirred suspension of 14 (10.5 mg, 0.024 mmol) andpotassium carbonate (30 mg, 0.217 mmol) in toluene (1 mL) was addedphenol (24.4 mg, 0.259 mmol). The reaction mixture was microwaved at150° C. for 5 h after which time the crude mixture was filtered anddirectly injected on a reverse-phase preparative HPLC column (Water'sX-Bridge C18 19×100 mm column; gradient using 0-50% acetonitrile inwater containing 0.05% TFA) to provide ER-886514 (4.5 mg, 0.013 mmol,54.1% yield) after combining the desired collected fractions,concentration and drying in vacuo.

ER-886515 (3.2 mg, 0.009 mmol, 37.6% yield) was prepared in a similarmanner to ER-886514 starting with 14 (10.6 mg, 0.024 mmol) and3-methylphenol (28.1 mg, 0.260 mmol).

ER-886516 (4.7 mg, 0.013 mmol, 52.4% yield) was prepared in a similarmanner to ER-886514 starting with 14 (10.6 mg, 0.024 mmol) and4-methylphenol (28.1 mg, 0.260 mmol).

ER-886605 (7.9 mg, 0.020 mmol, 85.1% yield) was prepared in a similarmanner to ER-886514 starting with 14 (10.3 mg, 0.024 mmol) and3,4-diflurorphenol (20 mg, 0.154 mmol). 1-Methylpyrrolidinone (1 mL) wasused instead of toluene in this preparation.

ER-886606 (7.2 mg, 0.019 mmol, 81.2% yield) was prepared in a similarmanner to ER-886605 starting with 14 (10.3 mg, 0.024 mmol) and3-flurorphenol (13.2 mg, 0.118 mmol).

ER-886624 (5.1 mg, 0.014 mmol, 59% yield) was prepared in a similarmanner to ER-886605 starting with 14 (10 mg, 0.023 mmol) and2-flurorphenol (10 mg, 0.089 mmol).

ER-886786 (8.2 mg, 0.022 mmol, 76.9% yield) was prepared in a similarmanner to ER-886605 starting with 14 (12.5 mg, 0.029 mmol) and2-methylphenol (28.1 mg, 0.260 mmol).

Other Examples using Compound 13 or ER-885493 as a starting material:

ER-885621: To a stirred solution of bis(2-methoxyethyl)aminosulfurtrifluoride (24.4 uL, 0.132 mmol) in DCM (0.1 mL) cooled to −78° C.under a N₂ atmosphere was added 13 (25 mg, 0.088 mmol) in DCM (0.1 mL).The reaction mixture was allowed to warm to −50° C. and stirred for 0.5h, warmed to 0° C., and stirred for 1.5 h. The reaction mixture waswarmed to 5° C. and stirred for 2 h after which time saturated NaHCO₃ inwater was added dropwise until reach pH 10. The layers were separatedand the organic layer was washed two times with water (1 mL), dried overMgSO₄, filtered and concentrated to dry. Purification over areverse-phase preparative HPLC column eluting with 0-50% acetonitrile inwater, provided ER-885621 (12.5 mg, 0.044 mmol, 49.8% yield) aftercombining the desired collected fractions, concentration and drying invacuo.

ER-885906: A stirred solution of 13 (85.5 mg, 0.302 mmol) in thionylchloride (2 mL) was warmed to 85° C. for 24 h, after which time theexcess thionyl chloride was removed and the crude product was purifiedover a reverse-phase preparative HPLC column eluting with 0-50%acetonitrile in water, provided ER-885906 (4.3 mg, 0.014 mmol, 4.7%yield) after combining the desired collected fractions, concentrationand drying in vacuo.

Preparation of ER-886431 & ER-886480 as examples of Compound 44, Scheme13

Compound 43 or ER-886250: To a stirred solution of 13 (200 mg, 0.706mmol) in DCM (5 mL) and pyridine (0.114 mL, 1.4 mmol) at 0° C. under anitrogen atmosphere was added Dess-Martin periodinane (359 mg, 0.846mmol) after which time the reaction was warmed to rt and stirred for 1h. The reaction was found to be incomplete thus additional Dess-Martinperiodinane (359 mg, 0.846 mmol) and pyridine (0.114 mL, 1.4 mmol) wereadded followed by stirring for an additional 30 min. The completedreaction was poured over saturated aqueous NaHCO₃ (4 mL) with 10%aqueous sodium thiosulfate (2 mL). The mixture was stirred for 30 minafter which time the mixture was extracted three times with DCM (4 mLeach). The combined organic layers were washed with brine (4 mL), driedover Na₂SO₄, filtered and concentrated. The crude product was purifiedover silica gel (Biotage SP4, 25 g, eluting with 10-100% EtOAc inheptane) to provide5-((2R,6R)-2-formyl-6-methylmorpholino)quinoline-8-carbonitrile, 43 orER-886250 (110 mg, 0.391 mmol, 55.4% yield) as a yellow syrup aftercombining the desired fractions, concentration and drying in vacuo.

To stirred solution of 43 (25 mg, 0.089 mmol) in THF (0.5 mL) at 0° C.under a nitrogen atmosphere was added 1 M vinyl magnesium bromide (0.098mL, 0.098 mmol) in THF dropwise over a 2-min period. The reaction wasstirred at 0° C. for 2 h after which time saturated ammonium chloride(0.5 mL) was added slowly followed by water (0.25 mL). The quenchedreaction was warmed to rt, stirred for an additional 10 min, andextracted two times with EtOAc (2 mL each). The combined organic layerswere washed with brine (1 mL), dried over Na₂SO₄, filtered andconcentrated. The crude product was purified on preparative TLC plates(Merck Silica Gel 60 F254, 2 20×20 cm plates, eluting with EtOAc) toprovide ER-886431 (3 mg, 0.010 mmol, 11.2% yield, Rf=0.75, EtOAc) andER-886480 (3 mg, 0.0.10 mmol, 11.2% yield, Rf=0.80. EtOAc) as a yellowsyrup after the desired fractions were eluted separately from the silicagel, concentration and drying in vacuo. The stereochemistry for the freealcohol functionality for both examples was arbitrarily assigned.

ER-886530 (11 mg, 0.032 mmol, 36.4% yield, Rf=0.80, EtOAc) and ER-886531(3 mg, 0.0.10 mmol, 11.2% yield, Rf=0.75, EtOAc) were prepared in asimilar manner to ER-886431 and ER-886480 starting with 43 (25 mg, 0.089mmol) and 2 M butylmagnesium chloride in THF (0.131 mL, 0.262 mmol). Thecrude product was purified over silica gel (Biotage SP4, 25 g, elutingwith 20-100% EtOAc in heptane. The stereochemistry for the free alcoholfunctionality for both examples was arbitrarily assigned.

ER-886532 (4 mg, 0.011 mmol, 6.3% yield, Rf=0.80, EtOAc) and ER-886533(4 mg, 0.011 mmol, 6.3% yield, Rf=0.75, EtOAc) were prepared in asimilar manner to ER-886530 and ER-886531 starting with 43 (49 mg, 0.174mmol) and 1.3 M cyclohexylmagnesium chloride in THF (0.20 mL, 0.260mmol). The stereochemistry for the free alcohol functionality for bothexamples was arbitrarily assigned.

ER-886567 (3.6 mg, 0.009 mmol, 5.3% yield, Rf=0.80, EtOAc) and ER-886568(8.6 mg, 0.022 mmol, 12.8% yield, Rf=0.75, EtOAc) were prepared in asimilar manner to ER-886530 and ER-886531 starting with 43 (49 mg, 0.174mmol) and 1 M phenethylmagnesium chloride in THF (0.26 mL, 0.260 mmol).The stereochemistry for the free alcohol functionality for both exampleswas arbitrarily assigned.

ER-886520 (26 mg, 0.084 mmol, 49.1% yield, Rf=0.80, EtOAc) was preparedin a similar manner to ER-886530 and ER-886531 starting with 43 (48 mg,0.171 mmol) and 2 M ethylmagnesium chloride in THF (0.128 mL, 0.256mmol). The diastereomeric mixture was used for additional studies.

ER-886564 and ER-886565 via Scheme 26

To a stirred solution of 22 (2.51 g, 7.8 mmol) in EtOH (40 mL) was added10% palladium on activated carbon in 50% water (1.66 g) followed bycharging the flask several times with hydrogen gas. The reaction wasmaintaining under a hydrogen atmosphere (balloon pressure) at 40° C. andstirred for 16 h, after which time the reaction was purged with nitrogengas several times while evacuating the system with house vacuum betweenpurges. The completed reaction was filtered over Celite 545, the filterpad washed two times with EtOH (85 mL each), followed by concentrationof the combined filtrates were concentrated and dried in vacuo. Thecrude product, (2R,6R)-tert-butyl2-(hydroxymethyl)-6-methylmorpholine-4-carboxylate, 89 (1.56 g, 6.7mmol, 86.5% yield) was used in the next step without furtherpurification.

To a stirred solution of 89 (1.501 g, 6.5 mmol) in DCM (30 mL) andpyridine (1.05 mL, 13.0 mmol) at 0° C. under a nitrogen atmosphere wasadded Dess-Martin periodinane (3.3 g, 7.8 mmol) after which time thereaction was warmed to rt and stirred for 1 h. The reaction was found tobe incomplete thus additional Dess-Martin periodinane (1.4 g, 3.3 mmol)and pyridine (0.52 mL, 6.4 mmol) were added followed by stirring for anadditional 2 h. The completed reaction was poured over saturated aqueousNaHCO₃ (37 mL) with 10% aqueous sodium thiosulfate (18 mL). The mixturewas stirred for 30 min after which time the mixture was extracted threetimes with DCM (40 mL each). The combined organic layers were washedwith brine (37 mL), dried over Na₂SO₄, filtered and concentrated. Thecrude product was purified over silica gel (Biotage 40+S, 40 g, elutingwith 10-100% EtOAc in heptane) to provide (2R,6R)-tert-butyl2-formyl-6-methylmorpholine-4-carboxylate, 90 (1.285 g, 5.6 mmol, 86.2%yield) as a colorless syrup after combining the desired fractions,concentration and drying in vacuo.

To stirred solution of 90 (208 mg, 0.907 mmol) in THF (5 mL) at 0° C.under a nitrogen atmosphere was added 1 M benzylmagnesium bromide (2.3mL, 2.3 mmol) in THF dropwise over a 2-min period. The reaction wasstirred at 0° C. for 2.5 h after which time saturated ammonium chloride(4.8 mL) was added slowly followed by water (2.5 mL). The quenchedreaction was warmed to rt, stirred for an additional 10 min, andextracted two times with EtOAc (20 mL each). The combined organic layerswere washed with brine (9.5 mL), dried over Na₂SO₄, filtered andconcentrated. The crude product over silica gel (Biotage SP4, 25 g,eluting with 25-100% EtOAc in heptane) to provide (2R,6R)-tert-butyl2-((R,S)-1-hydroxy-2-phenylethyl)-6-methylmorpholine-4-carboxylate, 91(172 mg, 0.539 mmol, 59.4% yield, R═—CH₂C₆H₅) as a colorless oil afterthe desired fractions were combined, concentration and drying in vacuo.

To a stirred solution of 91 (172 mg, 0.539 mmol) in DCM (1.2 mL) wasadded TFA (1.2 mL). The reaction was stirred for 30 min at rt afterwhich time the completed reaction was diluted with toluene (4.6 mL),concentrated and azeotroped to dry two times with toluene (4.6 mL each)to dryness to provide1-((2R,6R)-6-methylmorpholin-2-yl)-2-phenylethanol, 92 (179 mg, 0.534mmol, 99.0% yield, R═—CH₂C₆H₅) as the TFA salt without furtherpurification.

Crude 92 (179 mg, 0.534 mmol), was dissolved in N-methylpyrrolidone (3mL) followed by 3 (187 mg, 0.802 mmol) and DIPEA (0.2 mL, 1.1 mmol). Themixture was microwaved at 170° C. for 5 h after which time the cooledmixture was directly injected onto a C-18 reverse-phase preparative HPLCcolumn eluting with 10-60% acetonitrile in water with 0.1% TFA. The twoeluted fractions were separately concentrated to dry, azeotroped twotimes with MeOH (5 mL each). Each isomer was dissolved in MeOH (2 mL)and passed over a basic plug of silica gel (silica gel—CO₂) eluting twotimes with MeOH (2 mL each) followed by concentration and drying invacuo to provide separately 93 or ER-886564 (19 mg, 0.051 mmol, 9.5%yield, first fraction, R═—CH₂C₆H₅) and 94 or ER-886565 (23 mg, 0.062mmol, 11.5% yield, second fraction, R═—CH₂C₆H₅). The stereochemistry ofthe alcohol position was arbitrarily assigned.

ER-895200 (22.2 mg, 0.075 mmol, 32.1% yield, first fraction) andER-895310 (15.2 mg, 0.051 mmol, 21.8% yield, second fraction) wereprepared in a similar fashion to ER-886564 and ER-886564 starting with 3(54.6 mg, 0.234 mmol) and 1-((2R,6R)-6-methylmorpholin-2-yl)ethanol(68.2 mg, 0.470 mmol). The stereochemistry of the alcohol position wasarbitrarily assigned.

ER-895326: To a stirred solution ER-895200 (17.9 mg, 0.060 mmol) in THF(0.3 mL) was added sodium hydride (4.8 mg, 0.120 mmol, 60% oildispersion) followed by 2-bromopyrimidine (19 mg, 0.120 mmol). Thereaction was warmed to 60° C. and stirred for 30 min after which time itwas cooled to rt and slowly quenched with a dropwise addition of water(0.5 mL). The mixture was extracted three times with DCM (3 mL each) andthe combined organic layers were washed with brine (3 mL), dried overNa₂SO₄, filtered and concentrated to dry. The crude product was purifiedover silica gel (Biotage, eluting with a gradient of 0-10% EtOAc inheptane) to provide ER-895326 (20.3 mg, 0.054 mmol, 90.1% yield) aftercollection of the desired fractions, concentration and drying in vacuo.

ER-895327 (6.4 mg, 0.017 mmol, 63% yield) was prepared in a similarmanner to ER-895326 starting with ER-895310 (7.9 mg, 0.027 mmol) and2-bromopyrimidine (8 mg, 0.0.50 mmol).

ER-895412: To a stirred solution of 1.6 M n-butyl lithium in THF (1.36mL, 2.18 mmol) at −40° C. was added dropwise 2-bromopyridine (0.21 mL,2.20 mmol) in diethylether (2 mL) followed by stifling for 30 min at−40° C. 90 (500 mg, 2.18 mmol) in THF (2 mL) was added dropwise over a3-min period after which time the reaction mixture was stirred at −40°C. for 2 h and then at 0° C. for 1 h. The completed reaction was slowlyquenched with saturated ammonium chloride in water (2 mL) followedwarming to rt, separation of the layers and extracting the aqueous layertwo times with EtOAc (2 mL each). The combined organic layers werewashed with brine (2 mL), dried over Na₂SO₄, filtered and concentratedto dry. The crude product was purified first by passing over a silicagel (Biotage, eluting with 30% EtOAc in heptane followed bycrystallization from 3:1 DCM:MeOH to provide after filtering and dryingin vacuo (2R,6R)-tert-butyl2-((S)-hydroxy(pyridin-2-yl)methyl)-6-methylmorpholine-4-carboxylate(150 mg, 0.486 mmol, 22.3% yield)

To a stirred solution of (2R,6R)-tert-butyl2-((S)-hydroxy(pyridin-2-yl)methyl)-6-methylmorpholine-4-carboxylate(150 mg, 0.486 mmol) in DCM (5 mL) was added TFA (1 mL) followed bystifling at rt for 1 h. The completed reaction was concentrated andazeotroped to dry three times with toluene (5 mL each) followed bydiluting with DCM (10 ml) washing two times with saturated NaHCO₃ inwater (2 mL), brine (2 mL), drying over MgSO₄, filtering andconcentration and drying in vacuo to provide crude(S)-((2R,6R)-6-methylmorpholin-2-yl)(pyridin-2-yl)methanol (97.8 mg,0.469, 96.4% yield).

To a stirred solution of(S)-((2R,6R)-6-methylmorpholin-2-yl)(pyridin-2-yl)methanol (97.8 mg,0.469 mmol) and Compound 3 (54.6 mg, 0.234 mmol) in DMAC (1 mL) wasadded TEA (0.132 mL, 0.947 mmol). The reaction was microwaved at 105° C.for 3 h after which time the cooled reaction was directly purified overa reverse-phase preparative HPLC column (Water's X-Bridge C18 19×100 mmcolumn; gradient using 0-50% acetonitrile in water containing 0.1%formic acid) to provided ER-895296 (15.2 mg, 0.042 mmol, 18.0% yield,R=2-pyridyl) after combining the desired collected fractions,concentration and drying in vacuo.

Preparation of ER-886625 as an example of Compound 45, Scheme 13

To a stirred solution of ER-886520 (19 mg, 0.061 mmol) in DCM (0.5 mL)and pyridine (0.010 mL, 0124 mmol) at 0° C. under a nitrogen atmospherewas added Dess-Martin periodinane (31.1 mg, 0.073 mmol) after which timethe reaction was warmed to rt and stirred for 1 h. The reaction wasfound to be incomplete thus additional Dess-Martin periodinane (31.1 mg,0.073 mmol) and pyridine (0.010 mL, 0124 mmol) were added followed bystirring for an additional 30 min. The completed reaction was pouredover saturated aqueous NaHCO₃ (0.4 mL) with 10% aqueous sodiumthiosulfate (0.2 mL). The mixture was stirred for 30 min after whichtime the mixture was extracted three times with DCM (0.3 mL each). Thecombined organic layers were washed with brine (0.35 mL), dried overNa₂SO₄, filtered and concentrated. The crude product was purified oversilica gel (Biotage SP4, 25 g, eluting with 10-80% EtOAc in heptane) toprovide 45 or ER-886625 (7 mg, 0.023 mmol, 37.1% yield) as a yellowsolid after combining the desired fractions, concentration and drying invacuo.

ER-886626 (10.8 mg, 0.030 mmol, 90.9% yield) was prepared in a similarmanner to ER-886625 starting with the mixture of ER-886532 and ER-886533(12 mg, 0.033 mmol).

ER-886629 (6.6 mg, 0.017 mmol, 81% yield) was prepared in a similarmanner to ER-886625 starting with the mixture of ER-886567 and ER-886568(8 mg, 0.021 mmol).

Preparation of ER-886912 and ER-886913:

To a stirred solution of ER-886568 (124 mg, 0.32 mmol) in DCM (1.3 mL)at rt was added methanesulfonyl chloride (37 uL, 0.478 mmol) followed byDMAP (7.8 mg, 0.064 mmol) and DIPEA (0.17 mL, 0.959 mmol). The reactionwas stirred at rt for 2 h after which time water (1 mL) and DCM (5 mL)were added followed by stirring an additional 5 min and separation ofthe layers. The organic layer was washed with brine (1 mL), dried overNa₂SO₄, filtered and concentrated. The crude product was purified oversilica gel (Biotage SP4, 25 g, eluting with 20-100% EtOAc in heptane) toprovide(R)-1-((2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)-3-phenylpropylmethane-sulfonate(136 mg, 0.292 mmol, 93.5% yield) as a yellow solid after combining thedesired fractions, concentration and drying in vacuo.

A solution of(R)-1-((2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)-3-phenylpropylmethanesulfonate (38 mg, 0.082 mmol) in NMP (2 mL) and pyrrolidine (0.10mL, 1.21 mmol) was microwaved at 150° C. for 15 min followed by cooling,filtering and direct injection onto a C-18 HPLC (Water's X-Bridge C1819×100 mm column; gradient using 0-50% acetonitrile in water containing0.05% TFA). ER-886912 and ER-886913 fractions were separatelyconcentrated to dry, dissolved in MeOH (3 mL) and eluted over acarbonate impregnated silica gel column (Biotage Isolute SPE, Si—CO₃, 1g), washed with MeOH (3 mL), concentrated and dried in vacuo to provideER-886912 (1.4 mg, 0.003 mmol, 3.9% yield) as the first eluted peak andER-886913 (0.6 mg, 0.001 mmol, 1.5% yield) as the second eluted. Thestereochemistry for the amine functionality for both examples wasarbitrarily assigned.

Preparation of ER-886131: A modification of Scheme 7 via Scheme 27:

A stirred solution of commercially available (S)-2-propyloxirane, 95(3.0 g, 34.8 mmol, R=ethyl) in ammonium hydroxide (100 mL) was sealedand stirred for 24 h followed azeotroping to dryness three times withtoluene (100 mL each). The crude, colorless product(S)-1-aminopentan-2-ol, 96 (R=ethyl), was used in the next reactionwithout purification.

To a stirred solution of crude 96 (0.987 mg, 9.57 mmol) in EtOH (20 mL)was added (S)-methyl 2-chloropropanoate, 97 (1.568 g, 11.5 mmol,R′=methyl) followed by warming to 70° C. and stifling for 24 h. Thecomplete reaction was cooled to rt, concentrated to dry and the residuedissolved in EtOAc (20 mL). The organic solution was washed three timeswith 1 N aqueous HCL (5 mL each), brine (5 mL), dried over MgSO₄,filtered and concentrated to dry. The crude product was purified oversilica gel (Biotage, eluted with a gradient of 20-100% EtOAc inheptanes) to provide (S)-2-chloro-N—((S)-2-hydroxypentyl)propanamide, 98(0.356 g, 1.839 mmol, 19.2% yield, R=ethyl; R′=methyl).

To a stirred solution of 98 (0.356 g, 1.839 mmol) in THF (22 mL) at 0°C. was added sodium hydride (294.2 mg, 7.277 mmol, 60% oil dispersion).The reaction was stirred at 0° C. for 30 min then warmed to rt andstirred for an additional 5 h. The completed reaction was slowlyquenched with IPA (1 mL) followed by adding Dowex 50, H+ form until aneutral pH is demonstrated. The suspension was filtered and washed twotimes with IPA (5 mL each). The filtrate was concentrated followed bypurification over silica gel (Biotage 25 g, eluting with EtOAc).Obtained a mixture of (2S,6S)-2-methyl-6-propylmorpholin-3-one and(2R,6S)-2-methyl-6-propylmorpholin-3-one, 99 (168.2 mg, 1.07 mmol, 58.2%yield, R=ethyl; R′=methyl) in a 2:1, cis to trans, ratio aftercollection of the desired fractions, concentration and drying in vacuo.

To a stirred solution of 99 (168.2 mg, 1.07 mmol) in THF (0.8 mL) at rtwas added 1 M lithium tetrhydroaluminate (1 mL, 1 mmol) dropwise over a2-minute period. The reaction was stirred for an additional 2.5 h afterwhich time the completed reaction was cooled to 0° C. followed by theaddition of water (0.43 mL) and 1 M sodium hydroxide in water (0.03 mL)and then stirring for 30 min. The resultant precipitate was filteredover Celite 454 and eluted with EtOAc (2 mL), DCM (2 mL), and diethylether (2 mL). The combined filtrates were concentrated and dried invacuo to provide crude (2R,S;6S)-2-methyl-6-propylmorpholine, 100(R=ethyl; R′=methyl) that will be used directly in the next reaction.

Crude 100 was dissolved in NMP (5 mL) followed by 3 (150 mg, 0.636 mmol)and DIPEA (0.2 mL, 1.1 mmol). The mixture was microwaved at 145° C. for7 h after which time the cooled mixture was directly injected onto aC-18 reverse-phase preparative HPLC column eluting with 10-60%acetonitrile in water with 0.1% TFA. The two eluted fractions wereseparately concentrated to dry, azeotroped two times with MeOH (5 mLeach). Each isomer was dissolved in MeOH (2 mL) and passed over a basicplug of silica gel (silica gel—CO₂) eluting two times with MeOH (2 mLeach) followed by concentration and drying in vacuo to provideseparately ER-886131, 101 (64.2 mg, 0.217 mmol, 34.2% yield, cis-isomer,R=ethyl; R′=methyl), and ER-886132, 102 (25.2 mg, 0.85 mmol, 13.4%yield, trans-isomer, R=ethyl; R′=methyl).

ER-886212 (315.2 mg, 0.975 mmol, 8.5% overall yield) was prepared in asimilar manner to ER-886131 starting with commercially available(S)-1-aminoheptan-2-ol, 90 (3.08 g, 23.5 mmol, R=n-butyl) and (S)-methyl2-chloropropanoate, 97 (1.568 g, 11.5 mmol, R′=methyl).

Alternative examples of 101 using Scheme 28:

Preparation of ER-886211:

To a stirred solution of 2-ethyloxirane, 103 (621 mg, 8.61 mmol,R=ethyl) in DCM (60 mL) was added benzylamine (996 mg, 9.30 mmol)followed by scandium triflate (341 mg, 0.693 mmol) under a nitrogenatmosphere. The reaction mixture was stirred at rt for 20 h after whichtime the completed reaction was quenched with saturated NaHCO₃ (20 mL),extracted three times with DCM (10 mL each), and the combined organiclayers was dried over MgSO₄, filtered and concentrated to dry. The crudeproduct was purified over silica gel (Biotage 25 g, eluting with a10:10:0.1 ratio of heptanes:EtOAc:TEA) to provide1,1′-(benzylazanediyl)bis(butan-2-ol), 104 (658 mg, 2.628 mmol, 30.4%yield, R=ethyl) after concentration of the combined desired fractionsand drying in vacuo.

To a stirred solution of 104 (584 mg, 2.323 mmol) in water (0.3 mL) wasslowly added concentrated sulfuric acid (2 mL) over a 5-minute periodafter which time the reaction was heated at 150° C. for 2 h. Thecompleted reaction was cooled to rt and slowly poured over saturatedNaHCO₃ (20 mL) with stifling. The mixture was extracted two times withDCM (10 mL each) and the combined organic layers was washed with water(5 mL), brine (5 mL), dried over MgSO₄, filtered and concentrated todry. The crude product was purified over silica gel (Biotage 25 g,eluting with a 2:1 ratio of heptanes:EtOAc) to provide(3S,5R)-1-benzyl-3,5-diethylpiperidine, 105 (234.2 mg, 1.003 mmol, 43.2%yield, R=ethyl) and (3R,5R)-1-benzyl-3,5-diethylpiperidine, 106 (190.2mg, 0.815 mmol, 35.1% yield, R=ethyl) after separately concentration ofthe combined desired fractions and drying in vacuo.

To a stirred solution 105 (107.1 mg, 0.462 mmol) in MeOH (5 mL) wasadded 5% palladium on activated carbon (250 mg) followed by charging theflask several times with hydrogen gas. The reaction was maintainingunder a hydrogen atmosphere (balloon pressure) at rt and stirred for 12h, after which time the reaction was purged with nitrogen gas severaltimes while evacuating the system with house vacuum between purges. Thecompleted reaction was filtered over Celite 545, the filter pad washedtwo times with MeOH (2 mL each), followed by concentration of thecombined filtrates were concentrated and dried in vacuo. The crudeproduct, (3S,5R)-3,5-diethylpiperidine, 107 (0.066 g, 0.462 mmol, 99.9%yield, R=ethyl) was used in the next step without further purification.

To a stirred solution 107 (0.066 g, 0.462 mmol, R=ethyl) in NMP (2 mL)was added DIPEA (0.13 mL, 0.728 mmol) and 3 (86.3 mg, 0.370 mmol). Thereaction mixture was microwaved at 150° C. for 1 h after which time itwas directly purified over a reverse-phase preparative HPLC column(Water's X-Bridge C18 19×100 mm column; gradient using 0-50%acetonitrile in water containing 0.05% TFA) to provide an analog of 101or ER-886211 (45.2 mg, 0.153 mmol, 41.4% yield, R=ethyl) after combiningthe desired collected fractions, concentration and drying in vacuo.

Other Examples:

ER-885113: To a stirred solution of 2-(di-tert-butylphosphino)biphenyl(20 mg, 0.067 mmol) and tris(dibenzylideneacetone)dipalladium(0) (20 mg,0.022 mmol) in toluene (0.8 mL) under an nitrogen atmosphere was addedcommercially available 5-bromo-8-methoxyquinoline (201 mg, 0.844 mmol),sodium t-butoxide (122 mg, 1.27 mmol) and cis-2,6-dimethylmorpholine(125 mg, 1.085 mmol) at rt followed by toluene (0.8 mL). The reactionmixture was warmed to reflux and stirred for 3 h, after which time thecompleted reaction was cooled to rt followed by addition of water (5mL). The resultant mixture was extracted two times with EtOAc(5 mL each)and the combined organic layers were washed with brine (2 mL), driedover Na₂SO₄, filtered and concentrated to dryness. The crude product waspurified over silica gel twice (Biotage SP4, 25+S eluting with 12-100%EtOAc in heptane) to provide ER-885113 (49 mg, 0.180 mmol, 21.3% yield)after collection of the desired fractions, concentration and drying invacuo.

ER-887960 (13.7 mg, 0.049 mmol, 23.5% yield) was prepared in a similarmanner to ER-885113 starting with 5-bromo-8-chloro-1,7-naphthyridine (51mg, 0.210 mmol) and cis-2,6-dimethylmorpholine (31.4 mg, 0.273 mmol)

ER-886133 and ER-886134: A solution of (S)-2-((benzyloxy)methyl)oxirane(65 g, 0.396 mol) and 28% NH₄OH in water was stirred at rt for 14 hafter which time the completed reaction was concentrated and azeotropedtwo times with toluene (150 mL each) to obtained(S)-1-amino-3-(benzyloxy)propan-2-ol (70.6 g, 0.390 mol, 98% yield) as acrude white solid.

To a stirred solution of crude (S)-1-amino-3-(benzyloxy)propan-2-ol(54.4 g, 0.300 mol) in ethanol (400 mL) was addedmethyl(R)-(+)-2-chloropropionate (40.44 g, 0.330 mol) dropwise over a30-min period. The reaction was heated to 75° C. and stirred for 16 hafter which time the completed reaction was concentrated to dryness. Thecrude mixture was diluted with EtOAc (200 mL), washed with aq. 1 N HCl(100 mL), brine (100 mL), dried over Na₂SO₄, filtered and concentratedto dry. The crude product was purified over silica gel (Biotage, elutingwith a linear gradient of 30-80% EtOAc in heptane) to provide(R)—N—((R)-1-(benzyloxy)propan-2-yl)-2-chloropropanamide (65.7 g, 0.239mol, 79.7% yield) after combining the desired fractions, concentrationand drying in vacuo.

To a cooled stirred solution of(R)—N—((R)-1-(benzyloxy)propan-2-yl)-2-chloropropanamide (8.8 g, 0.032mol) in THF (440 mL) at 0° C. was added portion wise NaH (5.181 g, 0.130mol, as a 60% oil dispersion) over a 10-min period. The reaction mixturewas stirred at 0° C. then allowed to warm slowly to rt and stirred anadditional 6 h. The completed reaction was slowly quenched with IPA (20mL) followed by Dowex 50, H+ resin (30 g) followed by stifling until anacidic pH was registered. The quenched suspension was filtered, washedwith EtOAc (50 mL) and concentrated to dryness. The crude product waspurified over silica gel (200 g, eluting with a 30-50% gradient of EtOAcin heptane) to provide(2S,6S)-6-((benzyloxy)methyl)-2-methylmorpholin-3-one (6.12 g, 0.026mol, 81.3% yield) after combining the desired fractions, concentrationand drying in vacuo.

To a stirred solution of(2S,6S)-6-((benzyloxy)methyl)-2-methylmorpholin-3-one (6.12 g, 0.026mol) in THF (20 mL) under a nitrogen atmosphere at rt was added 1 Mtetrahydroaluminate in THF (30 mL, 0.030 mol) dropwise over a 15-minperiod. The reaction mixture was stirred for 2.5 h after which time itwas cooled to 0° C. followed by the slow addition of water (13 mL) andthen 1 N aq. NaOH (0.9 mL). The quenched reaction was stirred until theprecipitate became granular after which time Celite 545 (10 g) was addedfollowed by filtering over a Celite pad and rinsing three times with DCM(30 mL) and ethyl ether (30 mL). The combined filtrates wereconcentrated and purified over silica gel (Biotage, eluting with agradient of 0-5% MeOH in DCM) to provide(2S,6S)-2-((benzyloxy)methyl)-6-methylmorpholine (2.7 g, 0.012 mol,46.2% yield) after combining the desired fractions, concentration anddrying in vacuo.

To a stirred solution of(2S,6S)-2-((benzyloxy)methyl)-6-methylmorpholine (2.7 g, 0.012 mol) inDCM (50 mL) was added di-tert-butyldicaarbonate (6.807 g, 0.031 mol)followed by TEA (4.35 mL, 0.031 mol) and DMAP (100 mg, 0.82 mmol). Thereaction was stirred at rt for 3 h after which time the completedreaction was washed with 0.1 N HCl (50 mL) and brine (50 mL). Theorganic phase was concentrated followed by purification over silica gel(Biotage, eluting with a 10-20% gradient of EtOAc in heptane) to provideto provide (2S,6S)-tert-butyl2-((benzyloxy)methyl)-6-methylmorpholine-4-carboxylate (3.68 g, 11.4mmol, 95.4% yield) after combining the desired fractions, concentrationand drying in vacuo.

To a stirred solution of (2S,6S)-tert-butyl2-((benzyloxy)methyl)-6-methylmorpholine-4-carboxylate (3.102 g, 9.7mmol) in ethanol (15 mL) was added 5% Pd on carbon (300 mg) followed byevacuation and charging of the reaction vessel three times with hydrogengas. The reaction was heated to 40° C. maintaining under a hydrogenatmosphere (balloon pressure) and stirred overnight, after which timethe reaction was purged with nitrogen gas several times while evacuatingthe system with house vacuum between purges. The completed reaction wasfiltered over Celite 545, the filter pad washed two times with ethanol(10 mL each), followed by concentration of the combined filtrates wereconcentrated and dried in vacuo. The crude product, (2S,6S)-tert-butyl2-(hydroxymethyl)-6-methylmorpholine-4-carboxylate (2.15 g, 9.3 mmol,95.8% yield) was used in the next step without further purification.

To a stirred solution of (2S,6S)-tert-butyl2-(hydroxymethyl)-6-methylmorpholine-4-carboxylate (200 mg, 0.865 mmol)in DCM (5 mL) was added TFA (0.5 mL, 6.7 mmol) at rt. The reactionmixture was stirred for 1 h after which time it was concentrated andazeotroped to dry two times with toluene (5 mL each) and dried in vacuo.The crude deprotected morpholine was dissolved with stirring in DMAC (1mL) followed by DIPEA (0.23 mL, 1.3 mmol) and compound 3 (152.4 mg,0.654 mmol). The reaction mixture was microwaved at 140° C. and stirredfor 3 h after which time the completed reaction was cooled to rt,concentrated and purified over silica gel (Biotage, eluting with 30-80%EtOAc in heptane) to provide5-((2S,6S)-2-(hydroxymethyl)-6-methylmorpholino)quinoline-8-carbonitrileor ER-885477 (165.2 mg, 0.583 mmol, 89.2% yield) after concentration ofthe desired combined fractions and drying under vacuo.

To a cooled, stirred solution of bis(2-methoxyethyl)aminosulfurtrifluoride (Deoxo-Fluor®) (0.044 mL, 0.239 mmol) in DCM (2 mL) under anitrogen atmosphere at −78° C. was added dropwise ER-885477 (50.4 mg,0.178 mmol) in DCM (2 mL) over a 3-min period. The reaction mixture waswarmed to −50° C. and stirred for 30 min after which time it was warmedto 0° C. and stirred for 1.5 h. The completed reaction was slowlyquenched with a dropwise addition of saturated NaHCO₃ until a basic pHwas observed (˜5 mL). The mixture was diluted with DCM (10 mL), thelayers separated after which time the organic layer was washed two timeswith water (5 mL each), dried over MgSO₄, filtered and concentrated. Thecrude product was purified over a reverse phase HPLC column (X-BridgeC18 19×100 mm column; eluting with a linear gradient of 10%-90%acetonitrile in water with 0.1% formic acid) and concentrating thedesired peak followed by high vacuum to dryness to provide ER-886133(35.2 mg 0.123 mmol, 69.3% yield).

To ER-885477 (25.2 mg, 0.089 mmol) was added thionyl chloride (2 mL)followed by warming to 85° C. and stifling for 24 h. The completedreaction was concentrated to dry with azeotroping two times with toluene(5 mL each). The crude product was purified over a reverse phase HPLCcolumn (X-Bridge C18 19×100 mm column; eluting with a linear gradient of10%-90% acetonitrile in water with 0.1% formic acid) and concentratingthe desired peak followed by high vacuum to dryness to provide ER-886134(2.1 mg 0.007 mmol, 7.8% yield).

Preparation of ER-889363 using Scheme 14 : To a stirred suspension of3-butenylamine hydrochloride, 62 (5.45 g, 50.6 mmol) was in DCM (33 mL)was added NaHCO₃ (110 g) followed by o-nitrobenzenesulfonyl chloride(13.5 g, 60.8 mmol). Resultant mixture was vigorously stirred at rt for2 h after which time phenylhydrazine hydrochloride (2.9 g, 20 mmol) wasadded and stifling was continued for additional 1 h. The completedreaction mixture was extracted with MTBE (70 mL) and then sequentiallywashed with 20% aq. citric acid (35 mL), water (35 mL) and concentrated.Resultant purple solid (13.32 g) was dissolved in NMP (70 mL) andpotassium carbonate (21 g, 0.15 mol) was added followed by(R)-glycidol-benzyl ether, 6 (9.98 g, 60.8 mmol). The mixture was heatedto 50° C. and stirred for 22 h after which time it was diluted withwater (300 mL) and extracted two times with MTBE (200 mL each). Allorganic layers were combined and concentrated to give orange-coloredoil, which was subjected to silica gel column chromatography(n-heptane/MTBE 1:1) to give 64, (7.90 g, 18.8 mmol, 37% yield in 2steps) as orange colored oil.

To a stirred solution of 64 (7.90 g, 18.8 mmol) in DMAC (94.8 mL) wasadded copper (II) acetate (0.853 g, 4.70 mmol) followed by PdCl₂ (0.416g, 2.35 mmol) at rt. Resultant mixture was stirred under O₂ (balloon) atrt for 16 h after which time additional PdCl₂ (0.200 g, 1.13 mmol) wasadded and the mixture was heated to 40° C. and stirred for 6 h. Thecompleted reaction was quenched with pyridine (4.5 mL, 56 mmol), stirredfor 5 min followed by diluting with MTBE (400 mL). The mixture waswashed with water (250 mL) and the organic layer was separated,concentrated. The crude yellow oil was purified by silica gel columnchromatography (n-heptane/MTBE 1:1) to give 65 (0.740 g, 1.77 mmol, 9.4%yield, 31% yield based on recovered substrate).

To a cooled, stirred solution of 65 (1.480 g, 3.54 mmol) in DCM (14.8mL) at to 0° C. was added triethylsilane (2.96 mL, 18.6 mmol) followedby TFA (4.44 mL, 57.6 mmol). The reaction mixture was stirred at 0° C.for 1 h after which time the mixture was warmed to rt and stirred for anadditional 1 h. The completed reaction mixture was azeotroped two timeswith toluene (60 mL each) and then purified by silica gel columnchromatography (n-heptane/MTBE 1:1) to give 66 (1.382 g, 3.29 mmol, 92%yield) as yellow oil.

To a stirred solution of 66 (1.382 g, 3.29 mmol) in DMF (8.3 mL, 0.11mol) was added potassium carbonate (1.45 g, 10.5 mmol) followed bybenzenethiol (0.360 mL, 3.50 mmol). The resultant mixture was heated at40° C. for 2 h after which time the completed reaction was diluted withwater (12 mL). Di-tert-butyl dicarbonate (0.897 g, 4.11 mmol) was addedfollowed by stirring at rt for 1 h. The completed reaction was dilutedwith water (29 mL) and extracted two times with MTBE (40 mL each) andthe combined organic layers were concentrated to give yellow oil. Crudeproduct was purified by silica gel column chromatography (n-heptane/MTBE4:1) to provide 67 (847 mg, 2.52 mmol, 77% yield) as a colorless oil andits stereoisomer (8.3 mg, 0.25 mmol, 7.5% yield) as a colorless oil.

To a stirred solution of 67 (0.847 g, 2.52 mmol) in DCM (4.2 mL) wasadded TFA (4.2 mL, 0.055 mol) at rt and stirred for 30 min. Thecompleted reaction mixture was concentrated, azeotroped with toluene (20mL) and partitioned between saturated NaHCO₃ (8.5 mL) and DCM (20 mL).Organic layer was separated, dried over MgSO₄ (2.0 g), filtered, andconcentrated to dry. The crude intermediate was dissolved in NMP (2.12mL) followed by DIPEA (0.66 mL, 3.8 mmol) and then 3 (0.706 g, 3.03mmol). The resultant mixture was heated to 140° C. and stirred for 2 hafter which time the completed reaction was cooled to rt and partitionedbetween EtOAc(40 mL) and water (20 mL). Aqueous layer was extracted withEtOAc (20 mL) and the combined organic layers were washed with water (10ml) and concentrated to give crude product as brownish solid/oil. Thecrude product was purified over silica gel (eluting withn-heptane/EtOAc1:1) to give a 4:1 mixture of the desired intermediate:3(0.684 mg).

The crude intermediate mixture (0.684 mg) was suspended in acetonitrile(6.0 ml) followed by iodotrimethylsilane (0.377 mL, 2.65 mmol) followedby heating to 60° C. and stirring for 2 h. The completed reaction wascooled to 40° C. followed by the addition of water (3.0 ml) and thereaction was cooled to rt with stifling for an additional 1 h. 28% aq.ammonium hydroxide (1.0 mL) was added and the resultant mixture wasextracted two times with EtOAc(20 mL each) after which time the combinedorganic layers were concentrated followed by purification over silicagel (eluting with EtOAc100%) to give 68 or ER-889363 (404 mg, 1.36 mmol,53% yield) as yellow solid.

To a stirred solution of ER-889363 (355 mg, 1.194 mmol) in DCM (4 mL)was added p-toluenesulfonyl chloride (350 mg, 1.836 mmol) followed byDIPEA (0.32 mL, 1.837 mmol) and DMAP (10 mg, 0.082 mmol). The reactionmixture was stirred at rt for 16 h after which time the completedreaction was washed with water (2 mL) and brine (2 mL) followed bydrying over Na₂SO₄, filtering and concentrating to dryness. The crudeproduct was purified over silica gel (Biotage, SP4, 25+M eluting with10-60% EtOAc in heptane over 20 column volumes. The desired fractionswere combined, concentrated and dried in vacuo to provide((2R,7R)-4-(8-cyanoquinolin-5-yl)-7-methyl-1,4-oxazepan-2-yl)methyl4-methylbenzenesulfonate (476.6 mg, 1.056 mmol, 88.4% yield)

((2R,7R)-4-(8-cyanoquinolin-5-yl)-7-methyl-1,4-oxazepan-2-yl)methyl-4-methyl-benzenesulfonate(19.4 mg, 0.043 mmol) and 1,4′-bipiperidine (30 mg, 0.178 mmol) weredissolved in DMAC (0.5 mL) and then microwaved at 150° C. for 10 min.The cooled reaction was diluted with acetonitrile (0.5 mL), filtered andpurified by reverse-phase HPLC (Xbridge C18 column, eluting with agradient of 10-40% acetonitrile in water containing 0.1% formic acid).The combined desired fractions were concentrated, diluted with MeOH (1mL) and passed over a basic SiCO₃ column eluting with MeOH (2 mL)followed by concentrations and drying in vacuo to provide ER-889822 (11mg, 0.025 mmol, 57.2% yield).

Other Examples:

ER-890094: A solution of (3-(bromomethyl)phenyl)boronic acid (129.5 mg,0.603 mmol) and 1,4′-bipiperidine (190 mg, 1.129 mmol) in DMAC (1 mL)was microwaved at 150° C. for 10 min after which time the reaction wascooled and concentrated to dryness to be used in the next step as crude(3-([1,4′-bipiperidin]-1′-ylmethyl)phenyl)boronic acid.

A stirred solution containing 3 (44.5 mg, 0.191 mmol), crude(3-([1,4′-bipiperidin]-1′-ylmethyl)phenyl)boronic acid (86.5 mg, 0.286mmol), palladium(II) acetate (6 mg, 0.027 mmol),2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (12 mg, 0.029 mmol) and1 M sodium carbonate in water (0.029 ml, 0.029 mmol) in EtOH (0.6 mL)and toluene (0.6 mL) was heated to 70° C. for 16 h. The completedreaction was cooled, diluted with DCM (10 mL), washed with water (3 mL),dried over Na₂SO₄, filtered and concentrated to dryness. The crudeproduct was diluted with 1:1 DMSO: acetonitrile (2 mL) and directlypurified by HPLC (Xbridge C18, eluting with a 10-40% acetonitrile inwater containing 0.1% formic acid). The desired product was collectedand concentrated to dry. The resulting product was dissolved in MeOH (2mL) and passed over a basic silica plug (Biotage, 1 g, SiCO₃) elutingwith MeOH (5 mL) to provide after concentration and drying in vacuoER-890094 (5 mg, 0.012 mmol, 6.3% yield).

ER-890244 (63.2 mg, 0.153 mmol, 27.3% overall yield) was prepared in asimilar manner to ER-890094 starting with (4-(bromomethyl)phenyl)boronicacid (134.2 mg, 0.625 mmol) and 1,4′-bipiperidine (125 mg, 0.564 mmol).

ER-888200: A stirred solution containing 3 (251 mg, 1.077 mmol),(3-formyl-5-methylphenyl)boronic acid (350 mg, 2.135 mmol),bis(triphenylphosphine)palladium(II) chloride (150 mg, 0.214 mmol),lithium chloride (91 mg, 2.147 mmol), sodium carbonate (230 mg, 2.17mmol) and 10% sodium carbonate in water (2.3 ml) in DMF (11 mL) washeated to 90° C. for 3 h. The cooled reaction was diluted with EtOAc (48mL) and water (12 mL) with stifling followed by filtering through Celite545 (1.2 g) eluting with EtOAc (10 ml). The separated aqueous layer wasextracted two times with EtOAc (12 mL each) and the combined organiclayers was washed with water (24 mL) and brine (24 mL) followed bydrying over Na₂SO₄, filtering and concentrating to dry. The crudeproduct was purified over silica gel (Biotage SP4, Interchim 25 g,eluting with 20-100% EtOAc in heptane) after which time the desiredproduct fractions were combined, concentrated and dried in vacuo toprovide ER-888200 (163 mg, 0.599 mmol, 55.6% yield).

ER-888201: To a stirred solution of ER-888200 (21 mg, 0.077 mmol) inMeOH (2.1 mL) cooled to 0° C. was added sodium tetrahydroborate (3.2 mg,0.085 mmol). The reaction mixture was stirred for 1 h after which timewater (2.1 mL) was added, the mixture concentrated to half volume,followed by extraction with EtOAc (19 mL). The organic layer was washedwith brine (3.9 ml), dried over Na₂SO₄, filtered and concentrated to dryto provide ER-888201 (17.4 mg, 0.63 mmol, 82.4% yield).

ER-888644: To a stirred solution of ER-888201 (91 mg, 0.332 mmol) in DCM(1.8 mL) was added p-toluenesulfonyl chloride (101 mg, 0.530 mmol)followed by DMAP (2 mg, 0.016 mmol) and DIPEA (1.8 mL, 1.03 mmol). Thereaction mixture was stirred at rt for 3 h after which time additionalp-toluenesulfonyl chloride (101 mg, 0.530 mmol) was added followed bystifling for 2 h. The completed reaction was diluted with stirring withwater (1 mL) and DCM (5.2 mL). The layers were separated and the organiclayer was washed with brine (1 mL), dried over Na₂SO₄, filtered andconcentrated to dry. The crude product was purified over silica gel(Biotage SP4, Interchim 25 g, eluting with 20-100% EtOAc in heptane)after which time the desired product fractions were combined,concentrated and dried in vacuo to provide ER-888644 (63 mg, 0.212 mmol,65% yield).

ER-888645: A solution of ER-888644 (20 mg, 0.068 mmol) and4-hydroxypiperidine (70 mg, 0.692 mmol) in N-methylpyrrolidone (2 mL)was microwaved at 150° C. for 15 min. The cooled reaction was dilutedwith NMP (4 mL) and directly purified by HPLC using a C-18 column(Xbridge C18, eluting with a 10-40% acetonitrile in water containing0.1% TFA). The desired product was collected and concentrated to dry.The resulting product was dissolved in MeOH (2 mL) and passed over abasic silica plug (Biotage, 1 g, SiCO₃) eluting with MeOH (5 mL) toprovide after concentration and drying in vacuo ER-888645 (19.9 mg,0.056 mmol, 81.5% yield).

ER-888646 (17.9 mg, 0.047 mmol, 68.1% yield) was prepared in a similarmanner to ER-888645 starting with ER-888644 (20 mg, 0.068 mmol) and4-dimethylaminopiperidine (87.6 mg, 0.683 mmol).

ER-888647 (15.3 mg, 0.043 mmol, 62.8% yield) was prepared in a similarmanner to ER-888645 starting with ER-888644 (20 mg, 0.068 mmol) and1-methylpiperazine (68.4 mg, 0.683 mmol).

ER-889504 (46 mg, 0.108 mmol, 62% yield) was prepared in a similarmanner to ER-888645 starting with ER-888644 (51 mg, 0.174 mmol) and1,4′-bipiperidine (102 mg, 0.606 mmol).

General Screening Assay and Pharmacology Strategy.

To identify potent and selective TLR7/8 compounds, analogs wereinitially screened across a cell-based panel of human TLR4, TLR7, andTLR9 reporter lines (see Pharmacology Materials and Methods for moredetails). A subset of compounds that were potent and selective for TLR7were also tested for TLR8 activity (see Table 3 below) and for TLR7/8potency in the primary human PBMC assay (see Pharmacology Materials andMethods for more details). Certain compounds were advanced into theshort-term in vivo (STIV) assay to determine dose-dependent activity andduration-of-action against mouse TLR7 (see Pharmacology Materials andMethods for more details). Select compounds were then evaluated forimpact in one or more of the following mouse lupus disease models:BXSB-Yaa, NZBxNZW, and Pristane DBA/1.

Many compounds reported as embodiments herein demonstrate nanomolarpotency against both human and mouse TLR7 and human TLR8 when thesereceptors, expressed on either cell lines or primary cells, arestimulated by synthetic, small molecule (CL097, R848) or nucleic-acid(RNA) ligands. Conversely, most compounds reported as embodiments hereinare inactive against the TLR9 pathway.

Current lupus SOC drugs include anti-malarials such as chloroquine andhydroxychloroquine (HCQ) which have been shown to inhibit TLR7/9activation in vitro. This may at least partially explain theireffectiveness in controlling lupus flare. Embodiments of the disclosure,however, have been shown to offer significantly more potent inhibition.For example, compound ER-899742 (shown and discussed above) was found tobe approximately 1000-fold more potent against the RNA-Ig TLR7/8stimulus versus HCQ (IC₅₀=0.0009 uM, HCQ IC₅₀˜1.5 uM). This suggeststhat ER-899742 would offer much more effective TLR7/8 pathway inhibitionversus current lupus treatments. This is demonstrated by results shownin Table 1 below.

TABLE 1 Potency and selectivity of compound ER-899742 as compared tohydroxychloroquine (Plaquenil). Cell Recep- ER-899742 HCQ² Format:Ligand: tor(s): Analyte: IC50 (uM) IC50 (uM) HEK-293 LPS Human NFkB- >10N.D. TLR4 luciferase HEK-293 CL097 Human NFkB- 0.006 N.D. TLR7luciferase HEK-293 CpG-ODN Human NFkB- >10 N.D. TLR9 luciferase Hu PBMC¹RNA-Ig Human IL-6 0.0009 1-2 TLR7/8 Hu PBMC LPS Human IL-6 >10 TLR4 HuPBMC CpG-ODN Human IL-6 0.15-0.30 TLR9 TABLE KEY: ¹RNA-Ig = ssRNAderived from U1snRNA stem loop IV sequence in complex with antibody (seeMaterials and Methods for more details) ²HCQ = Hydroxychloroquine

The comparative potency of ER-899742 versus hydroxychloroquine wasfurther explored using cloned TLR7 and 8 in the HEK 293 cell line asdescribed below in In Vitro Pharmacology. Effects on mouse TLR7 werealso compared. Cells were stimulated overnight with TLR7/8 agonist CL097at pre-determined ED₇₀₋₈₀: 3 ug/ml for HEK-hTLR7, 1.5 ug/ml forHEK-mTLR7 and 12 ug/ml for HEK-hTLR8, before reading luminescenceintensity. Three tests were performed and IC50 value was determinedusing Graphpad Prism 6 nonlinear regression curve fit. Individual testresults and their average are shown in Table 2. The data show that inthis assay, ER-899742 had an average IC50 of 0.024 uM in the HEK/TLR7cell line, and an average IC50 of 0.0024 uM in the HEK/TLR8 cell line.

TABLE 2 ER-899742 effects on TLR7 and TLR8 response compared tohydroxychloroquine. IC50 (uM) Cell Format: Test ER-899742 HCQ HEK-mTLR7¹1 0.066 13.85 2 0.071 13.53 3 0.076 15 average 0.071 14.13 HEK-hTLR7 10.024 6.8 2 0.023 14.55 3 0.026 5.95 average 0.024 9.10 HEK-hTLR8 10.002 >>10 2 0.0025 >>10 3 0.0026 >>10 average 0.0024 >>10 ¹mTLRV, mouseTLR7; hTLRV, human TLR7; hTLR8, human TLR8

TABLE 3 Potency of select compounds against human TLR8 in the HEK-293assay format (see Materials and Methods for more details). CompoundHEK/hTLR8 Number IC50 (μM) ER-878952 0.0060 ER-878952 0.0195 ER-8794840.0180 ER-879713 0.0800 ER-880191 0.0100 ER-880639 0.0500 ER-8850470.0940 ER-885113 0.0110 ER-885493 0.1007 ER-885612 0.0550 ER-8856180.0050 ER-885621 0.0250 ER-885892 0.0370 ER-885906 0.0200 ER-8859300.1470 ER-886355 0.0660 ER-886431 0.0310 ER-886507 0.1820 ER-8865080.1860 ER-886509 0.1190 ER-886514 0.0050 ER-886530 0.0050 ER-8865320.0300 ER-886533 0.0140 ER-886565 0.0290 ER-886567 0.0050 ER-8865680.0050 ER-886624 0.0860 ER-886625 0.0100 ER-886626 0.0050 ER-8866290.0050 ER-886814 0.0600 ER-886816 0.1070 ER-886818 0.0810 ER-8868200.0780 ER-886854 0.0460 ER-886857 0.0720 ER-886858 0.0020 ER-8868690.1610 ER-886949 0.0780 ER-886953 0.0660 ER-886955 0.0830 ER-8871380.0130 ER-887139 0.0080 ER-887142 0.1150 ER-887143 0.1480 ER-8871440.0480 ER-887145 0.1050 ER-887199 0.0770 ER-887253 0.0020 ER-8872580.1750 ER-887259 0.0005 ER-887261 0.0770 ER-887269 0.0032 ER-8872710.0016 ER-887272 0.0029 ER-887443 0.1380 ER-887444 0.1930 ER-8875260.1220 ER-887528 0.1350 ER-887538 0.0850 ER-887539 0.0005 ER-8875400.0030 ER-887586 0.1265 ER-887587 0.0018 ER-887588 0.0005 ER-8877220.0210 ER-887723 0.0090 ER-887724 0.0060 ER-887725 0.0010 ER-8879270.0005 ER-887928 0.0110 ER-890963 0.0028 ER-894594 0.1160

Short-term in vivo (STIV) assay: To assess compound potency in vivoagainst mouse TLR7, a short-term in vivo (STIV) assay was utilized.Briefly, mice were orally dosed with compounds and at various timepoints afterwards were injected subcutaneously with agonist R848 tostimulate TLR7. The plasma IL-6 level following R848 stimulation wasthen measured by ELISA to assess compound potency andduration-of-action. Importantly, cytokine production following in vitroor in vivo stimulation with R848 was shown to be completelyTLR7-dependent utilizing TLR7-deficient mice. Therefore, the activity ofcompounds in the STIV assay can be confidently attributed to theirmodulation of the TLR7 pathway. A single oral dose of ER-899742 at 300mg/kg fully suppresses the R848/TLR7/IL-6 pathway in vivo for at least24 hours (see FIG. 1A and FIG. 1B). A summary of STIV assay potency fora panel of compounds appears in Table 4 below.

TABLE 4 Short-term in vivo (STIV) assay data summary for selectcompounds. Dose % Suppression vs. Vehicle Time (mg/kg) ER-878419ER-878629 ER-878952 ER-885493 ER-886611 ER-886788 ER-886814 ER-886820  3h 11 53 22 3 33 90 0 93 93 67 8 100 10 0 10 10 200 8 300 9 6 X 2 10 10 5 h 22 2 67 9 200 9  6 h 11  0 33 90 0 57 68 100 10 2 10 96 300 6 5 X 210 10 12 h 200 9 400 7 600 9 13 h 33 100 300 18 h 22 0 67 5 200 9 2 6009 19 h 11 19 33  0 0 14 43 100 10 1 19 35 300 3 1 X 2 10 39 24 h 33 100300 Dose % Suppression vs. Vehicle Time (mg/kg) ER-886948 ER-886953ER-887137 ER-887145 ER-887259 ER-887268 ER-887269 ER-887270  3 h 11 6 2233 46 9 10 9 67 100 89 9 10 9 200 300 10 9 10 X  5 h 22 67 200  6 h 11 38 33 35 9 99 9 84 9 95 98 100 44 9 10 9 99 9 10 300 81 9 10 X 99 98 12 h200 400 600 13 h 33 37 100 81 300 99 18 h 22 67 200 600 19 h 11 0 2 33 02 38 0 15 6 9 100 5 4 63 9 62 9 58 300 49 9 10 X 99 95 24 h 33 25 100 26300 10 X = Mice did not tolerate this dose. Dose Time (mg/kg) ER-887586ER-887723 ER-887724 ER-887725 ER-887927 ER-888070 ER-888201 ER-888281  3h 33 99 9 7 100 99 9 9 200 300 99 9  6 h 11 33 62 10 99 9 100 88 3 4 10099 10 99 9 100 10 5 7 300 10 10 99 9 100 10 4 13 hr 11 33 100 300 19 hr1.22 56 3.67 70 11 94 33 15 77 83 9 98 70 4 0 100 45 97 91 9 100 90 7 6300 95 10 99 9 100 99 7 24 hr 11 33 100 300 Dose Time (mg/kg) ER-888288ER-888320 ER-888321 ER-888322 ER-888480 ER-889469 3 h 33 10 98 100 10098 10 10 100 200 300  6 h 11 85 33 78 78 86 99 10 100 100 99 94 10 10 10100 300 97 10 13 hr 11 33 9 87 100 31 10 300 19 hr 1.22 3.67 11 63 33 5059 24 89 100 53 59 82 98 73 300 10 24 hr 11 33 14 100 0 300 55 *4/12mice found the compound incompatible Dose Time (mg/kg) ER-889470ER-889556 ER-889601 ER-889745 ER-890093 ER-890223 ER-890311 ER-890345  3h 33 10 10 93 8 10 67 100 98 10 96 93 92 99  6 h 11 33 96 10 95 94 92 82100 10 10 90 84 95 99 300 13 hr 33 0 98 100 99 10 300 95 19 hr 1.22 443.67 89 0 11 29 0 48 33 47 0 0 52 100 78 98 96 52 88 24 hr 33 0 100 64300 10 Dose Time (mg/kg) ER-890346 ER-890931 ER-890963 ER-890964ER-893881 ER-894206 ER-894550  3 h 33 9 10 90 96 95 9 67 100  6 h 11 3398 82 8 98 100 99 99 9 300 10 13 hr 33 31 0 4 72 100 80 19 7 97 300 1099 19 hr 1.22 3.67 11 0 0 33 2 53 45 0 100 24 hr 33 48 100 50 71 300 1099 ER- ER- ER- ER- ER- ER- ER- ER- ER- ER- ER- Time (mg/kg) 894551895204 ER897968 897969 898566 898694 898946 899017 899018 899122 899193899285  6 h 11 98 98 33 98 81 0 10 9 61 3 100 99 73 4 75 300 13 h 11 5237 33 56 22 3 29 73 2 2 0 90 100 98 43 35 54 86 3 16 0 12 10 5 0 300 X99 85 71 98 5 55 1 X 24 h 11 0 33 53 39 0 0 0 0 28 15 100 91 39 8 4 30 00  0 89 300 X 78 80 29 10 3 34 0 X X = Mice did not tolerate this doseDose ER- ER- ER- ER- ER- ER- ER- ER- ER- Time (mg/kg) 899322 ER-899337899369 899417 ER-899418 899457 899464 899476 899477 899481 899616  6 h100 95 99 98 71 19 10 9 99 96 5 79 13 h 100 70 30 62 0 10 74 9 65 68 527 Dose ER- ER- ER- Time (mg/kg) 899619 899688 899718 ER-899722ER-899742 ER-899745 ER-899820 ER-899835 ER-899836  6 h 100 79 10 74 8910 10 9 99 9 13 h 100 35 96 51 33 61 5 2 79 8

Mouse Lupus Disease Models. Two distinct lupus disease models (NZB/W andPristane) were chosen for compound POC evaluation because (1) the NZB/Wstrain develops spontaneous disease with polygenic etiology,demonstrating many hallmarks of human lupus such as DNA-associatedautoreactivity, proteinuria, and immune-complex mediated nephritis, and(2) positive TLR7 and/or TLR9 target validation results have beenreported for both disease models.

Key findings for ER-899742 in the SLE disease models are as follows (seeFIG. 2A-FIG. 2C, FIGS. 3A-3E, and FIGS. 7A-7G, and Table 7):

-   1) ER-899742 at several doses between 33 and 300 mg/kg afforded    pronounced survival benefit in the NZB/W model, corresponding to    significantly reduced proteinuria and histological signs of    glomerulonephritis.-   2) ER-899742 suppressed various auto-antibody specificities in the    Pristane model, with particularly robust impact on RNA-related    reactivity such as anti-RiboP titers. Decreased expression of some    IFN-modulated genes in whole blood resulted from treatment with    ER-899742 in this model. Control of arthritis by ER-899742 in this    model was also observed.

Key findings for ER-899464 in the SLE disease models are as follows (seeFIGS. 4-5):

-   1) ER-899464 at several doses between 33 and 300 mg/kg afforded    significant survival benefit in the NZB/W model, accompanied by    significantly reduced proteinuria.-   2) ER-899464 suppressed various auto-antibody specificities in the    Pristane model, with particularly robust impact on RNA-related    reactivity such as anti-RiboP titers.

PHARMACOLOGY MATERIALS & METHODS:

In vitro pharmacology:

HEK-293 cells (ATCC) were engineered to stably express a NF-kappaBtranscription factor inducible E-selectin (ELAM-1) luciferase reporterderived from the plasmid pGL3 (Promega) containing base pairs −2241 bpto −254 bp from the promoter of the human E-selectin gene (Accession No.NM_000450). These cells were then subsequently engineered to stably andindividually express human TLR4, TLR7 or TLR9 full-length ORF cDNAs.Human TLR4 cDNA (Accession No. NM_138554) was cloned into pcDNA 3.0expression vector (Invitrogen). TLR4 transfected cells were alsoengineered to express human MD-2 co-receptor [MD-2 cDNA (Accession No.NM_015364) was cloned into the pEF-BOS vector] and were supplementedwith 10 nM soluble CD14 (R&D Systems) in the media to optimize LPSresponsiveness. Human TLR9 cDNA (Accession No. NM_017442) was clonedinto the pBluescript II KS vector (Agilent). Human TLR7 cDNA (AccessionNo. NM_016562) was obtained from OriGene. HEK-293 cells stablyexpressing human TLR8 (Accession No. NM_138636) or mouse TLR7 (AccessionNo. NM_133211) were purchased from InvivoGen and were then stablytransfected with pNiFty2(NF-kappaB)-luciferase reporter plasmid(InvivoGen). Each cell type was plated in Dulbecco's modified Eagle'smedium (DMEM) containing 10% fetal bovine serum (FBS) at a density of2.22×10⁵ cells/ml into a 384-well plate and incubated for 2 days at 37°C., 5% CO₂. Varying concentrations of antagonist compounds were thenadded. Cells were then incubated for another 30 minutes before addingthe appropriate TLR agonist as follows (final concentrations indicated):lipopolysaccharide (LPS; Sigma) at 10 ng/ml for TLR4, CL097 (InvivoGen)at 3 ug/ml for human TLR7 and TLR8 and mouse TLR7, and CpG-2006-2A[sequence: TCGTCGTTAAGTCGTTAAGTCGTT (SEQ ID NO: 1) with phosphorothioatebackbone, synthesized by Sigma-Aldrich] at 0.6 uM for TLR9. The cellswere then incubated overnight, and NF-kappaB dependent luciferasereporter activation was quantified by measuring luminescence withSteadyGlo® (Promega) or Steadylite™ (Perkin Elmer) reagent as per themanufacturer's suggested protocol.

Human PBMC Cell-Based Assay. Human peripheral blood mononuclear cells(PBMC) were isolated from freshly-drawn heparinized (10 USP units/ml,Hospira, Lakeforest, Ill.) healthy donor whole blood by density gradient(Histopaque® 1077, Sigma, Inc., St. Louis, Mo.). Briefly, 25 ml bloodwas diluted with 15 ml PBS (without Ca²⁺, Mg²⁺) in a 50 ml conical tube,and 12 ml Histopaque was underlaid using a spinal needle. Tubes werecentrifuged for 45 minutes at 1200 rpm (350×g), and PBMC were collectedfrom the buffy coat. Cells were then washed twice in PBS, and red bloodcells were lysed by suspension in 5 ml ammonium chloride solution (1×Red Blood Cell Lysis Buffer, eBioscience) for 5 minutes at roomtemperature. After a final wash in PBS, PBMC were resuspended at a finalconcentration of 2×10⁶/ml in RPMI-1640 media with L-glutamine(Invitrogen) and supplemented with 25 mM HEPES (Mediatech, Inc, ManassasVa.), 10% fetal bovine serum (HyClone, Logan, Utah), andPenicillin-Streptomycin-Glutamine (Mediatech) and plated at 100 ul/well(2×10⁵ cells/well) in tissue culture treated 96-well plates (Falcon).

Antagonist compounds solubilized and serial diluted in 100% DMSO wereadded in triplicate to cells to yield a final concentration of 0.1% DMSO(v/v). Hydroxychloroquine (Acros Organics) solubilized and serialdiluted in PBS was added in triplicate to cells. PBMC were incubatedwith antagonist compounds or HCQ for 30 minutes at 37° C., 5% CO₂ beforeadding various TLR agonist reagents in 100 ul complete media per well asfollows (final concentrations indicated): R848 (Resiquimod; GLSynthesis,Worcester, Mass.) at 1 uM for TLR7 and TLR8, LPS (Sigma) at 10 ng/ml forTLR4, and CpG-2216 (InvivoGen) at 5 ug/ml for TLR9. To prepare a TLR7/8agonist that mimics RNA-containing auto-antibody immune complexes inlupus patients, a 26-mer RNA with a sequence derived from human U1 snRNAstem loop IV [(sequence: GGGGGACUGCGU-UCGCGCUUUCCC (SEQ ID NO: 2) withphosphorothioate backbone] was synthesized (Dharmacon, Inc., Lafayette,Colo.), which has been shown previously to be a potent TLR7 and TLR8agonist. This RNA molecule was diluted to 2.5 μM in serum-free RPMI, andmouse anti-human single stranded DNA monoclonal antibody (MAB3034,Millipore, Inc., Billerica, Mass.), which also cross-reacts with RNA,was added at a 1:25 dilution or at 1 ug/ml. The resulting “RNA-Ig”stimulus was incubated at room temperature for 15-30 minutes beforeadding to cells. PBMC were incubated with the various TLR agonists for20 hours at 37° C., 5% CO₂. Cell culture supernatants were collected,and levels of various human cytokines were assessed as indicated bystandard ELISA procedure according to the manufacturer's recommendedprotocol (BD Biosciences, Inc., San Diego, Calif.). Results are shown inTable 5. In a subsequent assay (Table 6) the ability of ER-899742 toblock stimulation of normal PBMC by various TLR7/8 ligands, but notDNA-mediated activation of TLR9, was examined. In this assay cells wereplated at 1×10⁵ cells/well in 100 ul in 96-well plates.

TABLE 5 PBMC Assay Data Summary for Selected Compounds Compound HumanPBMCs Number IC₅₀ (μM) ER-878952 0.151 ER-878952 0.151 ER-879570 0.113ER-879689 1.240 ER-880639 0.169 ER-884884 0.204 ER-885493 0.180ER-885612 0.614 ER-885618 0.023 ER-885807 0.331 ER-885906 0.033ER-886131 0.098 ER-886133 0.127 ER-886134 0.277 ER-886211 0.175ER-886355 0.177 ER-886360 0.486 ER-886516 0.056 ER-886564 0.108ER-886565 0.095 ER-886567 0.022 ER-886568 0.079 ER-886605 0.021ER-886606 0.015 ER-886608 0.001 ER-886609 0.004 ER-886624 0.023ER-886625 0.091 ER-886626 0.080 ER-886787 0.076 ER-886820 0.062ER-886853 0.004 ER-886854 0.020 ER-886855 0.034 ER-886856 0.111ER-886857 0.098 ER-887270 0.001 ER-887271 0.002 ER-887272 0.002ER-887442 0.047 ER-887443 0.032 ER-887526 0.050 ER-887528 0.056ER-887538 0.048 ER-887539 0.000 ER-887540 0.001 ER-887586 0.098ER-887587 0.001 ER-887588 0.001 ER-887589 0.036 ER-887612 0.053ER-887722 0.065 ER-887723 0.007 ER-887724 0.006 ER-887725 0.002ER-887927 0.000 ER-887960 0.041 ER-888070 0.003 ER-888200 0.016ER-888201 0.004 ER-888202 0.008 ER-888203 0.105 ER-888204 0.022ER-888205 0.040 ER-888285 0.014 ER-888286 0.223 ER-888288 0.015ER-888288 0.015 ER-888289 0.011 ER-888321 0.022 ER-888322 0.018ER-888330 0.154 ER-888479 0.091 ER-888480 0.001 ER-890345 0.001ER-890346 0.006 ER-890831 0.001 ER-890963 0.002 ER-890964 0.001ER-892253 0.066 ER-893881 0.009 ER-893926 0.008 ER-893948 0.150ER-894149 0.031 ER-894150 0.004 ER-894152 0.175 ER-894154 0.143ER-894155 0.042 ER-894159 0.042 ER-894160 0.011 ER-894483 0.209ER-894484 0.174 ER-894504 0.005 ER-894545 0.005 ER-894546 0.069ER-894547 0.012 ER-894548 0.028 ER-894549 0.014 ER-894550 0.097ER-894551 0.003 ER-894552 0.017 ER-894594 0.087 ER-894655 0.005ER-894656 0.007 ER-895200 0.026 ER-895204 0.023 ER-895310 0.034ER-895324 0.001 ER-895325 0.026 ER-895326 0.002 ER-895327 0.026ER-898563 0.122 ER-898565 0.198 ER-898566 0.011 ER-898694 0.002ER-898707 0.002 ER-898914 0.168 ER-898919 0.055 ER-898921 0.302ER-898922 >1.00 ER-898923 0.631 ER-898946 0.002 ER-899017 0.004ER-899018 0.009 ER-899019 0.014 ER-899020 0.035 ER-899021 0.005ER-899121 0.142 ER-899122 0.080 ER-886858 0.015 ER-886859 0.107ER-886860 0.240 ER-886866 0.050 ER-886867 0.034 ER-886868 0.050ER-886869 0.112 ER-886912 0.383 ER-886913 0.520 ER-886949 0.032ER-886950 0.114 ER-886951 0.079 ER-886953 0.026 ER-886955 0.129ER-886957 0.017 ER-886958 0.034 ER-887137 0.002 ER-887138 0.004ER-887139 0.005 ER-887140 0.110 ER-887141 0.049 ER-887142 0.147ER-887143 0.013 ER-887144 0.063 ER-887145 0.015 ER-887146 0.038ER-887177 0.000 ER-887199 0.117 ER-887252 0.002 ER-887253 0.001ER-887258 0.055 ER-887259 0.001 ER-887260 0.004 ER-887261 0.120ER-887262 0.103 ER-887268 0.005 ER-887269 0.001 ER-888603 0.007ER-888604 0.006 ER-888644 0.019 ER-888645 0.047 ER-888646 0.003ER-888647 0.012 ER-888701 0.018 ER-888896 0.050 ER-888977 0.217ER-889469 0.013 ER-889470 0.012 ER-889504 0.002 ER-889556 0.010ER-889557 0.085 ER-889571 1.000 ER-889728 0.021 ER-889744 0.008ER-889745 0.046 ER-889745 0.046 ER-889746 0.073 ER-889822 0.025ER-890093 0.022 ER-890108 0.009 ER-890113 0.022 ER-890119 0.008ER-890120 0.005 ER-890121 0.011 ER-890186 0.001 ER-890187 0.079ER-890188 0.087 ER-890189 0.114 ER-890250 0.116 ER-890252 0.042ER-890253 0.064 ER-890342 0.121 ER-890344 0.002 ER-895472 0.161ER-895477 0.013 ER-897385 0.142 ER-897445 0.104 ER-897446 0.053ER-897447 0.100 ER-897827 0.039 ER-897828 0.021 ER-897922 0.064ER-897938 0.016 ER-897940 0.021 ER-897945 0.002 ER-897964 0.020ER-897965 0.010 ER-897967 0.013 ER-897968 0.001 ER-897969 0.007 ER-79820.009 ER-899285 0.007 ER-899287 0.120 ER-899293 0.013 ER-899295 0.032ER-899332 0.014 ER-899337 0.002 ER-899366 0.001 ER-899367 0.012ER-899414 0.025 ER-899415 0.013 ER-899416 0.431 ER-899417 0.001ER-899418 0.005 ER-899431 0.347 ER-899457 0.003 ER-899459 0.016ER-899464 0.001 ER-899476 0.003 ER-899477 0.006 ER-899479 0.002ER-899481 0.008 ER-899588 0.007 ER-899688 0.011 ER-899742 0.001ER-899745 0.004 ER-899134 0.010 ER-899140 0.011 ER-899152 0.036ER-899154 0.014 ER-899160 0.252 ER-899161 0.125 ER-899193 0.009ER-899278 0.001 ER-899282 0.034 ER-899616 0.054 ER-899619 0.033ER-899626 0.001

TABLE 6 IL-6 and IFN-α blockade by ER-899742 in human PBMC acrossmultiple ligands compared to hydroxychloroquine IC50 (μM) RNA40-ODN2006- ODN2216- SL4-Ig DOTAP R848 DOTAP Ig Compound Donor # IL-6 IFN-αIL-6 IFN-α IL-6 IFN-α IL-6 IFN-α IL-6 IFN-α ER- 1 0.0077 NA¹ 0.035 0.0170.0034 0.01 >10 >10 NA NA 899742 2 0.0032 NA 0.023 NA 0.0065 NA >10NA >10 NA 3 0.0043 NA 0.054 0.0096 0.007 NA >10 >10 >10 NA 4 0.00430.0022 0.033 0.018 0.0049  0.012 >10 >10 >10 >10 5 0.0025 NA 0.029 NA0.0055 NA >10 NA NA NA 6 0.0033 0.0005 0.014 0.011 0.0081 0.011 >10 >10 >10 >10 Ave. 0.0042 0.0014 0.0313 0.0139 0.0059 0.011 >10 >10 >10 >10 HCQ 1 5.2 NA 10 0.49 >10 1.25 1.2 0.91 NA NA 23.7 NA 10.75 NA >10 NA 1.24 NA 0.6 NA 3 3.2 NA >10 0.41 >10 NA 1.54 4.17.3 NA 4 3.6 0.459  15.5 0.99 >10 2.57 2.4 3.1 1.24 0.28 5 4.3 NA 18NA >10 NA 1.58 NA NA NA 6 4.6 0.324  6.1 0.502 >10 2.03 2.37 3.96 0.380.29 Ave. 4.10 0.3915 12.07 0.598 >10 1.95 1.72 3.02 2.38 0.29 ¹NA, datanot presented because values below detection limit, or replicates showedhigh variability

Mouse Spleen cell-based assay. Spleens were harvested from female BALB/cmice (Jackson Labs, Bar Harbor, Me.) euthanized by CO₂. A single cellsuspension was obtained by passing spleens through a 40 μm nylon cellstrainer. Cells were washed twice with 50 ml PBS (Mediatech, Inc.,Manassas, Va.) and red blood cells were lysed in 5 ml RBC Lysis buffer(eBioscience, Inc., San Diego, Calif.) for 5 minutes at roomtemperature. Cells were washed twice more in PBS and finally resuspendedin supplemented RPMI-1640 at 2.5×10⁶ cells/ml. Cells were plated at 100μl/well (2.5×10⁵ cells/well) in 96-well tissue culture treated plates(Falcon). Serial dilutions of compounds solubilized in 100% DMSO wereadded in triplicate to cells to yield a final concentration of 0.1%DMSO. Cells were incubated with compound for 30 minutes at 37° C., 5%CO₂ before adding 100 μl/well of 740 nM R848 (Resiquimod; GLSynthesis,Worcester, Mass.) in complete media for a final concentration of 370 nMR848. Cells were incubated for 20 hours at 37° C., 5% CO₂. Culturesupernatants were collected, and levels of IL-6 were assessed bystandard ELISA procedure according to the manufacturer's recommendedprotocol (BD Biosciences, Inc., San Diego, Calif.). Data is presentedbelow in Table 7.

TABLE 7 Mouse Splenocyte Results Compound Mouse Splenocytes Number IC₅₀(μM) ER-878952 1.611 ER-885493 0.517 ER-887253 0.049 ER-887268 2.124ER-887722 0.463 ER-887723 0.047 ER-887724 0.070 ER-887927 0.026ER-888070 0.076 ER-888288 0.135 ER-888480 0.087 ER-889469 0.097ER-889470 0.152 ER-889556 0.432 ER-889601 0.179 ER-889745 0.090ER-890093 0.088 ER-890311 0.428 ER-890831 0.170 ER-890963 0.250ER-893881 0.270 ER-893948 0.420 ER-894152 0.660 ER-894655 0.084ER-894656 0.023 ER-895204 0.051 ER-895325 0.120 ER-895326 0.090

In vivo pharmacology:

Short-term in vivo (STIV) assay. Six to eight week old female BALB/cmice (Jackson Labs, Bar Harbor, Me.) were dosed by oral gavage in 200 ulvolume with antagonist compounds formulated in 0.5% aqueousmethyl-cellulose (Sigma, St. Louis, Mo.). At various time pointsafterwards, mice were injected subcutaneously (s.c.) in 100 ul volumewith 15 ug R848 (Resiquimod; GLSynthesis, Worcester, Mass.) to stimulateTLR7. Blood plasma was collected by cardiac puncture, and levels of IL-6at 1.5 hours after TLR7 stimulation were then assessed by standard ELISAprocedure according to the manufacturer's recommended protocol (R&DSystems).

Mouse lupus disease model strains. Female NZBWF1/J mice were purchasedfrom Jackson Labs (Bar Harbor, Me.), both of which manifest withspontaneous lupus disease. Female DBA/1 mice were purchased from HarlanLaboratories (Indianapolis, Ind.) and at the indicated ages given anintraperitoneal injection of 0.5 ml pristane(2,6,10,14-Tetramethylpentadecane; Sigma, St. Louis, Mo.) to chemicallyinduce lupus disease or of 0.5 ml PBS to generate age-matched,non-diseased control mice.

Further testing of an embodiment is shown in FIG. 2A through FIG. 2C,which demonstrates testing of ER-899742 in the NZBxNZW strain(abreviated hereafter as NZBWF1/J or NZB/W) lupus disease model. FemaleNZBWF1/J mice were received at 5 weeks of age, baseline bleeds wereperformed, and mice were monitored for disease progression by followinganti-dsDNA titers. At 27 weeks of age, mice were randomized into groupswith equivalent median anti-dsDNA titers and treated at 29 weeks of agewith Vehicle (Veh; 0.5% methyl-cellulose) alone or 33, 100, or 300 mg/kgonce-a-day orally (QD PO). At 46 weeks of age after 17 weeks oftreatment, mice were bled and tested for anti-dsDNA titers. All micewere sacrificed at 50 weeks of age (21 weeks of compound treatment).FIG. 2(A) shows that just prior to termination at 50 weeks of age(following 21 weeks of treatment), urine was collected from individualmice, and the Urinary Albumin Creatinine Ratio (UACR, proteinuria) wasdetermined for each animal as an indirect measure of kidney function.FIG. 2(B) shows a timecourse of mortality observed in this study for thehighest and lowest dose groups. No mortality was seen with compoundtreatment. Further, no mortality was observed in the middle dose group(not shown). FIG. 2(C) shows impact of treatment on anti-dsDNA titersafter 17 weeks of dosing, at 46 weeks of age. No statisticallysignificant effect was observed.

At the end of the experiment kidneys were collected from the animalstested in FIG. 2A through 2C, fixed in 10% formalin for 24 hours,embedded in paraffin, and H&E stained sections were generated forhistopathology assessment in a blinded fashion (Grade 0/1+: WNL tominimal; Grade 2: Mild; Grade 3: Moderate to Marked; Grade 4: Severe).Results are shown in Table 8.

TABLE 8 ER- ER- ER- 899742, 899742, 899742, Vehicle 33 mpk 100 mpk 300mpk Total # Mice Examined 19 18 17 18 GN Score 0 0 11 15 9 2+ 1 5 1 7 3+4 1 1 0 4+ 14 1 0 2 % combined incidence of 74% 11% 6% 11% Grade 3 and 4

Assessment of auto-antibody titers by ELISA. Anti-dsDNA, -Sm/nRNP,-RiboP, and -Histone titers were evaluated by standard ELISA approach.Briefly, 96-well EIA/RIA ELISA plates (Corning) were coated with 100 ulof diluted antigen in PBS for 90 minutes at room temperature as follows(final concentrations indicated): 10 U/ml Sm/nRNP complex(Immunovision), 10 ug/ml calf thymus dsDNA (Sigma), 5 U/ml RiboP(Immunovision), and 5 ug/ml Histone (Immunovision). Plates were washedwith PBS/0.05% Tween20 (washing buffer) and blocked overnight withPBS/1% BSA (blocking buffer) at 4° C. Plates were washed, mouse plasmasamples diluted in blocking buffer (ranging from 1:25-1:10,000 dependingon the model and the antigen) were added to wells in 100 ul volume perwell, and plates were incubated for 90 minutes at room temperature.Plates were then washed, 100 ul anti-mouse-IgG-HRPO (Southern Biotech)diluted 1:50,000 in PBS/1% BSA/0.05% Tween was added to each well, andplates were incubated for 90 minutes at room temperature. Plates werewashed, and 100 ul of a 1:1 mix of substrate components from the OptEIATMB substrate kit (BD Biosciences) was added to the wells. Plates wereincubated at room temperature, and after sufficient color developmentthe reaction was stopped by adding 100 ul of 0.18M sulfuric acidsolution. Plates were read by spectrophotometry at 450 nm.

Assessment of proteinuria. Urine was collected manually from individualmice or by housing 1-2 mice per metabolic cage for 18 hours, and theUrinary Albumin Creatinine Ratio (UACR) was determined for each animalas an indirect measure of kidney function (UACR calculated as the ratioof mg of albumin/g of creatinine per dL of urine). Albumin levels in theurine samples were determined using a custom sandwich ELISA protocolusing an anti-mouse albumin antibody set (Bethyl Labs), which included acoating antibody and a secondary antibody tagged with an HRP conjugatefor detection. Creatinine levels were determined using a commercialcreatinine assay kit (Cayman).

Histological assessment of nephritis. Kidneys were collected fromindividual mice, fixed in 10% formalin for 24 hours, embedded inparaffin, and H&E stained sections were generated for histopathologyassessment in a blinded fashion. Features of Nephritis Disease Scoresare as follows: Grade 0—normal limits; Grade 1—ribbon-like capillarywall thickening; Grade 2—hypercellularity, segmentation, crescentformation; Grade 3—see Grade 2, increased severity and extent (%glomeruli affected) of glomerular lesions; Grade 4—sclerosis; severeglomerular disease (non-functional organ).

Assessment of interferon gene expression in whole blood. The expressionof IFN-regulated genes in whole blood was measured by qPCR. Briefly,mice were euthanized, blood was collected via the vena cava, and 100 ulwas preserved in tubes containing RNAlater (Ambion, Austin Tex.). TotalRNA was isolated using the Mouse RiboPure Blood RNA Isolation Kit(Ambion). RNA concentrations were determined using a NanoDrop ND-1000spectrophotometer (Thermo Scientific, Waltham Mass.). First strand cDNAwas synthesized from 100 ng total RNA using SuperScript® VILO™ MasterMix (Life Technologies, Grand Island, N.Y.). After reversetranscription, cDNA was diluted with nuclease-free water and mixed withTaqMan® Fast Advanced Master Mix (Applied Biosystems). The mixture wasthen applied to a custom TaqMan® Low Density Array (TLDA) manufacturedby Applied Biosystems, and qPCR was performed on the ABI 7900HT FastReal-time PCR System (Applied Biosystems). Raw data was collected usingRQ Manager 1.2.1 (Applied Biosystems) and analyzed using GeneDataAnalyst 2.2 software (GeneData).

The TLDA panel contained as many as 45 target genes chosen from Table 9below, and 3 housekeeping genes for normalization. The housekeeping geneHprt1 was chosen for normalization based on coefficient-of-variation.Relative quantities were determined for the target genes and used tocalculate a fold change for each diseased mouse relative to thenon-diseased control group receiving intraperitoneal PBS injection only.A standard Student's t-test was performed to determine which targetgenes were significantly increased between the non-diseased group (PBStreated) and the vehicle-treated diseased group (pristane treated),thereby representing the disease-regulated gene set. For FIG. 7G a falsediscovery rate (FDR) correction was done using the p.adjust command inpackage “base” with default option. Holm, S. A simple sequentiallyrejective multiple test procedure. Scandinavian Journal of Statistics,1979. 6(2): p. 65-70. An “IFN score” was subsequently calculated foreach mouse as the median fold change of all disease-regulated genesidentified in the t-test.

TABLE 9 Gene symbol Taqman ID Gene name 18S Hs99999901_s1 Eukaryotic 18SrRNA Bst2 Mm01609165_g1 bone marrow stromal cell antigen 2 C1qaMm00432142_m1 complement component 1, q subcomponent, alpha polypeptideC3 Mm00437858_m1 complement component 3 C3ar1 Mm02620006_s1 complementcomponent 3a receptor 1 Ccl2 Mm00441243_g1 chemokine (C-C motif) ligand2 Ccl5 Mm01302427_m1 chemokine (C-C motif) ligand 5 Ccr2 Mm00438270_m1chemokine (C-C motif) receptor 2 Cd274 Mm00452054_m1 CD274 antigenCd300e Mm00468131_m1 CD300e antigen Cd38 Mm01220906_m1 CD38 antigen Cd40Mm00441891_m1 CD40 antigen Cdkn2c Mm00483243_m1 cyclin-dependent kinaseinhibitor 2C (p18, inhibits CDK4) Cmpk2 Mm00469582_m1 cytidinemonophosphate (UMP-CMP) kinase 2 Cxcl10 Mm00445235_m1 chemokine (C-X-Cmotif) ligand 10 Cxcl11 Mm00444662_m1 chemokine (C-X-C motif) ligand 11Ddx60 Mm00460708_m1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 ElaneMm00469310_m1 elastase, neutrophil expressed Epsti1 Mm00712734_m1epithelial stromal interaction 1 (breast) Fcgr1 Mm00438874_m1 Fcreceptor, IgG, high affinity I Fpr1 Mm00442803_s1 formyl peptidereceptor 1 Gapdh Mm99999915_g1 glyceraldehyde-3-phosphate dehydrogenaseHerc6 Mm01341950_m1 hect domain and RLD 6 Hprt Mm00446968_m1hypoxanthine guanine phosphoribosyl transferase Ifi202b Mm00839397_m1interferon activated gene 202B Ifi204 Mm00492602_m1 interferon activatedgene 204 Ifi2712a Mm01329883_gH interferon, alpha-inducible protein 27like 2A Ifi35 Mm00510329_m1 interferon-induced protein 35 Ifi44Mm00505670_m1 interferon-induced protein 44 Ifih1 Mm00459183_m1interferon induced with helicase C domain 1 Ifit1 Mm00515153_m1interferon-induced protein with tetratricopeptide repeats 1 Ifit2Mm00492606_m1 interferon-induced protein with tetratricopeptide repeats2 Ifit3 Mm01704846_s1 interferon-induced protein with tetratricopeptiderepeats 3 Il3ra Mm00434273_m1 interleukin 3 receptor, alpha chain Il6Mm00446190_m1 interleukin 6 Il6ra Mm00439653_m1 interleukin 6 receptor,alpha Irf5 Mm00496477_m1 interferon regulatory factor 5 Irf7Mm00516788_m1 interferon regulatory factor 7 Isg15 Mm01705338_s1 ISG15ubiquitin-like modifier Isg20 Mm00469585_m1 interferon-stimulatedprotein Lta Mm00440228_gH lymphotoxin A Ly6e Mm01200460_g1 lymphocyteantigen 6 complex, locus E Mmp8 Mm00439509_m1 matrix metallopeptidase 8Mmp9 Mm00442991_m1 matrix metallopeptidase 9 Mpo Mm00447886_m1myeloperoxidase Ms4a6c Mm00459296_m1 membrane-spanning 4-domains,subfamily A, member 6C Mx1 Mm00487796_m1 myxovirus (influenza virus)resistance 1 Oas3 Mm00460944_m1 2-5 oligoadenylate synthetase 3 Oasl2Mm00496187_m1 2-5 oligoadenylate synthetase-like 2 Ppia Mm02342430_g1peptidylprolyl isomerase A (cyclophilin A) Prf1 Mm00812512_m1 perforin 1(pore forming protein) Rsad2 Mm00491265_m1 radical S-adenosyl methioninedomain containing 2 Siglec1 Mm00488332_m1 sialic acid binding Ig-likelectin 1, sialoadhesin Stat1 Mm00439531_m1 signal transducer andactivator of transcription 1 Tlr7 Mm00446590_m1 toll-like receptor 7Tlr9 Mm00446193_m1 toll-like receptor 9 Tnf Mm00443258_m1 tumor necrosisfactor Tnfsf10 Mm01283606_m1 tumor necrosis factor (ligand) superfamily,member 10 Tnfsf13b Mm00446347_m1 tumor necrosis factor (ligand)superfamily, member 13b Treml4 Mm00553947_m1 triggering receptorexpressed on myeloid cells-like 4 Trex1 Mm00810120_s1 three prime repairexonuclease 1 Usp18 Mm00449455_m1 ubiquitin specific peptidase 18 Xaf1Mm01248390_m1 XIAP associated factor 1

We claim:
 1. A compound of formula (I) or pharmaceutically acceptablesalt thereof:

wherein at least one of R₁ and R₂ is H, methyl, or ethyl, and the otheris —H; or the other is C₁-C₆ alkyl that is optionally substituted with:—OH, methoxy, ethoxy, —OCH(CH₃)₂, —O(CH₂)₂CH₃, phenyl, furanyl,—O(CH₂)₂OH, phenoxy, methylthio, —F, —N(CH₃)₂, cyano, pyridinyloxy,fluorophenoxy, isochromanyl, phenol, benzylamino, —NHCH₃, oxo-, amino,carboxyl, 7-member spiroaminyl, a three to six member cycloalkyl,saturated or unsaturated and optionally including one or moreheteroatoms selected from O and N, and optionally substituted at one ormore C or N atoms by methyl, cyano, fluoro, methylamino, ortrifluoromethyl; or the other is C₃-C₇ cycloalkane, saturated orunsaturated, optionally bridged, optionally including one or moreheteroatoms selected from O, S, and N, and optionally substituted at oneor more C or N atoms by methyl, ethyl, pyridinyl, azetidinyl,acetamidyl, carboxamidyl, cyano, fluoro, methylamino, ortrifluoromethyl; or R₁ and R₂, together with the nitrogen atom to whichthey are attached, form an 8 to 11 member spirodiamine, an 8 memberbicyclodiamine, a 7 member spiroxamine, a piperidinyl optionallysubstituted with ethyl, or a four to six member cycloalkyl, optionallysubstituted with at least one of carboxamidyl, aminomethyl, methyl,(ethylamino)methyl, (dimethylamino)methyl, dimethylamino,(methylamino)methyl, and amino; and wherein R₃ is —H or methyl.
 2. Thecompound or pharmaceutically acceptable salt of claim 1, wherein saidcompound or salt has a stereochemical configuration selected from one ofthose shown in the group consisting of Formula (Ia), Formula (Ib),Formula (1c), and Formula (1d):


3. The compound or pharmaceutically acceptable salt of claim 1, whereinsaid compound or salt is selected from the group consisting of:5-((2R,6R)-2-formyl-6-methylmorpholino)quinoline-8-carbonitrile;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-ethyl-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-isopropyl-6-methylmorpholine-2-carboxamide;5-((2R,6R)-2-formyl-6-methylmorpholino)quinoline-8-carbonitrile;(2R,6R)-methyl4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxylate;(6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamide;5-((2R,6R)-2((S)-3-ethylpiperazine-1-carbonyl)-6-methylmorpholino)quinoline-8-carbonitrile;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(3,4-difluorobenzyl)-6-methylmorpholine-2-carboxamide;5-((2R,6R)-2-((S)-3-aminopyrrolidine-1-carbonyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-(azetidine-1-carbonyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-([1,4′-bipiperidine]-1′-carbonyl)-6-methylmorpholino)quinoline-8-carbonitrile;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-cyclopropyl-6-methylmorpholine-2-carboxamide;5-((2R,6R)-2-(3-aminoazetidine-1-carbonyl)-6-methylmorpholino)quinoline-8-carbonitrile;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2-hydroxyethyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2-methoxyethyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((R)-2-hydroxypropyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((S)-1-hydroxypropan-2-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((R)-1-hydroxypropan-2-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((S)-1-hydroxybutan-2-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((S)-1-hydroxy-3-methylbutan-2-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((S)-2-hydroxy-1-phenylethyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((R)-2-hydroxy-1-phenylethyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2-hydroxybutyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2-ethoxyethyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((R)-1-hydroxybutan-2-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(1,3-dihydroxypropan-2-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2,3-dihydroxypropyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(((R)-tetrahydrofuran-2-yl)methyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((tetrahydrofuran-2-yl)methyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(2-propoxyethyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((R)-1-hydroxypentan-2-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2-isopropoxyethyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(1-methoxybutan-2-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2-(2-fluorophenyl)-2-hydroxyethyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((R)-1-hydroxy-3-methylbutan-2-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2,2-dimethoxyethyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2-(2-hydroxyethoxy)ethyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((1S,2S)-2-hydroxycyclohexyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2-hydroxycyclohexyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(1-hydroxyhexan-2-yl)-6-methylrnorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((S)-1-hydroxy-3,3-dimethylbutan-2-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((S)-1-hydroxyhexan-2-yl)-6-methylmorpholine-2-carboxannide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((2S,3S)-1-hydroxy-3-methylpentan-2-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((S)-1-hydroxy-4-methylpentan-2-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((R)-1-hydroxy-4-methylpentan-2-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((4-methylmorpholin-2-yl)methyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((S)-1-hydroxy-4-(methylthio)butan-2-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(2-phenoxyethyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(2-phenoxypropyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2-hydroxy-3-phenylpropyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(2-(pyridin-3-yloxy)propyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2-(4-fluorophenoxy)ethyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2-(3-fluorophenyl)-2-hydroxyethyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((S)-1-cyclohexyl-3-hydroxypropan-2-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(isochroman-1-ylmethyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2-hydroxy-3-phenoxypropyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((1S,2R)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((1S)-1,3-dihydroxy-1-phenylpropan-2-yl)-6-methylmorpholine-2-carboxamide,(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2-hydroxy-3-(piperazin-1-yl)propyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-N-(azetidin-3-yl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((S)-pyrrolidin-3-yl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((R)-pyrrolidin-3-yl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((S)-piperidin-3-yl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((R)-piperidin-3-yl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((S)-pyrrolidin-2-ylmethyl)morpholine-2-carboxamide;(2R,6R)-N-(2-(benzylamino)ethyl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(pyridin-2-yl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(6-methylpyridin-2-yl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(5-methylisoxazol-3-morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(2,2,2-trifluoroethyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2,2-difluoroethyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(3,3,3-trifluoropropyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2-(dimethylamino)-2-methylpropyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((S)-morpholin-2-ylmethyl)morpholine-2-carboxamidehydrochloride;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(((S)-4-methylmorpholin-2-yl)methyl)morpholine-2-carboxamideacetic acetate;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2-fluoroethyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(3-fluoropropyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((S)-1,1,1-trifluoropropan-2-yl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((R)-1,1,1-trifluoropropan-2-yl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(1,3-dimethyl-1H-pyrazol-5-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(1-methyl-1H-pyrazol-5-yl)morpholine-2-carboxamide;(2R,6R)-N-(cyanomethyl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-N-(1-cyanocyclopropyl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(1,2,4-thiadiazol-5-yl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(3-methyl-1,2,4-thiadiazol-5-yl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(piperidin-4-yl)morpholine-2-carboxamide;5-((2R,6R)-2-methyl-6-(2,6-diazaspiro[3.4]octane-2-carbonyl)morpholino)quinoline-8-carbonitrilehydrochloride;5-((2R,6R)-2-methyl-6-(3-((methylamino)methyl)azetidine-1-carbonyl)morpholino)quinoline-8-carbonitrilehydrochloride;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((4-fluoropiperidin-4-yl)methyl)-6-methylmorpholine-2-carboxamidehydrochloride;(2R,6R)-N-(azetidin-3-ylmethyl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamidehydrochloride;5-((2R,6R)-2-methyl-6-(2,6-diazaspiro[3.5]nonane-2-carbonyl)morpholino)quinoline-8-carbonitrile hydrochloride;5-((2R,6R)-2-methyl-6-(1,6-diazaspiro[3.4]octane-1-carbonyl)morpholino)quinoline-8-carbonitrile hydrochloride;5-((2R,6R)-2-methyl-6-(1,7-diazaspiro[4.4]nonane-7-carbonyl)morpholino)quinoline-8-carbonitrile hydrochloride;(2R,6R)-N-(3-carbamoyl-1-methyl-1H-pyrazol-4-yl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(oxetan-3-ylmethyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(tetrahydro-2H-pyran-4-yl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(tetrahydrofuran-3-yl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((3-methyloxetan-3-yl)methyl)morpholine-2-carboxamide;5-((2R,6R)-2-methyl-6-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)morpholino)quinoline-8-carbonitrile;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(oxetan-3-yl)morpholine-2-carboxamide;(2R,6R)-N-((3-(aminomethyl)oxetan-3-yl)methyl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(oxetan-2-ylmethyl)morpholine-2-carboxamide;5-((2R,6R)-2-methyl-6-(piperazine-1carbonyl)morpholino)quinoline-8-carbonitrilehydrochloride;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(2-(methylamino)ethyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((S)-3,3,3-trifluoro-2-hydroxypropyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((R)-3,3,3-trifluoro-2-hydroxypropyl)morpholine-2-carboxamide; Methyl2-((2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamido)acetate;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(2-(dimethylamino)ethyl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((S)-4,4,4-trifluoro-3-hydroxybutyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((R)-4,4,4-trifluoro-3-hydroxybutyl)morpholine-2-carboxamide;(2R,6R)-N-(3-amino-4,4,4-trifluorobutyl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamide;2-((2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamido)aceticacid;1-((2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carbonyl)azetidine-3-carboxamide;5-((2R,6R)-2-methyl-6-(2,7-diazaspiro[4.4]nonane-2-carbonyl)morpholino)quinoline-8-carbonitrile hydrochloride;5-((2R,6R)-2-methyl-6-(3,9-diazaspiro[5.5]undecane-3-carbonyl)morpholino)quinoline-8-carbonitrile hydrochloride;(2R,6R)-N-(3-carbamoylpyridin-4-yl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((R)-morpholin-2-ylmethyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(pyridin-4-yl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(pyridin-3-yl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)morpholine-2-carboxamidehydrochloride;(2R,6R)-N-(1-(azetidin-3-yl)-1H-pyrazol-4-yl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamidehydrochloride;(2R,6R)-N-((1H-pyrazol-5-yl)methyl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-N-((1H-pyrazol-4-yl)methyl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((3-(trifluoromethyl)pyridin-2-yl)methyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(1-(pyridin-2-yl)ethyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(pyridin-2-ylmethyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((6-methylpyridin-2-yl)methyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((1-methylpiperidin-2-yl)methyl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((3-methylpyridin-2-yl)methyl)morpholine-2-carboxamide;(2R,6R)-N-(4-cyano-1H-pyrazol-3-yl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((3S,4R)-4-fluoro-1-methylpyrrolidin-3-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((3S,4R)-4-fluoropiperidin-3-yl)-N,6-dimethylmorpholine-2-carboxamidehydrochloride;5-((2R,6R)-2-(3-(aminomethyl)azetidine-1-carbonyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-(3-((ethylamino)methyl)azetidine-1-carbonyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-(3-((dimethylamino)methyl)azetidine-1-carbonyl)-6-methylmorpholino)quinoline-8-carbonitrile;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(1-methylazepan-4-yl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(((2R,6R)-6-methylmorpholin-2-yl)methyl)morpholine-2-carboxamide;5-((2R,6R)-2-methyl-6-(octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)morpholino)quinoline-8-carbonitrile;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((R)-pyrrolidin-2-ylmethyl)morpholine-2-carboxamide hydrochloride;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((S)-piperidin-2-ylmethyl)morpholine-2-carboxamide hydrochloride;(2R,6R)-N-((1R,3R,5S)-8-azabicyclo[3.2.1]octan-3-yl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamidehydrochloride;(2R,6R)-N-(azepan-4-yl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamidehydrochloride;(2R,6R)-N-((1R,5S,6S)-3-azabicyclo[3.1.0]hexan-6-yl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamidehydrochloride;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-6-dimethylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(((2S,6R)-4,6-dimethylmorpholin-2-yl)methyl)-6-methylmorpholine-2-carboxamide;5-((2R,6R)-2-(4-(dimethylamino)piperidine-1-carbonyl)-6-methylmorpholino)quinoline-8-carbonitrile;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(1-methylpiperidin-4-yl)morpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((3S,4R)-4-fluoropyrrolidin-3-yl)-6-methylmorpholine-2-carboxamide hydrochloride;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((3S,4R)-4-fluoropiperidin-3-yl)-6-methyl morpholine-2-carboxamidehydrochloride;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(2-azaspiro[3.3]heptan-6-yl)morpholine-2-carboxamidehydrochloride;(2R,6R)-N-(1-(2-amino-2-oxoethyl)piperidin-4-yl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxarnide;5-((2R,6R)-2-(4-aminopiperidine-1-carbonyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-(4-amino-4-methylpiperidine-1carbonyl)-6-methylmorpholino)quinoline-8-carbonitrile;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N,6-dimethyl-N-((R)-piperidin-3-yl)morpholine-2-carboxamidehydrochloride;(2R,6R)-N-(2-carbamoylpyridin-4-yl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamidehydrochloride;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-6-dimethyl-N-((S)-piperidin-3-yl)morpholine-2-carboxamidehydrochloride;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(1-ethylpiperidin-4-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(1-ethylpiperidin-3-yl)-6-methylmorpholine-2-carboxamide;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-((R)-1-methylpiperidin-3-yl)morpholine-2-carboxamidehydrochloride;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(4-methylpiperidin-4-yl)morpholine-2-carboxamide;(2R,6R)-N-(2-amino-2-methylpropyl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamide;rel-(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((3R,4S)-4-fluoropyrrolidin-3-yl)-6-methylmorpholine-2-carboxamidehydrochloride;rel-(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((3S,4R)-4-fluoropyrrolidin-3-yl)-6-methylmorpholine-2-carboxamide hydrochloride;(2R,6R)-N-(azepan-3-yl)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholine-2-carboxamidehydrochloride;(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(1-methylazepan-3-yl)morpholine-2-carboxamidehydrochloride;(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(1,4-dimethylpiperidin-4-yl)-6-methylmorpholine-2-carboxamide;and(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-(4-fluoro-1-methylpiperidin-3-yl)-6-methylmorpholine-2-carboxamidehydrochloride.
 4. The compound or pharmaceutically acceptable salt ofclaim 3, wherein said compound or salt is selected from the groupconsisting ofrel-(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((3R,4S)-4-fluoropyrrolidin-3-yl)-6-methylmorpholine-2-carboxamidehydrochloride and(2R,6R)-4-(8-cyanoquinolin-5-yl)-6-methyl-N-(1-methylpiperidin-4-yl)morpholine-2-carboxamide.5. A compound of Formula (le) or pharmaceutically acceptable saltthereof, with relative stereochemistry indicated:


6. A compound of Formula (II) or pharmaceutically acceptable saltthereof:

wherein R₄ is methyl; R₅ is C₁-C₅ alkyl that is saturated, partiallysaturated, or unsaturated, and that is optionally substituted with: —H,—cl, —F, —OH, —NH₂, oxo- , —N(CH₂CH₃)₂, phenyl, cyclohexyl,phenyltriazolyl, cyclohexyltriazolyl, pyridinyl, pyrrolidinyl,morpholinyl optionally substituted with methyl or hydroxymethyl, —O—,substituted with: C₁-C₆ alkyl, methylphenyl, methylcyclohexyl,pyridinyl, diazinyl, or phenyl optionally substituted with —F or methyl,—NH—, substituted with: C₂-C₇ alkyl that is linear, branched, or cyclic,saturated or unsaturated, and optionally substituted with oxo-, phenyl,methyl, or —OH, pyridinyl optionally substituted with methyl, methoxy,phenyl, or amino, diazinyl optionally substituted with ethyl,benzoimidazolyl, methylphenyl, phenylpyrazolyl, naphthyridyl, phenyloptionally substituted with —F, methyl, ethyl, or ethoxy, imidazolidinyloptionally substituted with methyl or R₅ is

 wherein n is 1-3, and wherein the cyclic amine is optionallysubstituted with C₁—C₃ alkyl optionally substituted with —OH, —F,phenyl, -—NH₂, cyclohexyl, —N(CH₃)₂, —c(O)NH₂, methylsulfonamidyl,benzenesulfonamidyl, methylbenzenesulfonamidyl, or pyrrolidinyloptionally substituted with methyl or hydroxyl, or —NHC(O)R₆, wherein R₆is C₁-C₅ alkyl, phenyl, pyridinyl, fluorophenyl, methylsulfonyl,fluorobenzenesulfonyl, dimethyl pyrazole sulfonyl, or pyrazolyloptionally substituted with methyl; piperidinyl optionally substitutedwith —C(O)CH₃, —C(O)CH₂CH₃, methyl, oxo-, C(O)Ph, —NH₂, —NH—C(O)CH₃, or

piperazinyl optionally substituted with —C(O)OC(CH₃)₃, methyl, —C(O)CH₃,—C(O)Ph, C(O)CH(CH₃)₂, —C(O)CH₃, or methylsulfonyl; or R₅ is

 where n is 1 or 2, and wherein the cyclic diamine is optionallysubstituted on at least one carbon atom with methyl, oxo-, —N(CH₃)₂,amino, —CH₂CH₃, or piperidinyl optionally substituted with methyl,—C(O)CH₃, —C(O)CH(CH₃)₂, —C(O)Ph, or —C(O)OC(CH₃)₃, and wherein R₇ is—H, phenyl, —C(O)CH₃, C₁-C₃ alkyl, —C(O)NH₂, or —C(O)Ph; and R₈ ismethoxy or cyano.
 7. The compound or pharmaceutically acceptable salt ofclaim 6, wherein said compound or salt is selected from the groupconsisting of:5-((2R,6S)-2,6-dimethylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2,6-dimethylmorpholino)quinoline-8-carbonitriledihydrochloride;5-((2R,6S)-2,6-dimethylmorpholino)quinoline-8-carbonitrilemethanesulfonate;5-((2R,6S)-2,6-dimethylmorpholino)quinoline-8-carbonitrilebis(2,2,2-trifluoro-acetate);5-((2R,6S)-2,6-dimethylmorpholino)quinoline-8-carbonitrilebis(sulfonate);5-((2R,6S)-2,6-dimethylmorpholino)quinoline-8-carbonitrile sulfonate;5-((2S,6R)-2,6-dimethylmorpholino)quinoline-8-carbonitrile2,3-dihydroxy-succinate;5-((2S,6R)-2,6-dimethylmorpholino)quinoline-8-carbonitriledimethanesulfonate;N-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylniorpholin-2-yl)methy)acetamide;N-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)pivalamide;5-((2S,6S)-2,6-dimethylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(aminomethyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-(2-(hydroxymethyl)-6-methylmorpholino)quinoline-8-carbonitrile;(2R,6S)-4-(8-methoxyquinolin-5-yl)-2,6-dimethylmorpholine;5-((2R,6S)-2,6-dimethylmorpholino)quinoline-8-carboxamide;5-((2R,6R)-2-(hydroxymethyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-(methoxymethyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-((benzyloxy)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-(fluoromethyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-(ethoxymethyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-(isopropoxymethyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-(isobutoxymethyl)-6-methylmorpholino)quinoline-8-carbonitrile,5-((2R,6R)-2-(chloromethyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-((hexyloxy)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-((cyclohexylmethoxy)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-propylmorpholino)quinoline-8-carbonitrile;5-((2S,6S)-2-(fluoromethyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6S)-2-(chloromethyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-((2,6-dimethylphenoxy)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2,6-diethylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-pentylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-formyl-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-((benzyloxy)methyl)-6-ethylmorpholino)quinoline-8-carbonitrile;N-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)-2-phenylpropanamide;5-((2R,6R)-2-(1-hydroxyallyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-((S)-1-hydroxyallyl)-6-nnethylmorpholino)quinoline-8-carbonitrile;N-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)-1-phenylcyclobutanecarboxamide;5-((2R,6R)-2-((R)-1-hydroxyallyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(pyrrolidin-1-ylmethyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((diethylamino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((benzylamino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-methyl-6-(phenoxymethyl)morpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-methyl-6-((m-tolyloxy)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-methyl-6-((p-tolyloxy)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-(1-hydroxypropyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-((R)-1-hydroxypentyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-((S)-1-hydroxypentyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-((R)-cyclohexyl(hydroxy)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-((S)-cyclohexyl(hydroxy)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;N-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)-2-phenylacetamide;5-((2R,6R)-2-((R)-1-hydroxy-2-phenylethyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-((S)-1-hydroxy-2-phenylethyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-((R)-1-hydroxy-3-phenylpropyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-((S)-1-hydroxy-3-phenylpropyl)-6-nnethylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((phenylamino)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((m-tolylamino)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((o-tolylamino)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((p-tolylamino)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-((3,4-difluorophenoxy)nnethyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-((3-fluorophenoxy)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((1,2-dimethyl-1H-benzo[d]imidazol-5-yl)amino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((1-ethyl-2-methyl-1H-benzo[d]imidazol-5-yl)amino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((cyclohexylamino)methyl)-6methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-((2-fluorophenoxy)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-methyl-6-propionylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-(cyclohexanecarbonyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-methyl-6-(3-phenylpropanoyl)morpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-methyl-6-((o-tolyloxy)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((pyrimidin-2-ylamino)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((pyridin-2-ylamino)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((6-methylpyridin-2-yl)amino)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((5-methylpyridin-2-yl)amino)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((R)-2-(hydroxymethyl)pyrrolidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2((2,2-dimethylpyrrolidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((2-isopropylpyrrolidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((S)-2-methylpyrrolidin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((S)-3-phenylpyrrolidin-1-yl)methyl)morpholino)quinoline-8-carbonitrile,5-((2R,6S)-2-methyl-6-(((R)-3-methylpyrrolidin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((S)-3-hydroxypyrrolidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((4-methylpyridin-2-yl)amino)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((3-phenylpyrrolidin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((6-methoxypyridin-3-yl)amino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((R)-2-methylpyrrolidin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((2,5-dimethylpyrrolidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((4-methoxypyridin-2-yl)amino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((6-methoxypyridin-2-yl)amino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((1-phenyl-1H-pyrazol-5-yl)amino)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((S)-2-(hydroxymethyl)pyrrolidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((S)-3-methylpyrrolidin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((3,3-dimethylpyrrolidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-methyl-6-((R)-3-phenyl-1-(pyrrolidin-1-yl)propyl)morpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-methyl-6-((S)-3-phenyl-1-(pyrrolidin-1-yl)propyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((3-methoxypyridin-2-yl)amino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((R)-3-hydroxypiperidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile,5-((2S,6R)-2-(((2R,6S)-2,6-dimethylpiperidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((S)-3-hydroxypiperidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((4-hydroxypiperidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((2-(hydroxymethyl)piperidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-(2R,6S)-2-methyl-6-((2-methylpiperidin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((2-ethylpiperidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2((2,3-dimethylpiperazin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((pyridin-3-ylamino)nnethyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((pyridin-4-ylamino)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((S)-2-(trifluoromethyl)pyrrolidin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((4-methylpiperidin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((4,4-difluoropiperidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((4-phenylpiperidin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((4-fluoropiperidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((cyclopentylamino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((3-methylcyclohexyl)amino)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((3-methylpyridin-2-yl)amino)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-ethyl-6-(hydroxymethyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((4-phenylpyridin-2-yl)amino)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(piperazin-1-ylmethyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((4-phenylpiperazin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((6-aminopyridin-2-yl)amino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((2,5-dimethylpiperazin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((4-acetylpiperazin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((2S,4R)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((R)-2-methylpiperazin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((R)-3-methylpiperazin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((S)-3-methylpiperazin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((2R,5R)-2,5-dimethylpiperazin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((2R,5S)-2,5-dimethylpiperazin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((4-methylcyclohexyl)amino)methyl)morpholino)quinoline-8-carbonitrile;5-(-(2S,6R)-2-((cyclobutylamino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((cycloheptylamino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((4-hydroxycyclohexyl)amino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((2-hydroxycyclopentyl)amino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((2-methylcyclohexyl)amino)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((5-phenylpyridin-2-yl)amino)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((3-phenylpyridin-2-yl)amino)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((((1S,3R)-3-hydroxycyclopentyl)amino)methyl)-6-methyl-morpholino)quinoline-8-carbonitrile;5-(-(2S, 6R)-2-(((3-ethoxypyridin-2-yl)amino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((2-phenylpyridin-4-yl)amino)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((6-phenylpyridin-2-yl)amino)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((2-methyl-5-oxopiperazin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((4-methylpiperazin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((4-propylpiperazin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((4-(dimethylamino)piperidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-([1,4′-bipiperidin]-1′-ylmethyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-([1,4′-bipiperidin]-1′-ylmethyl)-6-methylmorpholino)quinoline-8-carbonitriledihydrochloride;5-((2S,6R)-2-(((R)-3-aminopiperidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;(2R,6S)-4-(8-chloro-1,7-naphthyridin-5-yl)-2,6-dimethylmorpholine;5-((2S,6R)-2-((4-aminopiperidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile,5-((2S,6R)-2-(((5-fluoropyrimidin-2-yl)amino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(piperidin-1-ylmethyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(morpholinomethyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((2S,6R)-2,6-dimethylmorpholino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((2R,6R)-2-(hydroxymethyl)-6-methylmorpholino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((4-(pyridin-2-yl)piperazin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((4-(pyridin-4-yl)piperazin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)piperidin-4-yl)acetamide;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)piperidin-4-yl)acetamidehydrochloride;5-((2S,6R)-2-(((1,8-naphthyridin-2-yl)amino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)piperidine-4-carboxamide;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)piperidin-4-yl)benzamide;5-((2S,6R)-2-((4-isopropylpiperazin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;4-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)piperazine-1-carboxamide;5-((2S,6R)-2-((4-cyclohexylpiperidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((4-(pyrrolidin-1-yl)piperidin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-((4-cyclohexyl-1H-1,2,3-triazol-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-methyl-6-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((2-oxo-[1,4′-bipiperidin]-1′-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((5-ethylpyrimidin-2-yl)amino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((6-amino-3,5-dimethylpyridin-2-yl)amino)methyl)-6-methyl-morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((pyrazin-2-ylamino)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((1,3-dimethyl-1H-pyrazol-5-yl)amino)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,7R)-2-(hydroxyrnethyl)-7-methyl-1,4-oxazepan-4-yl)quinoline-8-carbonitrile;5-((2S,6R)-2-((4-ethylpiperazin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((3-(pyrrolidin-1-yl)azetidin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((3-(piperidin-1-yl)azetidin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((R)-2,4-dimethylpiperazin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((4-(hydroxymethyl)piperidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((R)-[1,3′-bipyrrolidin]-1′-ylmethyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((R)-3-(piperidin-1-yl)pyrrolidin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((4-methyl-1,4-diazepan-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((4-benzoylpiperazin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)piperidin-4-yl)nicotinamide;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)piperidin-4-yl)isonicotinamide;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)piperidin-4-yl)picolinamide;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)piperidin-4-yl)hexanamide;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)piperidin-4-yl)isobutyramide;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)piperidin-4-yl)isobutyramidehydrochloride;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)piperidin-4-yl)pivalamide;5-((2S,7R)-2-([1,4′-bipiperidin]-1′-ylmethyl)-7-methyl-1,4-oxazepan-4-yl)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((4-morpholinopiperidin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;tert-butyl4-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)piperidin-4-yl)piperazine-1-carboxylate; tert-butyl4-(4-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)piperazin-1-yl)piperidine-1-carboxylate;5-((2R,6S)-2-methyl-6-((4-(piperazin-1-yl)piperidin-1yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((4-(piperidin-4-yl)piperazin-1yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((3-(4-methylpiperazin-1yl)azetidin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-([4,4′-bipiperidin]-1-ylmethyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(1′-acetyl-[4,4′-bipiperidin]-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((1′-methyl-[4,4′-bipiperidin]-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6((3-(piperazin-1-yl)azetidin-1-yl)ethyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((3-(4-acetylpiperazin-1-yl)azetidin-1-yl)methyl)-6-methyl-morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((1′-isobutyryl-[4,4′-bipiperidin]-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((3-(4-benzoylpiperazin-1-yl)azetidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((1′-benzoyl-[4,4′-bipiperidin]-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((4-(1-methylpiperidin-4-yl)piperazin-1-yl)methyl)-morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((4-(1-acetylpiperidin-4-yl)piperazin-1-yl)methyl)-6-methyl-morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(4-(1-isobutyrylpiperidin-4-yl)piperazin-1-yl)methyl)-6-methyl-morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((4-(1-benzoylpiperidin-4-yl)piperazin-1-yl)methyl)-6-methyl-morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((3-(4-isobutyrylpiperazin-1-yl)azetidin-1-yl)methyl)-6-methyl-morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((4-(4-acetylpiperazin-1-yl)piperidin-1-yl)methyl)-6-methyl-morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((4-(4-isobutyrylpiperazin-1-yl)piperidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((4-(4-benzoylpiperazin-1-)piperidin-1-yl)methyl)-6-methyl-morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((4-(4-methylpiperazin-1-yl)piperidin-1-yl)methyl)-morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((4-(4-methylpiperazin-1-yl)piperidin-1-yl)methyl)-morpholino)quinoline-8-carbonitriletrihydrochloride;5-((2S,6R)-2-([1,4′-bipiperidin]-1′-ylmethyl)-6-methylmorpholino)-2-methyl-quinoline-8-carbonitrile;N-((R)-1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)-pyrrolidin-3-yl)acetamide;N-((R)-1-(((-(2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)-pyrrolidin-3-yl)isobutyramide,5-((2R,6S)-2-methyl-6-(((S)-3-(piperidin-1-yl)pyrrolidin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((S)-3-(piperidin-1-yl)pyrrolidin-1-yl)methyl)morpholino)-quinoline-8-carbonitriledihydrochloride;5-((2R,6S)-2-methyl-6-((3-morpholinoazetidin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((3-((S)-2-methylpyrrolidin-1-yl)azetidin-1-yl)methyl)-morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((S)-2-methylpiperazin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((S)-2,4-dimethylpiperazin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((R)-3,4-dimethylpiperazin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((S)-3,4-dimethylpiperazin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((S)-3-ethylpiperazin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(((S)-3-ethylpiperazin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitriledihydrochloride;5-((2S,6R)-2-(((S)-3-ethyl-4-methylpiperazin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-(4-(azepan-1-yl)piperidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((S)-[1,3′-bipyrrolidin]-1′-ylmethyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((3-(4-aminopiperidin-1-yl)azetidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;N-(1-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)-azetidin-3-yl)piperidin-4-yl)acetamide;5-((2R,6S)-2-methyl-6-((3-(4-(methylsulfonyl)piperazin-1-yl)azetidin-1-yl)methyl)-morpholino)quinoline-8-carbonitrile;5-((2S,6R)-2-((3-((S)-3-hydroxypyrrolidin-1-yl)azetidin-1-yl)methyl)-6-methyl-morpholino)quinoline-8-carbonitrile;N-(1(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)piperidin-4-yl)-1,3-dimethyl-1H-pyrazole-4-carboxamide;N-(1-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)-azetidin-3-yl)piperidin-4-yl)-1,3-dimethyl-1H-pyrazole-4-carboxamide;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)piperidin-4-yl)methanesulfonamide;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)piperidin-4-yl)benzenesulfonamide;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyppiperidin-4-yl)-4-fluorobenzenesulfonamide;5-((2S,6R)-2-((3-aminoazetidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)azetidin-3-yl)acetamide;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)azetidin-3-yl)-4-fluorobenzamide;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)azetidin-3-yl)methanesulfonamide;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)azetidin-3-yl)-4-fluorobenzenesulfonamide;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)azetidin-3-yl)-1,3-dimethyl-1H-pyrazole-4-sulfonamide;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)piperidin-4yl)-1,3-dimethyl-1H-pyrazole-4-sulfonamide;N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methypazetidin-3-yl)isobutyramide;5-((2R,6S)-2-methyl-6-(((S)-2-methyl-5-oxopiperazin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((R)-2-methyl-5-oxopiperazin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((R)-2-methyl-3-oxopiperazin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-(((S)-2-methyl-3-oxopiperazin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((2,4,5-trimethylpiperazin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6S)-2-methyl-6-((2,3,4-trimethylpiperazin-1-yl)methyl)morpholino)quinoline-8-carbonitrile;N-((R)-1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)pyrrolidin-3-yl)benzamide;5-((2S,6R)-2-(((R)-3-(dimethylamino)pyrrolidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;N-((S)-1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)-pyrrolidin-3-yl)acetamide;N-((S)-1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)-pyrrolidin-3-yl)isobutyramide;N-((S)-1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)-pyrrolidin-3-yl)benzarnide;5-((2S,6R)-2-(((S)-3-(dimethylamino)pyrrolidin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-methyl-6-((pyrazin-2-yloxy)methyl)morpholino)quinoline-8-carbonitrile,N-(1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)azetidin-3-yl)benzamide;5-((2S,6R)-2-((3,3-dimethylpiperazin-1-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitriledihydrochloride;5-((2R,6S)-2-methyl-6-((3,3,4-trimethylpiperazin-1-yl)methyl)morpholino)quinoline-8-carbonitrile dihydrochloride;5-((2R,6R)-2-((R)-1-hydroxyethyl)-6-methylmorpholino)quinoline-8-carbonitrile;1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)-N-ethylpiperidine-4-carboxamide;1-(((2S,6R)-4-(8-cyanoquinolin-5-yl)-6-methylmorpholin-2-yl)methyl)-N-ethylpiperidine-4-carboxamidehydrochloride;5-((2R,6R)-2-((S)-1-hydroxyethyl)-6-methylmorpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-methyl-6-((pyridin-2-yloxy)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-methyl-6-((pyrimidin-2-yloxy)methyl)morpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-methyl-6-((R)-1-(pyrimidin-2-yloxy)ethyl)morpholino)quinoline-8-carbonitrile;5-((2R,6R)-2-methyl-6-((S)-1-(pyrimidin-2-yloxy)ethyl)morpholino)quinoline-8-carbonitrile;and5-((2R,6R)-2-((S)-hydroxy(pyridin-2-yl)methyl)-6-methylmorpholino)quinoline-8-carbonitrile.8. The compound or pharmaceutically acceptable salt of claim 6, whereinsaid compound or salt is selected from the group consisting of5-((2S,6R)-2-([1,4′-bipiperidin]-1′-ylmethyl)-6-methylmorpholino)quinoline-8-carbonitrileand5-((2R,7R)-2-(hydroxymethyl)-7-methyl-1,4-oxazepan-4-yl)quinoline-8-carbonitrile.9. A compound of Formula (III) or pharmaceutically acceptable saltthereof:

wherein R₁₁ is H or methyl; R₁₀ is H or, when both R₁₁ and R₉ are H, ismethyl-1,4′-bipiperidinyl; R₉ is —H or is —CH₂- substituted by1,4′-bipiperidinyl, oxo-, hydroxyl, methylpyridinyl, or piperidinyloptionally substituted with hydroxyl, —N(CH₃)₂, or piperidinyl.
 10. Thecompound or pharmaceutically acceptable salt of claim 9, wherein saidcompound or salt is selected from the group consisting of:5-(3-([1,4′-bipiperidin]-1′-ylmethyl)pheny)quinoline-8-carbonitrile;5-(4-([1,4′-bipiperidin]-1′-ylmethyl)pheny)quinoline-8-carbonitrile;5-(3-formyl-5-methylphenyl)quinoline-8-carbonitrile;5-(3-(hydroxymethyl)-5-methylphenyl)quinoline-8-carbonitrile;5-(3-(chloromethyl)-5-methylphenyl)quinoline-8-carbonitrile;5-(3((4-hydroxypiperidin-1-yl)methyl)-5-methylphenyl)quinoline-8-carbonitrile;5-(3((4-(dimethylamino)piperidin-1-yl)methyl)-5-methylphenyl)quinoline-8-carbonitrile;5-(3-methyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)quinoline-8-carbonitrile;and5-(3-([1,4′-bipiperidin]-1′-ylmethyl)-5-methylphenyl)quinoline-8-carbonitrile.11. A method for treatment of lupus, comprising administering apharmaceutically effective amount of a compound or pharmaceuticallyacceptable salt of claim
 1. 12. The method of claim 11, wherein saidcompound is administered as a pharmaceutically acceptable salt.
 13. Amethod for antagonizing TLR7, comprising administering apharmaceutically effective amount of a compound or pharmaceuticallyacceptable salt of claim
 1. 14. A method for antagonizing TLR8,comprising administering a pharmaceutically effective amount of acompound or pharmaceutically acceptable salt of claim
 1. 15. Apharmaceutical composition comprising at least one compound orpharmaceutically acceptable salt of claim 1 and at least onepharmaceutically acceptable carrier.
 16. The pharmaceutical compositionof claim 15, wherein said compound or pharmaceutically acceptable saltthereof has an IC50 less than or equal to 100 nM against human TLR7receptors in a HEK-293 cell line.
 17. The pharmaceutical composition ofclaim 15, wherein said compound or pharmaceutically acceptable saltthereof has an IC50 less than or equal to 20 nM against human TLR7receptors expressed in a HEK-293 cell line.
 18. The pharmaceuticalcomposition of claim 15, wherein said compound or pharmaceuticallyacceptable salt thereof has an IC50 less than or equal to 5 nM againsthuman TLR7 receptors expressed in a HEK-293 cell line.
 19. Thepharmaceutical composition of claim 16, wherein the IC50 against humanTLR7 receptors expressed in a HEK-293 cell line is measured by (1)plating cells of the HEK-293 cell line stably expressing TLR7 in aDulbecco's modified Eagle's medium containing 10% fetal bovine serum ata density of 2.22×105 cells/ml into a 384-well plate and incubating for2 days at 37° C., 5% CO2; (2) adding the compound or pharmaceuticallyacceptable salt thereof and incubating the cells for 30 minutes; (3)adding CL097 (InvivoGen) at 3 ug/ml and incubating the cells forapproximately 20 hours; and (4) quantifying NF-kappaB dependent reporteractivation by measuring luminescence.
 20. A method for treatment of asystematic lupus erythematosus, cutaneous lupus, or neuropsychiatriclupus, comprising administering a pharmaceutically effective amount of acompound or pharmaceutically acceptable salt of claim
 1. 21. The methodof claim 20, wherein said compound is administered as a pharmaceuticallyacceptable salt.
 22. A pharmaceutically acceptable salt of claim 5,wherein the pharmaceutically acceptable salt, with relativestereochemistry indicated, isRel-(2R,6R)-4-(8-cyanoquinolin-5-yl)-N-((3S,4R)-4-fluoropyrrolidin-3-yl)-6-methylmorpholine-2-carboxamidehydrochloride.
 23. A method for treatment of lupus, comprisingadministering a pharmaceutically effective amount of thepharmaceutically acceptable salt of claim
 22. 24. A pharmaceuticalcomposition comprising the pharmaceutically acceptable salt of claim 22and at least one pharmaceutically acceptable carrier.
 25. A method fortreatment of systematic lupus erythematosus, cutaneous lupus, orneutopsychiatric lupus, comprising administering a pharmaceuticallyeffective amount of the pharmaceutically acceptable salt of claim 22.26. A method for antagonizing TLR7, comprising administering apharmaceutically effective amount of the pharmaceutically acceptablesalt of claim
 22. 27. A method for antagonizing TLR8, comprisingadministering a pharmaceutically effective amount of thepharmaceutically acceptable salt of claim
 22. 28. A method for treatmentof lupus, comprising administering a pharmaceutically effective amountof the pharmaceutically acceptable salt of claim
 5. 29. A pharmaceuticalcomposition comprising the pharmaceutically acceptable salt of claim 5and at least one pharmaceutically acceptable carrier.
 30. A method fortreatment of systematic lupus erythematosus, cutaneous lupus, orneutopsychiatric lupus, comprising administering a pharmaceuticallyeffective amount of the pharmaceutically acceptable salt of claim
 5. 31.A method for antagonizing TLR7, comprising administering apharmaceutically effective amount of the pharmaceutically acceptablesalt of claim
 5. 32. A method for antagonizing TLR8, comprisingadministering a pharmaceutically effective amount of thepharmaceutically acceptable salt of claim 5.